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ABSTRACT 
Evaluating Utilization of Beta-Blockers as Secondary Prevention for Post 
Myocardial Infarction in a Medicaid Population 
 
Ancilla W. Fernandes 
 
Acute myocardial infarction (AMI) is associated with high mortality and costs to the US 
healthcare system.  Beta-blockers are known to reduce mortality and re-infarction rates 
when used for long-term prevention following an AMI.  They are recommended by the 
American College of Cardiology (ACC)/American Heart Association (AHA) guidelines 
in post-AMI patients.  However, this therapy is both underused (error of omission in 
eligible patients) and misused (error of commission in ineligible patients).  This study 
involved two phases.  Phase one included evaluating utilization of beta-blockers in a 
Medicaid population and determining the effect of their utilization on patient outcomes 
such as mortality, morbidity, utilization of healthcare services and expenditures.  Phase 
two involved determining the association of physician-related factors such as knowledge 
of contraindications, willingness to prescribe, physician demographics and physician 
practice characteristics on their beta-blocker prescribing behavior.  Phase one of the study 
revealed 37% inappropriate (misuse and underuse) utilization.  During the 12-month 
follow-up after the incident AMI the appropriately prescribed group had a significantly 
lower all-cause mortality and lower, but insignificant, cardiac mortality compared to the 
inappropriately prescribed group.  The appropriately prescribed group had significantly 
higher cardiovascular morbidity and higher utilization in the follow-up period.  However, 
there were indications that the appropriate group was more severely ill as compared to the 
inappropriate group.  Thus, the increase in morbidity and utilization could be due to 
patient severity rather than appropriate therapy.  In phase two, a survey was mailed to 
1,019 physicians involved in post-AMI care in WV, of which 261(25.61%) responded.  
Physician knowledge of contraindications was not associated with their self-reported 
beta-blocker prescribing behavior.  Physicians’ willingness to prescribe was positively 
associated with their beta-blocker prescribing behavior.  Younger age and affiliation with 
a larger hospital were associated with better beta-blocker prescribing behavior.  
Multivariate analysis including knowledge, willingness to prescribe, demographics and 
practice characteristics revealed that willingness to prescribe was the only significant 
predictor of their beta-blocker prescribing behavior.  Findings of this phase indicated a 
profile of general specialty/family practice physician, older in age, non-university or non-
hospital affiliated, and attached to a smaller hospital as the target for interventions to 
improve beta-blocker prescribing behavior.
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CHAPTER ONE 
INTRODUCTION 
 
Acute Myocardial Infarction (AMI), also known as “heart attack” is defined as the 
death of heart muscle due to loss of blood supply (Bellenir, 2000).  Coronary artery 
disease (CAD) is the primary underlying process that leads to an AMI (Stringer & Lopez, 
1999).  It is the number one killer among both men and women in the United States 
(Stringer & Lopez, 1999).  Each year approximately 900,000 people experience an AMI.  
Apart from being a serious health issue, coronary disease is also responsible for severe 
economic losses in the United States.  For instance, in 1997, the financial consequence 
due to coronary artery disease to the U.S. healthcare system was estimated to be 
approximately $91 billion (Stringer & Lopez, 1999).  Thus, therapeutic interventions that 
reduce mortality and improve morbidity, as well as primary and secondary prevention 
strategies, could have a significant impact on the US healthcare system.   
Of the 900,000 people who suffer from an AMI every year, over 800,000 people 
survive  (Bradford, Chen & Krumholz, 1999).  Therapy with beta-blockers has shown to 
be an effective means of reducing mortality following a heart attack (Bradford, et al., 
1999).  Prophylaxis with beta-blockers after the onset of an AMI has been reported to be 
effective since the 1960s (Snow, 1965).  Thousands of patients have participated in 
randomized trials which have demonstrated that cardiovascular mortality and re-
infarction rates decrease with beta-blocker use following an AMI (Bradford, et al., 1999).  
There is also strong evidence that beta-blockers are safe and effective therapies.  
However, there are certain conditions, such as bradycardia, hypotension and 
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atrioventricular (AV) block in patients where there is evidence that therapy is not useful 
or may be harmful [American College of Cardiology (ACC)/American Heart Association 
(AHA), 1996].  The national cardiology consensus committees have acknowledged this 
fact by publishing recommendations for its use in patients to whom it is beneficial and 
listing those conditions, in the presence of which, this therapy should not be used 
(ACC/AHA, 1996).   
Despite the benefits of beta-blocker therapy and the established guidelines for 
proper use, they are not prescribed appropriately in patients after an AMI (Bradford, et 
al., 1999).  Many patients who are eligible and should receive prescription for beta-
blocker therapy at discharge do not get a prescription (error of omission or under use).  
While it is not as well documented, there are a few reports that suggest that sometimes 
patients who have contraindications and are not eligible for therapy receive a prescription 
for beta-blockers (error of commission or misuse) (Brand, Newcomer, Freiburger, & 
Tian, 1995).  This inappropriate prescribing of a useful therapeutic agent can affect 
patient outcomes such as morbidity, mortality, and increase healthcare utilization and 
costs.  Thus, this study will assess the effects of inappropriate prescribing of beta-
blockers for secondary prevention following an AMI.  This study will also assess 
practitioner knowledge and willingness to prescribe long-term beta-blocker therapy in 
post AMI patients.  The following sections will concentrate on beta-blocker therapy, 
evidence of its inappropriate prescribing, consequences of inappropriate prescribing, and 
the physician’s role in drug prescribing.   
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Beta-blocker Therapy  
By definition, beta-blockers block beta-receptors (Khan, 2000).  Structurally they 
resemble catecholamines.  They competitively inhibit beta-receptors depending on the 
ratio of their concentration to catecholamine concentration.  When given to an AMI 
patient, they are known to rapidly reduce systolic blood pressure, by reducing cardiac 
output (Plosker & Clissold, 1992).  They are also known to reduce myocardial oxygen 
demand.  These beneficial effects are believed to decrease the incidence of 
cerebrovascular complications and new myocardial infarctions, thus providing clinical 
efficacy.  Beta-blockers also have certain adverse effects such as fatigue, sexual 
dysfunction, nightmares and difficulty to detect hypoglycemia in diabetes.  
Numerous studies have provided evidence that beta-blocker therapy is effective 
following an AMI (Bradford, et al., 1999).  In a meta-analysis of 65 studies, Yusuf et al. 
concluded that long-term beta-blocker therapy for perhaps a year or so following 
discharge after an AMI reduces the odds of death and re-infarction by about 25% (Yusuf, 
Peto, Lewis, Collins & Sleight, 1985).  Hjalmarson’s review of data from 5 clinical trials 
reported a 36% reduction in mortality in two studies, a 26% reduction in one study, and a 
13-14% reduction in mortality in the other two studies (Hjalmarson, 1988).  Goldstein 
reported that the beneficial effects of oral beta-blocker therapy were maintained for at 
least six years after myocardial infarction, and discontinuation was associated with 
accelerated mortality (Goldstein, 1996).  He also reported a reduction in cardiovascular 
mortality, re-infarction rate, and sudden death due to beta-blocker use following an AMI.   
Furberg and Byinton examined data from the Beta-Blocker Heart Attack Trial 
(BHAT) (Furberg & Byinton, 1983).  They examined the difference in outcomes between 
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patients in the tails of the distribution of expected mortality risk.  They found a relative 
risk reduction of 40% in the group receiving beta-blocker agents in this limited set of 
patients.  Olsson et al., analyzed individual patient level data from 5 randomized trials 
(Olsson, et al., 1992).  They found an overall reduction in relative risk of mortality of 
19%.  Also, a higher benefit to women (23%) was observed as compared to men (16%).  
The reduction in total mortality was mainly due to a reduction in sudden cardiac deaths.  
These studies also reported reductions in re-infarction rates, angina pectoris severity, and 
congestive heart failure severity (Bradford, Chen & Krumholz, 1999). 
The ACC/ AHA relied on the evidence of these beneficial effects to develop 
guidelines for beta-blocker use for secondary prevention after an AMI (ACC/AHA, 1996 
& 1999).  These guidelines suggest that all patients, except those with absolute 
contraindications to beta-blocker therapy, should begin treatment within a few days of 
AMI and continue it indefinitely.  The absolute contraindications for beta-blocker use are 
few and include AV block, bradycardia, and hypotension (ACC/AHA, 1996 & 1999, 
Philips et al., 2000).  However, a variety of conditions are listed as relative 
contraindications.  These include: heart rate less than 60 bpm, systolic arterial pressure 
less than 100 mm Hg, moderate or severe left ventricular (LV) failure, signs of peripheral 
hypoperfusion, PR interval greater than 0.24 second, second or third degree AV block, 
severe chronic obstructive pulmonary disease (COPD), history of asthma, insulin 
dependent diabetes mellitus (IDDM), and severe peripheral vascular disease (ACC/AHA, 
1996).  Though patients with relative contraindications are recommended to receive 
therapy, they need to be monitored for adverse reactions.   
 
 5
Evidence of Inappropriate Prescribing 
Considerable variation in beta-blocker use for secondary prevention following an 
AMI has been reported.  Rogers et al., examined the National Registry of Myocardial 
Infarction (NRMI) to investigate beta-blocker use from 1990 to 1993 (Rogers et al., 
1994).  Oral beta-blockers were used in only 36% of registered thrombolytic recipients, 
whereas in patients who did not receive thrombolysis, the utilization was 30%.  Soumerai 
et al., and Krumholz et al., reported results of two recent studies investigating beta-
blocker use.  The first study linked Medicare claims data to two databases covering 
pharmaceutical usage in New Jersey for these Medicare patients.  This study reported that 
while 70% of the patients were eligible for therapy, only 21% of these patients received a 
prescription for beta-blockers (Soumerai, McLaughin, Speilgelman, Hertzmark, Thibault 
& Goldman, 1997).  The second study collected data through an intensive chart review of 
Medicare AMI patients selected from the Cooperative Cardiovascular Project (CCP).  
The CCP collected data on over 200,000 patients in 45 states over an 8-month period 
from 1994 to 1995.  This study reported an eligible population of about 39%, of which 
only 50% had a prescription of beta-blocker at discharge (Krumholz, Radford, Wang, 
Chen, Heiat, & Marciniak, 1998).  
A geographical variation in beta-blocker usage has also been established.  There 
was a significant state and region variation in beta-blocker utilization in the CCP 
(Krumholz et al., 1998).  The 5 states with the highest use were Connecticut (77.1%), 
Massachusetts (74.2%), Maine (68.3%), New Hampshire (68.9%), and Vermont (66.7%).  
The lowest use occurred in Mississippi (30.2%), Puerto Rico (32.1%), Oklahoma 
(33.5%), Arkansas (33.5%), and Nevada (36.4%).  Meehan et al., examined variations in 
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a small area using data from six hospitals in Connecticut (Meehan, Hennen, Radford, 
Petrillo, Elstein, & Ballard, 1995).  The overall utilization of therapy was 41% among 
eligible patients.  Also, there was a large variation based on hospitals.  The utilization 
varied from 39-54% for the low-mortality hospitals to 29-33% for the high mortality 
hospitals.  Pilote et al., also reported regional variation when data from the Global 
Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary 
Arteries trial (GUSTO-1) was analyzed (Pilote et al., 1995).  They found that New 
England had the highest utilization of therapy with 71% of patients receiving a beta-
blocker prescription at discharge.  In comparison, the Mountain and South Central 
regions had the lowest utilization at 47% and 49%, respectively.  Other studies have 
reported below optimal beta-blocker utilization for certain patient subgroups such as the 
elderly, women, and blacks (Fishkind, Paris, & Aronow, 1997; Pashos, Normand, 
Garfinkle, Newhouse, Epenstein, & McNeil, 1994, for details see Chapter 2).   
In contrast to the under use in eligible patients, there is also evidence of 
prescribing of beta-blocker therapy to patients in the presence of contraindications.  
Brand et al., reported that about 11% of patients were prescribed therapy in the presence 
of contraindications (Brand et al., 1995).  Another study reported 24% utilization in 
patients with potential contraindications (Sial, Malone, Freeman, Battiola, Nachodsky & 
Goodwin, 1994).   
Thus, despite established guidelines for beta-blocker therapy as secondary 
prevention following an AMI, there are several reports of instances where eligible 
patients are not prescribed therapy – thereby establishing under use, and a few reports of 
patients who are not eligible for therapy being prescribed therapy – thereby establishing 
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misuse.  Both under use and misuse of therapy are examples of inappropriate use and 
non-adherence of the 1999 ACC/AHA guidelines.  
 
Consequences of Inappropriate Prescribing 
The inappropriate utilization of any medication can result in adverse patient 
outcomes.  Medication use or prescribing can be considered inappropriate based on a 
wide variety of criteria such as medication use without indication, medication use with 
contraindication, over or under dosing, incorrect directions, drug-drug interactions, drug-
disease interactions, therapeutic duplication, and longer or shorter duration of therapy 
than necessary (Schmader, Hanlon, Landsman, Samsa, Lewis & Weinberger, 1997).  For 
beta-blocker use as a secondary preventive agent in post AMI patients, inappropriate 
prescribing is usually a result of under use (error of omission) or misuse (error of 
commission).  When patients eligible for beta-blocker use receive a prescription, lower 
mortality rates have been reported.  For example, Krumholz et al., reported a 14% lower 
risk of mortality at 1 year after discharge, among eligible patients who received a 
prescription for beta-blockers at discharge, when compared to eligible patients who did 
not receive a prescription (Krumholz et al., 1998).  In other words, under use was 
associated with higher mortality.  Similarly, Soumerai et al, reported a 43% lower 
mortality rate among beta-blocker recipients compared to non-recipients (Soumerai et al., 
1997).  Additionally, this study also reported that beta-blocker recipients were re-
hospitalized 22% less often than non-recipients.  Thus, in this study, under use was 
associated with higher mortality and higher re-infarction rates.  Other healthcare 
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utilization variables such as physician visits, emergency room visits, length of stay and 
expenditures have not been investigated so far with regards to under use.  
While there is no information on the consequences of misuse of beta-blocker 
therapy, several studies dealing with other chronic diseases suggest some of the potential 
consequences of misuse of drug therapy.  Shireman et al., demonstrated that drug 
utilization patterns for asthma, when not consistent with established guidelines, had 
undesirable outcomes (Shireman, Heaton, Gay, Cluxton & Moomaw, 2002).  Patients 
receiving excessive doses of beta agonists, an agent that should be used on an as-needed 
basis, had significantly greater emergency department visits.  Anis et al., reported that 
those asthma patients with inappropriate medication use (defined as excessive use of beta 
agonists, an as-needed medication, and below optimal use of corticosteroid, a 
recommended medication), were more likely to be admitted to a hospital, and required 
more emergency room admissions compared to patients with appropriate medication use 
(Anis, et al., 2001).  This study also reported that those patients with excessive use of 
beta-agonists visited a significantly greater number of physicians for their prescriptions.  
A study exploring the monetary effects of inappropriate medication use reported that 77% 
of the cost of albumin, a plasma expander, was related to inappropriate use which was 
defined as use when not necessary, or use when other less expensive therapeutic options 
were available (Remohi, Arcos, Ramos, Palome, & Aznar, 2000).  An investigation of an 
increase in prescription drug expenditures associated with peptic ulcer disease in 
Vermont’s Medicaid program was also related to inappropriate use (Soons, Lynch, 
Seagrave & Rolley, 1997).  Physicians were prescribing H2 antagonists for greater than 
the recommended 6 to 8 weeks in 60% of the cases, resulting in a 21% increase of 
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prescription expenditures for gastrointestinal drugs.  Finally, a study focusing on 12 
major categories of drugs used to treat chronic diseases among older patients revealed 
that under supply and over supply of medication affected healthcare utilization (Stroupe, 
Murray, Stump & Callahn, 2000).  Patients with under supply and over supply of 
medication had greater emergency department visits and hospital admissions compared to 
patients with a normal supply of medication.  Thus, there is evidence that inappropriate 
medication use can affect patient outcomes.  However, there are no studies investigating 
the outcomes of inappropriate beta-blocker therapy and therefore there is a need to 
undertake such an investigation.   
 
Physicians’ Role in Drug Prescribing  
Many studies have attempted to understand physician’s role in beta-blocker 
therapy.  Ayanian et al., examined treatment decisions of cardiologists, internists and 
family practitioners for their patients with AMI (Ayanian, Hauptman, Guadagnoli, 
Antman, Pashas & McNeil, 1994).  They found that cardiologists were much more likely 
to prescribe beta-blockers compared to either internists or family practitioners.  Another 
study compared cardiologists’ compliance with practice guidelines for beta-blocker use 
after an AMI.  Of the 60% of patients, who were eligible for beta-blocker therapy, only 
48% actually received therapy (Brand, et al., 1995).  This study also reported that 11% of 
patients with contraindications were prescribed beta-blockers.  Jollis et al., studied 
physician specialty and treatment outcomes using the CCP data (Jollis et al., 1996).  They 
found that cardiologists were more aggressive in their treatments and used more 
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resources compared to other physicians.  Also, their patients had lower mortality rates 
and better outcomes compared to patients of other physician specialties. 
Similar information on other chronic disease treatments reveal that in addition to 
some of the above characteristics, there are other physician traits that affect prescribing 
behavior.  For example, there is wide variability in preventive aspirin use among teaching 
and non-teaching hospitals (Venturini, Romero & Tognoni, 1999).  Similarly, younger 
physicians are more likely to select hypertensive agents consistent with guideline 
recommendations compared to older physicians (Mehta, Wilcox & Schulman, 1999).  A 
study that characterized physicians who frequently but inappropriately prescribed long-
acting benzodiazepines to the elderly, demonstrated that these physicians were more 
likely to be generalists, have graduated before 1979, practiced in long-term care settings 
and graduated from medical school from a particular region (Monette, Tamblyn, Mclead 
& Gayton, 1997).  
In addition to demographic and practice-related factors, knowledge, opinions and 
beliefs of physicians have also been related to prescribing behavior.  For example, a study 
investigating the reasons for under prescribing of beta-blockers in post AMI patients 
reported that physicians believed that the adverse effects of beta-blockers would result in 
a negative quality of life (Kennedy & Rosensen, 1995).  Additionally, they had 
exaggerated concerns about the relative contraindications, despite reports of benefits to 
patients with these conditions.  This study also reported that commercial influences of 
pharmaceutical companies contributed to negative attitudes of physicians regarding beta-
blocker therapy.   
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There is evidence that despite knowledge of guidelines, certain beliefs of 
physicians may affect prescribing behavior.  For example, Huse et al. explored how well 
physicians who treat hypertension know the indications and contraindications for 
particular antihypertensive therapies, and how closely their opinions and practices agreed 
with national guidelines for their use (Huse, Roht, Alpert & Hartz, 2001).  The study 
revealed that the degree of specialization and knowledge of indications and 
contraindications were positively related.  However, this knowledge did not result in 
adherence to treatment guidelines.  This was primarily due to study physician’s beliefs 
that the adverse effects of some therapies would affect patient compliance. 
Knowledge has also been reported to affect prescribing behavior through 
interaction with practice characteristics of physicians.  For example, a study assessed 
physician’s knowledge, attitudes and prescribing behaviors with regard to the association 
between Chlamydia pneumoniae and cardiovascular diseases (Sanchez, Jernigan, 
Strausbaugh, Slemp, Perilla, & Dowell, 2001).  A higher knowledge score was 
documented among infectious disease specialists and cardiologists than generalists.  The 
study also reported higher knowledge score among those physicians who saw relatively 
more patients with a myocardial infarction.  Additionally, the results revealed that 
previous experience with managing cardiovascular disease was a good predictor of 
awareness, knowledge, and the probability of treating patients with anti-microbial agents.  
In addition to demographics, practice characteristics, knowledge, attitudes, 
opinions and beliefs, the interaction of all of these factors can also affect prescribing 
behavior.  Thus, it is important to investigate how these factors individually, and in 
combination, affect prescribing behavior among physicians for beta-blockers following 
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an AMI.  Identification of these physician factors could explain the underlying causes of 
inappropriate prescribing behavior, which would facilitate the targeting of appropriate 
educational efforts.  
 
STATEMENT OF PROBLEM 
 Beta-blockers have been demonstrated to yield better health outcomes when used 
for secondary prevention in post AMI patients.  However, in many instances it is 
inappropriately prescribed in such patients.  There is evidence of under-prescribing in 
patients who should be prescribed, and there is some, although limited, evidence of 
prescribing in patients with contraindications.  Many studies have investigated the effect 
of under prescribing of therapy on mortality and morbidity.  However, these have 
examined data from clinical trials, which could be different from real life use or have 
investigated the elderly population in Medicare, which is a unique population segment.  
There has been very little literature examining the effects of this under prescribing on 
healthcare utilization and expenditures.  Additionally, literature that examines patient 
outcomes due to misuse of therapy is lacking.  Thus, there is a need to determine the 
effect of inappropriate prescribing on patient outcomes.  
In addition to examining the effects of inappropriate prescribing on patient 
outcomes, this study will also explore the association of physicians’ knowledge and 
willingness to prescribe beta-blocker therapy with their prescribing behavior.  Previous 
studies have found ample variation of medication use by physician characteristics 
(demographic, practice and knowledge).  However, there is a need to understand how 
these factors interact individually and in combination with prescribing behavior for beta-
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blockers post AMI.  An understanding of these physician factors would facilitate in 
developing and targeting educational efforts towards changing prescribing behavior to be 
consistent with the published guidelines. 
  
CONCEPTUAL FRAMEWORK 
  In Phase I, the study will evaluate the impact of appropriate and inappropriate 
prescribing of beta-blocker therapy by physicians, following an AMI, on patient 
outcomes and utilization of health services.  In Phase II, the study will determine 
physician-related factors that are related to beta-blocker prescribing in post-AMI patients.  
Phase I will involve the use of secondary data and Phase II will require primary data 
collection (Figure 1).  
 
Phase I 
 The following sections will describe the rational for selection of the Medicaid 
population for this study, cohort definition, classification of patients, risk adjustment and 
evaluation of patient outcomes that will be required for this phase of the study.  
 
Selection of Medicaid Population  
This study will examine and compare the effects of appropriate and inappropriate 
prescribing of beta-blockers therapy as a post AMI secondary preventive agent on patient 
outcomes in a Medicaid population.  Medicaid programs provide health insurance 
coverage to its members for physician visits, inpatient and outpatient hospitalizations,  
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Figure 1: Conceptual Framework 
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laboratory tests, nursing home care, family planning services and supplies, home health 
care and pharmaceuticals.  Thus, a retrospective analysis of Medicaid claims data can 
provide all necessary information about study patients in one place.  Also, the effect of 
post AMI beta-blocker use has not been previously investigated in this population.  While 
AMI has been established as a condition prevalent in the elderly, there is substantial 
evidence that it is common among younger people, too.  Consequently the age of the 
patient population (less than 65 years of age) is not as big a disadvantage.  In support, a 
recent study at the University of Michigan revealed that more than 1 in 10 patient with 
AMI is less than 46 years old. (Doughty, et al., 2002).  Specifically, data from the West 
Virginia (WV) Medicaid population will be utilized for Phase I of this study. 
 
Cohort Definition 
 The WV Medicaid program maintains data on each medical and pharmaceutical 
paid claim for its recipients from providers for health care services.  The data includes the 
date when the service was provided, type of service, amount paid, type of provider, and 
recipient number.  Information about utilization and expenditures for services for 
individual recipients can be retrieved for various time periods from the claims data.  For 
this study, paid claims data from January 1, 1996 to June 30, 2001 will be used.  All AMI 
patients who are less than 64 years of age and are not in managed care during the years 
1997, 1998, 1999, and up to June 30, 2000 will be extracted.  Recipients who are 65 years 
or older will not be included to avoid the issue of incomplete information since they will 
have Medicare as their primary payer for health services.  For similar reasons, patients 
who are part of managed care will also be excluded. 
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For this cohort of AMI patients, those patients whose information is missing after 
being initially present will be used to investigate the effect of appropriate or inappropriate 
beta-blocker prescribing on mortality.  Patients who have follow-up information and are 
continuously eligible for a period of 12 months after the incidence of AMI will be 
considered to study the effect of appropriate or inappropriate beta-blocker prescribing on 
morbidity and health care utilization.  The age-limit is set at 64 to avoid including those 
patients who will become eligible for Medicare, during the period of follow-up after 
being initially present.  Claims data for services, prescriptions, and hospitalizations for a 
period of one year before the incident AMI will be extracted for each patient.  This 
information will be used for risk adjustment of the patient, and to determine eligibility of 
the patient to receive beta-blockers after an AMI.  Therefore, for each patient being 
investigated for morbidity and health care utilization, there will be one year of data prior 
to the incident AMI and one year of data following the incident AMI (Figure 2).   
 
Classification of Patients 
 The AHA/ACC guidelines divide patients into three classes with respect to any 
therapy and/or procedure - Class I, Class II and Class III (ACC/AHA, 1996).  Class I 
includes those patients with conditions for which there is evidence and/or general 
agreement that the therapy is beneficial, useful, and effective.  Class II is sub-divided into 
IIa and IIb.  Class IIa includes patients with conditions for which the weight of 
evidence/opinion is in favor of usefulness/efficacy of therapy and Class IIb includes 
patients with conditions for which usefulness/efficacy of therapy is less well established 
by evidence/opinion.  Class III includes patients with conditions in the presence of which 
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there is evidence and/or general agreement that a therapy is not useful/effective, and in 
some cases may be harmful.  For beta-blocker therapy, Class I patients are non low-risk 
without a clear contraindication to beta-blocker therapy and survivors of non-ST-segment 
elevation (ACC/AHA, 1999).  Class IIa includes low-risk patients without a clear 
contraindication to beta-blocker therapy and survivors of non-ST-segment elevation 
AMI.  Class IIb are patients with moderate or severe left ventricular failure.  Patients with 
relative contraindications to beta-blocker therapy are also included in this class, provided 
they are monitored closely.  None of these patients belong to Class III.  Apart from the 
above classifications, these guidelines also state that high-risk patients would be those 
with evidence of large or anterior infarction.  Additionally, low risk patients include those 
without: previous infarction, anterior infarction, advanced age, complex ventricular 
ectopy, or hemodynamic evidence of LV systolic dysfunction.   
 Based on the above guidelines and recent reports, for all practical purposes 
patients can be classified as Class I, Class II and Class III for receiving beta-blocker 
prescription for secondary prevention following an AMI (ACC/AHA, 1999; Philips et al., 
2000).  A Class I and Class II patient for beta-blocker therapy at hospital discharge is one 
who has no absolute contraindications to therapy.  Patients with relative contraindications 
are also included in this category (Class II).  A patient would be Class III for beta-blocker 
therapy at hospital discharge if the patient has absolute contraindications to beta-blocker 
therapy.  For study purposes, patient data during the year before the incident AMI and at 
the time of the incident AMI will be utilized from claims for this classification.  
After classifying the patients into the afore-mentioned three categories, the 
prescription of beta-blockers during discharge can be determined from the prescription 
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claims data.  Based on appropriate and inappropriate prescribing criteria described above, 
the AMI patients in the study can be further divided into two groups - the appropriately 
prescribed and the inappropriately prescribed.  Patients who are classified as Class I and 
Class II and receive therapy and patients who are classified as Class III and do not 
receive therapy will be categorized as “appropriately prescribed”.  In contrast to this, 
patients who are classified as Class I and Class II and do not receive therapy and patients 
who are classified as Class III but receive therapy will be categorized as “inappropriately 
prescribed”.   
 
Risk Adjustment 
 In observational studies, investigators have no control over inherent risks that 
patients bring into the study.  Therefore, large differences on observed covariates in the 
selected groups may exist, and these differences can lead to biased estimates of 
outcomes.  An important statistical technique developed to overcome this kind of 
selection bias is estimation of propensity scores.  This method involves estimating the 
conditional probability of an event such as receiving specific therapy, on a treatment 
outcome, based on observable characteristics.  The propensity score calculated from 
observational characteristics of patients are then used to reduce bias and increase 
precision.  The three commonly used techniques that use propensity scores are matching, 
stratification (also called sub-classification), and regression adjustment (D’Agostinio, 
1998).  Each of these techniques is a way of making an adjustment for covariates prior to 
(matching and stratification) or during (stratification and regression adjustment) 
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calculation of the treatment effect.  While the method of calculation of the propensity 
score is the same in all three techniques, the application is different. 
In matching, control subject selection is based on whether they match with the 
treated subjects on background covariates that the investigator believes need to be 
controlled (D’Agostinio, 1998).  However, it is often difficult to find subjects similar in 
all important covariates even when there are only a few background covariates of interest.  
In stratification, the subjects are grouped into strata determined by the observed 
background characteristics (D’Agostinio, 1998).  Once strata are defined, treated and 
control subjects in the same stratum are compared directly.  The number of strata depends 
on the number of covariates.  For example, if all the covariates are dichotomous then 
there would be 2k subclasses for k covariates.  If k is large, then some strata might 
contain subjects from only the treated group, which would make it impossible to estimate 
a treatment effect in that stratum.  In regression adjustment, a large set of background 
covariates are used to estimate the propensity score, which is then used to adjust the final 
estimate of the treatment effect (D’Agostinio, 1998).  Here the investigator can include 
only a subset of the most important variables and the propensity score in the final model.  
 The proposed study involves two groups of patients, those that were appropriately 
prescribed beta-blocker therapy and those that were inappropriately prescribed beta-
blocker therapy.  Irrespective of whether the patients receive therapy appropriately or not, 
there are certain patient characteristics that affect prognosis and outcomes after an AMI.  
For example, a younger patient (age <50) is likely to have a better recovery from an AMI 
when compared to an older patient.  This would be true regardless of whether the patient 
received beta-blocker therapy appropriately or not.  Similarly, a patient who has had a 
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previous AMI would have a worse prognosis, and thus would have more adverse 
outcomes after an AMI.  There are a variety of such patient conditions and characteristics 
that affect patient outcomes after an AMI but are not related to beta-blocker prescribing.  
It is possible that patients in the two groups, appropriately prescribed and inappropriately 
prescribed, differ based upon these characteristics.  These characteristics require to be 
adjusted for patients before the effect of appropriate and inappropriate prescribing on 
outcomes can be determined.  Therefore, selection bias due to the inherent risk of patients 
in this study needs to be accounted for to get a more precise effect of 
appropriate/inappropriate prescribing of beta-blocker therapy on patient outcomes.  A 
propensity score that combines all background covariates will be utilized to adjust for 
differences in the study groups.  This propensity score can then be utilized in all the 
analysis where the effect of appropriate/inappropriate prescribing on patient outcomes 
will be assessed.   
The different characteristics which will be utilized in estimating this propensity 
score are demographic characteristics such as age, gender, and/or race; presence of 
relative contraindications for beta-blocker therapy; medical history such as presence of 
diabetes, hypertension, previous AMI, previous congestive heart failure, previous 
angioplasty or open heart surgery, stroke; procedures during the incident AMI such as 
percutaneous coronary transluminal angioplasty (PCTA), and coronary artery bypass 
graft (CABG); length of stay during incident AMI; other discharge medications such as 
aspirin, Angiotensin converting enzyme (ACE) inhibitors, calcium channel blockers, and 
loop diuretics; and use of beta-blockers before the incident AMI.  These characteristics 
have been demonstrated to affect outcomes for AMI patients (Soumerai et al., 1997).  
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Due to the large number of characteristics and conditions that need to be adjusted, 
regression adjustment would be the best method of applying the estimated propensity 
score.   
 
Evaluation of Outcomes 
Beta-blocker therapy when appropriately used for secondary prevention following 
an AMI has been demonstrated to reduce cardiovascular morbidity and mortality.  Thus, 
the selected cohort of appropriately prescribed and inappropriately prescribed patients 
will be followed to detect changes in cardiovascular mortality and morbidity related to 
the use of beta-blocker therapy.  Beta-blockers are associated with maximum reduction of 
risk for cardiovascular death and morbidity in the first few years after an AMI (Philips et 
al., 2000, Goldman et al., 1988).  The protective effect provided by beta-blockers has 
been reported to subside in the subsequent years.  In this study, the patients will be 
followed for a period of one year after the incidence of AMI.  Another reason for 
restricting the follow-up period to 1 year is that the number of continuously eligible 
patients decreases as the number of years increase.  Thus, when multiple years are 
involved, the number of patients in the cohort would be small and pose problems of 
power for statistical tests.    
Medicaid data contains information on the diagnostic and therapeutic procedures 
performed on all continuously eligible patients who have utilized health care services.  
Patients, who stop having information after being present in the system initially, do so for 
several reasons.  They may have become ineligible to receive Medicaid benefits, have 
moved away, or died (which can be confirmed with death certificate information 
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available from the WV Bureau of Vital Statistics and the National Death Index (NDI)).  
However, the unique ID of those patients with missing information during the follow-up 
period can be used to determine the actual reason for the missing information.  If the 
person with the missing information is confirmed to be dead from Vital Statistics records, 
the cause of death can be obtained from their death certificates.  If the cause is related to 
cardiovascular illness such as an AMI, heart failure, stroke, angina, other forms of 
ischemia, essential hypertension, coronary artery disease/artherosclerosis or cardiogenic 
shock, these patients will be involved in investigating the effect of 
appropriate/inappropriate prescribing of beta-blockers on mortality using survival 
analysis.  An increase in mortality in the inappropriately prescribed group will be proof 
of poor outcomes in this group.   
Among patients with follow-up information, those eligible in the 12-month period 
after the incident AMI will be examined for morbidity and the extent of health care 
utilization.  Claims associated with cardiac conditions and procedures will be extracted to 
study outcomes in the follow-up period.  An increase in cardiac conditions for the 
inappropriately prescribed group compared to the appropriately prescribed group will 
provide evidence of poor outcomes associated with morbidity for this group.  The various 
patient characteristics that affect treatment outcomes will be adjusted for by using them 
to estimate a propensity score.  This score along with group status (inappropriate or 
appropriate) can then be included in a survival analysis where the dependent variable will 
be the time to first hospitalization due to an event.  Here the event will be any 
cardiovascular event such as a successive AMI, heart failure, stroke, angina, and other 
forms of ischemia, essential hypertension, cardiogenic shock, disease of endocardium, 
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conduction disorders, or cardiomyopathy.  In addition to the incidence of these conditions 
in the follow-up period, survival analysis will be used to evaluate the distribution of the 
time to incidence of these events.  Studying the distribution of incidence will give a better 
idea about the effect of appropriate and inappropriate beta-blocker prescribing on 
outcomes.  This is preferable to assessing differences in patients outcomes based on 
number of incidence of morbidity data alone. 
Similarly, to study the effect on healthcare service utilization for the above 
mentioned cardiac conditions, the number of physician visits, hospitalization episodes, 
length of stay, and emergency room visits will be compared between patients in the 
appropriately prescribed and inappropriately prescribed cohorts.  The hypothesis is that 
there is no difference in utilization of these services between the inappropriately 
prescribed group and the appropriately prescribed group.  Regression analysis will be 
conducted with each of these utilization-related variables with group status as the 
independent variable.  Patient characteristics that affect treatment outcomes will be 
adjusted for by using the propensity score as a co-variate.  Regression analysis is a better 
way to compare these utilization-related variables as it allows for adjustment of multiple 
patient factors compared to other methods such as analysis of variance (ANOVA). 
  
Phase II  
 
The purpose of phase II of the study is to determine physician-related factors that 
are associated with prescribing of beta-blockers for secondary prevention of cardiac 
problems after an AMI.  This phase of the study will involve surveying physicians in the 
specialties of cardiology, internal medicine, family practice and general practice in the 
state of WV (Figure 3).  
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The target physicians will be sent a survey that measures the following: 
knowledge about contraindications to beta-blocker therapy, willingness to prescribe beta-
blockers, practice characteristics and socio-demographics.  One major reason for the non-
prescribing of beta-blockers in patients without contraindications is that internists and 
family practitioners have been shown to be less aware or less certain than cardiologists of 
the cardiovascular medical advances established through clinical trails (Bradford et al, 
1999).  Thus, the survey will be designed to assess physicians’ knowledge about 
contraindications for beta-blocker therapy post-AMI, to determine whether or not there 
are differences in knowledge when compared by specialty.  Specifically, they will be 
compared for (1) knowledge of absolute contraindications when therapy with beta-
blocker should not be initiated; and (2) knowledge of relative contraindications when 
therapy with beta-blockers can be, and should be, initiated.   
In addition to knowledge, physician willingness to prescribe beta-blocker therapy 
for post AMI patients will be explored.  A section will be dedicated to inquire about 
physicians’ willingness to prescribe beta-blockers as post-AMI therapy in patients with 
different ailments. 
The last section of the survey will focus on socio-demographic and practice 
characteristics.  These have been reported to affect the provider’s knowledge, beliefs, and 
practice (Ayanian et al., 1994).  Specific characteristics reported include age, gender, 
specialty of practice, year of board certification in the primary field of practice, number 
of patients treated within a specific time, number of beds at practice site, and whether 
practice site is associated with teaching status.   
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Physician prescribing behavior for beta-blockers will be determined by asking the 
respondents to recall the number of AMI patients that they prescribed long-term beta-
blockers for secondary prevention, out of the last 10 AMI patients treated.  Percent 
prescribing rate will be calculated based on the response of the physicians [i.e. 
(response/10)*100].  This will be used as a proxy for prescribing behavior.  Though this 
is not the best method of measuring prescribing behavior, questions which ask the 
respondents the average number of post-AMI patients prescribed beta-blocker in the past 
month or longer duration of time will involve higher recall bias and thus may be 
unreliable.  Also, whether the prescribing of the physicians for the last 10 patients was 
appropriate or inappropriate cannot be determined through a survey.  This is because 
prescribing is unique for every patient and depends on patient co-morbidties.  To obtain 
detailed information for each individual patient would involve a very lengthy survey, 
which can increase burden for the respondents for time of completion and effort to recall 
each specific case.  This can also result in a very low response rate.  Thus, given the time 
and resource constraints this method of getting a proxy for prescribing behavior appears 
to be the best. 
The association of this estimated prescribing rate or the proxy prescribing 
behavior will be statistically investigated with knowledge of contraindications, 
willingness to prescribe and physicians socio-demographic and practice characteristics, 
individually and in combination.  A sub-analysis will also be conducted to determine the 
association of socio-demographic and practice characteristics on physicians’ knowledge 
of contraindications and willingness to prescribe.  Thus, this phase of the study will give 
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a better understanding of the role of physician characteristics that affect their prescribing 
behavior.  
 
STUDY GOALS, AND RESEARCH QUESTIONS 
Phase I 
The overall goal of phase I is to study prescribing patterns of beta-blocker therapy 
in Medicaid patients following an AMI and its effect on patient outcomes.  Specific 
research questions necessary to achieve this goal are as follows: 
 
Research Question 1:  
To what extent do physicians adhere to AHA/ACC guidelines for appropriate beta-
blocker therapy for secondary prevention in patients who have had an AMI in the WV 
Medicaid program? 
Rationale: This is an exploratory question to assess the prescribing of beta-blockers in 
the WV Medicaid population with regards to published guidelines and to classify them as 
appropriate or inappropriate.  Medicaid patients have not been studied before for such an 
investigation.  Thus, it would determine whether or not prescribing of beta-blockers in 
post-AMI Medicaid patients is similar to those reported in other patient populations such 
as the elderly (Medicare), and those in managed care.   
 
Research Question 2: 
What is the relationship between appropriate and inappropriate prescribing of beta-
blockers following an AMI and all cause and cardiac mortality in WV Medicaid? 
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Null Hypothesis A: There is no difference in all cause mortality rates between AMI 
patients who receive appropriate beta-blocker therapy and those who receive 
inappropriate beta-blocker therapy for secondary prevention.  
Null Hypothesis B: There is no difference in cardiac mortality rates between AMI patients 
who receive appropriate beta-blocker therapy and those who receive inappropriate beta-
blocker therapy for secondary prevention. 
 
Research Question 3: 
What is the relationship between appropriate and inappropriate prescribing of beta-
blockers following an AMI and subsequent morbidity due to the following conditions in 
the WV Medicaid program (irrespective of whether they suffered from these conditions 
prior to the AMI under consideration)? 
- Angina 
- Cardiogenic shock 
- Disease of endocardium, conduction disorders & cardiomyopathy 
- Essential hypertension 
- Heart failure 
- Other ischemic disease 
- Stroke 
- Successive or recurrent AMI 
Null Hypothesis C: There is no difference in cardiovascular morbidity between AMI 
patients who receive appropriate beta-blocker therapy and those who receive 
inappropriate beta-blocker therapy for secondary prevention.  
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Research Question 4: 
What is the relationship between appropriate and inappropriate prescribing of beta-
blockers following an AMI and utilization of health care services (physician services, 
hospitalization services, hospital length of stay, ER visits) and expenditures due to the 
following conditions in WV Medicaid (irrespective of whether they suffered from these 
conditions prior to the AMI under consideration)? 
- Angina 
- Cardiogenic shock 
- Disease of endocardium, conduction disorders & cardiomyopathy 
- Essential hypertension 
- Heart failure 
- Other ischemic disease 
- Stroke 
- Successive or recurrent AMI 
Null Hypothesis D: There is no difference in utilization of services due to the above listed 
conditions between AMI patients who receive appropriate beta-blocker therapy and those 
who receive inappropriate beta-blocker therapy for secondary prevention.  
Null Hypothesis E: There is no difference in costs due to the above listed conditions 
between AMI patients who receive appropriate beta-blocker therapy and those who 
receive inappropriate beta-blocker therapy for secondary prevention. 
 
Phase II 
The goal of phase II is to determine how physician characteristics such as 
knowledge, willingness to prescribe, demographic and practice characteristics, and 
interactions of these different characteristics affect their prescribing behavior for beta-
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blockers as secondary preventive agents after an AMI.  Specific research questions for 
this phase are as follows: 
 
Research Question 5:  
How does WV physicians’ knowledge of absolute and relative contraindications of beta-
blocker therapy affect their self-reported prescribing behavior of this therapy as a 
secondary preventive agent following an AMI? 
Null Hypothesis F: There is no relationship between knowledge of absolute and relative 
contraindications of beta-blocker therapy and physician prescribing behavior of this 
therapy as a secondary preventive agent. 
 
Research Question 6:  
How does WV physicians’ willingness to prescribe beta-blocker therapy affect their self-
reported prescribing behavior of this therapy as a secondary preventive agent following 
an AMI? 
Null Hypothesis G: There is no relationship between WV physicians’ willingness to 
prescribe beta-blocker therapy and their prescribing behavior of this therapy as a 
secondary preventive agent following an AMI. 
 
Research Question 7:  
How does demographic (age, gender, location, year of graduation) and practice 
(specialty, affiliation, size of primary practice hospital) characteristics of WV physicians 
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affect their self-reported prescribing behavior of beta-blocker therapy as a secondary 
preventive agent following an AMI? 
Null Hypothesis H: There is no relationship between demographic and practice 
characteristics of WV physicians and their prescribing behavior of beta-blocker therapy 
as a secondary preventive agent following an AMI. 
 
Research Question 8:  
How does demographic (age, gender, location, year of graduation) and practice 
(specialty, affiliation, size of primary practice hospital,) characteristics of WV physicians 
affect their knowledge and willingness to prescribe beta-blocker therapy as a secondary 
preventive agent following an AMI? 
Null Hypothesis I: There is no relationship between demographic and practice 
characteristics of WV physicians and their knowledge of absolute and relative 
contraindications of beta-blocker therapy as a secondary preventive agent following an 
AMI. 
Null Hypothesis J: There is no relationship between demographic and practice 
characteristics of WV physicians and their willingness to prescribe beta-blocker therapy 
as a secondary preventive agent following an AMI. 
 
Research Question 9:  
Which factors among physician demographic and practice characteristics, physicians’ 
knowledge of beta-blocker contraindications, and willingness to prescribe them, are the 
best predictors of their self-reported prescribing behavior of beta-blocker therapy as a 
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secondary preventive agent following an AMI? (This simultaneously controls for all 
aspects described in research question 5, 6 & 7). 
Null Hypothesis K: There is no association between WV physicians’ prescribing of beta-
blocker therapy as a secondary preventive agent following an AMI and physician factors 
(demographic and practice characteristics, knowledge of beta-blocker contraindications, 
and willingness to prescribe). 
 
Research Question 10:  
What are the reasons reported by physicians for not prescribing beta-blockers in post-
AMI patients? 
Rationale: A previous study reported reasons such as adverse effects, exaggerated 
concerns for relative contraindications and commercial influences of pharmaceutical 
companies as reasons for under prescribing of beta-blockers as post-AMI medications 
(Kennedy & Rosensen, 1995).  This research question is a follow-up on this report to 
determine whether the reasons for not prescribing beta-blockers in post-AMI patients are 
the same or have changed over the years. 
 
STUDY SIGNIFICANCE 
In Phase I, the effect of appropriate/inappropriate prescribing of beta-blockers by 
physicians on patient outcomes following an AMI will be evaluated in this study.  In 
Phase II, physician characteristics that affect prescribing behavior of beta-blocker therapy 
post AMI will be determined.  Information from Phase I will help in identifying 
consequences of inappropriate prescribing if any, such as mortality, morbidity, health 
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care utilization (hospitalization, ER visits, and physician visits) and health care 
expenditures from a payer’s perspective.  Based on past studies, it is hypothesized that 
inappropriate use may increase mortality and morbidity in those patients and 
consequently increase health care utilization and expenditures.  This is vital information 
from a payer’s perspective because it provides information about both the quality of care 
provided to its members as well as cost-efficiencies within the financing of the system.  
Beta-blockers are a very inexpensive way of ensuring the quality of care by reducing 
mortality and morbidity received by post-AMI patients, and concurrently reducing costs 
due to unnecessary health care services utilization.  This is a good example in which 
improving the quality of care and reducing costs are not competing interests.  The above 
concerns are especially important from the perspective of a Medicaid program, which is a 
public health insurance program and supported by federal and state tax dollars.   
Phase II will help in understanding physician related factors that are associated 
with prescribing of beta-blocker therapy following an AMI.  This information can be 
utilized in designing active interventions to meet specific needs such as group or one-on-
one education, and individual outreach visits.  Implementation of these active 
interventions will have better results in comparison to passive interventions such as 
dissemination of printed materials, reminders at the time of prescribing, and formulary 
control, which do not involve physician input (Figueiras, Sastre & Gestal-Otero, 2001).  
Therefore, these active interventions may be more successful in improving prescribing 
behavior of physicians for secondary prevention following an AMI with beta-blockers, 
and more likely to lead to better adherence of guidelines.   
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Identifying the consequences of inappropriate beta-blocker use and the factors 
contributing to physicians prescribing of beta-blockers are the first steps towards 
improving quality of care provided to AMI patients.  While quality concerns by itself is a 
strong reason, reducing the avoidable health care utilization and expenditures is also vital 
to a system that is facing ever-increasing costs. 
 
STUDY LIMITATIONS  
The limitations of each phase of the study are discussed below: 
In Phase I, the limitations are associated with the data being used.  Medicaid data 
does not include utilization claims for individuals aged 65 years and over and these 
patients will not be a part of the study cohort.  Patients who are a part of managed care 
will also be excluded due to lack of utilization claims data.  Furthermore, patients who do 
not have continuous eligibility during the study period will be excluded.  These selection 
criteria will exclude a significant portion of the Medicaid recipients.  Thus, whether the 
effect of inappropriate prescribing is different for the excluded group cannot be 
determined and is beyond the scope of this study.  Also, AMI is a condition more 
predominant in the elderly.  Thus, when a younger group such as Medicaid patients is 
used to study this condition, the number of patients in the study will be relatively lower 
when compared to previous studies that involved the elderly.  This may pose problems 
with power and effect size when complex statistical analyses are involved.  Also, younger 
patients with AMI will have better prognosis than older patients, thus results from this 
study may not be extended to older patients.   
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Another limitation is the fact that demographic characteristics of people from 
West Virginia may not necessarily be similar to demographic characteristics of other 
states.  Therefore, results may not be generalized to other states.  The study will use 
claims data and this does not allow adjusting for all the contraindications for beta-
blockers, as some of them do not have an ICD-9 (International classification of disease, 
9th edition) code.  For example, peripheral hypoperfusion, intolerance or allergies to beta-
blockers are relative contraindications which cannot be identified.  However, ICD-9 code 
for peripheral vascular disease can be used as a proxy for patients with peripheral 
hypoperfusion and the percentage of patients allergic to beta-blockers has been reported 
to be low ranging from 7.7% to 12.5% in previous studies (Phillips et al., 2000).  Some of 
the attributes which classify patient risk levels can be identified only from patient charts 
and are not coded in patient claims.  Therefore, true risk levels of the patients cannot be 
identified through claims data and thus the study will be unable to adjust for severity of 
the AMI.  Since claims data is being used to determine presence and absence of 
conditions, errors due to billing and coding cannot be ruled out.  Also, the study will not 
be able to consider the effect of other possible confounding factors such as obesity, 
smoking, or other life-style related conditions, which are not included in claims data.  
Some of the limitations of Phase II are inherent due to the cross-sectional study 
design method of data collection i.e. mail survey.  Factors that affect prescribing behavior 
such as disease severity, multiple co-morbidities, and patient choice will not ascertained 
through the survey used, and thus cannot be included in the analysis.  A major limitation 
is that prescribing percent, which is the proxy for prescribing behavior, will be computed 
based on last 10 patients treated and may not be representative of the physicians 
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prescribing behavior in general.  Also, prescribing percent calculated will not reflect 
whether prescribing was appropriate or inappropriate.  Thus, in reality association of 
physician related factors with prescribing percent will be investigated and not their 
association with appropriate and inappropriate prescribing percent. 
Mail surveys usually have a response rate between 30-40 percent (Dillman, 1978).  
Hence, generalization of the results obtained to those who did not respond may be 
limited.  There exists a lack of control over item non-response in mail surveys.  Mail 
surveys are insensitive to substitution of respondents, thus whether the physician 
answered the survey or someone else cannot be determined.  The questions in the survey 
can be interpreted differently by different respondents and thus it can fail to provide 
standardized understanding of survey questions among respondents.  Other limitations 
such as recall bias, and limitations to recall, may also exist for the section associated with 
knowledge and prescribing behavior. 
 
This chapter gave a brief introduction to the problem, the need, the research 
questions, and the significance of the study.  The next chapter will give a extensive 
review of the existing literature associated with AMI, and beta-blocker therapy.  
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CHAPTER TWO 
REVIEW OF LITERATURE 
 
This literature review will provide a background to understand – acute myocardial 
infarction (AMI), beta-blocker drug therapy, their effectiveness, recommendations for 
their use, variation in their use, implications of this variation in use and the physicians 
role in this variation of use.  The final section in the chapter will provide a brief 
description of the Medicaid program and West Virginia (WV) Medicaid, the sample 
frame for this study.   
 
Acute Myocardial Infarction  
 Acute Myocardial Infarction (AMI) is the death of heart muscle due to the loss of 
blood supply (Bellenir, 2000).  This loss of blood supply is usually caused by a complete 
blockage of a coronary artery by a blood clot.  Coronary arteries are blood vessels, which 
supply blood to the heart muscle.  Coronary artery disease (CAD) is the primary 
underlying process that leads to AMI (Stringer & Lopez, 1999).  Cholesterol, a fatty 
chemical, is a part of the outer lining of cells in the body.  Cholesterol plaque is the 
formation of a hard, thick substance on the artery walls, which is caused by the 
deposition of cholesterol on the artery walls, a process that begins early in life.  With 
time, this accumulation causes thickening of the artery walls and narrowing of the 
arteries, a process called as atherosclerosis.  Plaque accumulation can be accelerated by 
specific risk factors such as hypertension, diabetes mellitus, smoking, and 
hyperlipidemia.  Atherosclerosis can progress and cause significant narrowing of the 
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coronary arteries.  These narrowed arteries cannot increase the blood supply to meet the 
increase in oxygen demand by the heart muscle during exercise or excitement.  This 
condition called ischemia gives rise to chest pain or angina.  However, this is not the 
etiology of AMI.  The surface of a cholesterol plaque can become sticky due to a rupture 
or fissure, precipitating thrombus formation.  When a blood clot forms on top of this 
plaque, the artery becomes completely blocked, causing the death of the heart muscle or 
AMI.  
Pain or pressure in the chest is a common symptom of AMI (Bellenir, 2000).  
AMI’s most frequently occur from 4 AM to 10 AM due to high adrenaline amounts 
released from the adrenal glands during the morning hours.  AMI’s do not usually occur 
during exercise, although exercise is commonly associated with angina.  About one-
fourth of AMI’s are silent, without chest pain.  In addition to chest pain, patients may 
complain of sweating, jaw pain, heartburn, arm pain, indigestion, back pain, general 
malaise, nausea and shortness of breath.   
 
Diagnosis 
 Initial diagnosis is made by a combination of clinical symptoms and 
electrocardiogram (EKG) changes (Bellenir, 2000).  An EKG is a recording of the 
electrical activity of the heart and can detect areas of muscle deprived of oxygen and /or 
dead tissue in the heart.  However, confirmation of an AMI can only be made hours later 
through detection of elevated creatinine phosphokinase (CPK) in the blood.  CPK is 
muscle enzyme released into the blood by dying heart muscles when their surrounding 
membranes dissolve. 
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Treatment 
 The primary goal of the treatment is to open the blocked arteries and restore blood 
flow to the heart muscles, called as reperfusion (Bellenir, 2000; Stringer & Lopez, 1999).  
Once the artery is open, the patient becomes pain free.  Early reperfusion minimizes the 
extent of damage to the heart muscle and preserves its pumping function.  Delay in 
reperfusion can result in irreversible death to the heart muscle cells and may reduce the 
pumping force of the remaining heart muscle.  The future quality of life and longevity for 
the patients depends on the amount and health of the remaining heart muscle. 
The fastest method of opening a blocked artery is to perform a percutaneous 
transluminal coronary angioplasty (PTCA).  Here a tiny plastic catheter with a balloon at 
the end is advanced over a fine guide wire to the site of blockage and inflated, under X-
ray guidance.  This pushes the plaque and clot out of the way.  PTCA can be effective in 
opening up to 95% arteries within 60 minutes.  Medications if given early are also 
effective in opening arteries.  Clot dissolving medications also called as thrombolytic 
agents such as tissue plasminogen activator (t-PA) and Streptokinase are given 
intravenously.  These are reported to open 80% of the blocked arteries within 90 minutes.   
Anti-platelet agents, such as aspirin, reduce platelet clumping and clot-formation.  
This decreases the recurrent closure of artery and improves the chances of survival.  
Anticoagulant agents, such as heparin, given intravenously, act as a blood-thinning agent 
and prevent blood clots and maintains the artery open during the initial 24 hours.  
Nitroglycerin, a vasodilator, is given either under the tongue or intravenously, to prevent 
blood vessel spasm and minimize the area of the heart attack.  Angiotensin-converting 
enzyme (ACE) inhibitors are given orally after an AMI to improve the heart muscle 
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healing process.  Beta-blockers act as antiarrhythmic and are given either intravenously 
or orally to decrease the magnitude of infarction and incidence of associated 
complications and the rate of infarction in patients (Bellenir, 2000).  Other 
antiarrhythmics such as lidocaine, amiodarone, procainamide can also be used.  Other 
classes of drugs such as calcium channel blockers, e.g. nifedine, verampil and inotropic 
agents such as digitalis may also be used [American College of Cardiology 
(ACC)/American Heart Association (AHA), 1996].  When PTCA and medications fail to 
achieve reperfusion or maintain open arteries, patients are subjected to coronary artery 
bypass graft (CABG) surgery (Bellenir, 2000).   
Patients are monitored in the hospital for 3-6 days prior to discharge.  Rhythm 
disturbances, shortness of breath, or recurrent pain are indications for further therapy 
either through PTCA, medications, or bypass surgery (Bellenir, 2000).  Patients gradually 
increase their activity under observation.  Before discharge, stress tests are useful for 
detecting any narrowing in the coronary arteries, rhythm changes, and heart muscle 
failure.  These also help in prescribing discharge medications.  Several weeks are needed 
for the heart to heal before resuming full activity. After a small AMI, patients can resume 
normal activities after 2 weeks.  A moderate AMI requires gradual increase in activity 
after 4 weeks while a large AMI needs up to 6 weeks for recovery.  During this time 
patients should avoid vigorous exertion and heavy lifting or activities which cause 
shortness of breath or sweating.   
 After initial recovery, patients are required to take medications to prevent a 
second AMI (ACC/AHA, 1996).  These usually include aspirin, beta-blockers, ACE 
inhibitors, lipid lowering drugs, anticoagulants, and nitroglycerine.  Additionally, patients 
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are required to quit smoking, reduce weight and dietary fat consumption, control blood 
pressure and diabetes, reduce serum cholesterol and follow a regular prescribed exercise 
regime (ACC/AHA, 1996). These measures are known to improve quality of life and 
longevity after an AMI.  Achievements of treatment goals can be facilitated through 
participation in formal cardiac rehabilitation program or home rehabilitation if patient is 
motivated (ACC/AHA, 1996).  Cardiac rehabilitation combines prescriptive exercise 
training with education about coronary risk factor modification techniques.  Formal 
rehabilitation programs have been shown to effectively improve functional capacity, 
promote compliance, decrease emotional distress, improve quality of life, reduce 
cardiovascular mortality, mitigate ischemic symptoms, promote reversal of 
atherosclerosis, and reduce risk of future coronary events.   
 
Beta-Blocker Therapy 
 Beta-blockers exert an effect by blocking beta-receptors (Khan, 2000).  
Structurally they resemble catecholamines.  Beta-blockers are competitive inhibitors, 
their action depending on the ratio of beta-blocker concentration to catecholamine 
concentration at the beta-receptor sites.  Beta-receptors are sub-divided into two types: 
the beta1-receptors present mainly in the heart and intestine and beta2-receptors present 
mainly in the bronchial and vascular smooth muscles.  Thus, beta-blockers can be divided 
into cardioselective and non-cardioselective.  Cardioselectivity implies that the drug 
blocks chiefly the receptors on the heart muscle and therefore partially spares the 
receptors on the lungs and blood vessels.  However, selectivity may be lost at higher 
doses precipitating bronchospasm in susceptible individuals.  Beta-blockers can also be 
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divided based on the presence of intrinsic sympathomimetic activity (ISA).  Intrinsic 
sympathomimetic activity (ISA) indicates partial agonist activity.  Beta-blockers with 
ISA cause a slightly lower incidence of bradycardia compared with non-ISA drugs.  
However, this carries little or no advantages in angina at rest, or in angina at low exercise 
levels.  This could, on the other hand, produce adverse effects on ventricular fibrillation 
threshold.   
 Physiologically, when used for AMI, beta-blockers rapidly reduce systolic blood 
pressure and there is reduction in cardiac output (Plosker & Clissold, 1992).  However, 
several weeks of therapy are required to achieve the maximum reduction in diastolic 
pressure and this reduction appears to result from a gradual decrease in total peripheral 
resistance (Benfield, Clissold, & Brodgen, 1986).  In addition to decreasing systemic 
arterial pressure, beta-blockers also decrease heart rate and contractility (Olsson, Ablad & 
Ryden, 1990).  They are known to reduce myocardial oxygen demand (ACC/AHA, 
1996).  Prolongation of diastole due to heart rate reduction probably facilitates blood flow 
through poorly perfused regions of the myocardium (Plosker & Clissold, 1992).  They 
delay cardiac ventricular repolarization, slow conduction velocity through the 
atrioventricular (AV) node, increase sinoatrial node recovery time and decrease 
automacity (Edvardsson & Olsson, 1981; Camm, Ward & Whitmarsh, 1982; Frishman & 
Silverman, 1979; McDevitt, 1983).  In accord with their electrophysiological effects, 
beta-blockers have shown antiarrhythmic activity in post myocardial infarction patients 
(Murray, Murray & Little, 1986; Olsson & Rehnqvist, 1984).  They also involve 
prevention of the final thrombo-embolic process and/or progression of atherosclerotic 
lesions (Linden, Carmejo, Wilkund, Warnold, Olofsson & Bondjers, 1988).  A decrease 
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in ejection velocity reduces hydraulic stress on the arterial wall, and this action may 
reduce the incidence of plaque rupture and thus protect from coronary thrombosis and 
fatal or non-fatal infarction (Khan, 2000).  Beta-blockers may prevent early morning 
platelet aggregation induced by catecholamines, and decrease the early morning peak 
incidence of an AMI (Khan, 2000).  They may also cause structural changes in plasma 
low density lipoprotein (LDL) resulting in a reduction of its potential for deposition in the 
arterial wall (Linden, Carmejo, Wilkund, Warnold, Olofsson & Bondjers, 1988).  These 
additional beneficial effects are believed to decrease the incidence of cerebrovascular 
complications and new myocardial infarctions, thus providing clinical efficacy.  
 Beta-blockers have certain side effects on the different systems it interacts with.  
Thus, in the cardiovascular system it can precipitate heart failure, atrioventricular (AV) 
block, hypotension, severe bradycardia, intermittent claudication, cold extremities, 
Raynaud’s phenomenon and dyspnea.  Dizziness, weakness, fatigue, vivid dreams, 
insomnia, and rare loss of hearing are central nervous system (CNS) side effects.  Other 
side effects include nausea, vomiting, bronchospasm, respiratory distress, skin rashes, 
decreased libido and impotence (Khan, 2000).  
 
Effectiveness of Beta-Blockers for Post AMI 
 Fifteen major randomized controlled trials of beta-blocker therapy administered 
after AMI were reported between 1974 and 1990 (Frishman & Cheng, 1999).  The mean 
follow-up time for these extended from 24 hours to six years.  More than 18,000 patients 
with AMI were studied to document reductions in total deaths, cardiovascular death, 
coronary death, sudden death, and nonfatal re-infarction.  The time between onset of AMI 
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and initiation of treatment ranged from less than 24 hours to approximately 7.5 years.  
Patients with low and intermediate risk were studied in 12 of these trials whereas three 
trials involved patients with high risks.  Results from 12 of the 15 long-term trials showed 
a lower mortality rate in the beta-blocker groups than the control groups.  In three of the 
largest studies, the reduction in mortality rates was statistically significant, whereas in the 
remaining nine trials the results were not conclusive with regard to overall deaths.  By 
combining the results of all 15 beta-blocker trials, a mortality rate reduction of 
approximately 21% was calculated.  In eight trials that evaluated sudden cardiac death, 
lower rates were observed in the treatment groups.  These trials yielded a trend of greater 
overall reduction in sudden cardiac deaths compared to all-cause deaths.  An even larger 
benefit was recorded for instantaneous deaths, with an average reduction of 47%.  Ten of 
the 11 trials reporting the incidence of nonfatal re-infarction showed lower rates in the 
treatment groups compared to the control groups, however in only one of these trials, this 
was statistically significant.   
 In addition to these major randomized clinical trials, there have been various 
reviews and reports to study effectiveness of beta-blockers.  A meta-analysis of about 65 
studies, including long-term and short-term treatment with beta-blocker therapy was 
conducted by Yusuf et al., (Yusuf, Peto, Lewis, Collins & Sleight, 1985).  The overall 
results for the short-term trials demonstrated an effect on infarct size and on arrhythmias.  
However, a 6% risk reduction in mortality was found in the treatment group.  This small 
difference did not reach statistical significance due to inadequate numbers in the 
randomization process.  The long-term component included results of eight randomized 
trials, involving over 3,000 patients.  Therapy was started orally a few days or weeks 
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after myocardial infarction and continued for a period of some months or years thereafter.  
A crude overview of the results of these studies suggested a risk reduction of about 20%.  
After weighting the average of the relative risks reduction, a pooled relative risk estimate 
of 0.77 was obtained.  Though the trials had adequate numbers to demonstrate a main 
effect, it was not possible to select out sub-groups (defined by age, site, or severity of 
disease) of patients among whom therapy was advantageous and subgroups among whom 
it was not.  To elucidate the mechanism by which death was prevented, deaths were 
classified as sudden and non-sudden based on time to death from the onset of pain.  In 
several of the studies, reductions in sudden death were statistically significant with odds 
reduced by about 30%.  Not all trials reported the frequency of nonfatal re-infarction.  
Among those which did, treatment with long-term beta-blockers reduced the odds of re-
infarction by about one-fourth and this was enormously significant (P<.0001).  The meta-
analysis concluded that long-term beta-blockade for perhaps a year or so following 
discharge after an AMI would reduce the odds of death and re-infarction by about 25%.  
Differences among benefits of different beta-blockers were not apparent and side effects 
of therapy, being reversible by changing the beta-blocker or discontinuation of treatment, 
were not considered to be a major problem.   
 Hjalmarson conducted a review of data from five clinical trials that dealt with 
early and late interventions with beta-blockers following an AMI (Hjalmarson, 1988).  
Two of these trials, the Norwegian (NMS- Norwegian Multicenter Study) and the 
Goteborg, examined the effects of prophylactic use of beta-blocker therapy.  The 
Norwegian trial had a 2-year follow-up with timolol as the beta-blocker and demonstrated 
a 36% reduction in mortality.  The Goteborg trial also demonstrated a 36% reduction in 
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mortality with metoprolol as the beta-blocker, however it involved a 3-month follow-up 
period.  The American Beta-blocker Heart Attack Trial (BHAT) reported a 26% 
reduction in mortality and involved propranolol as the beta-blocker.  Effect of early 
intervention was also assessed in the Goteborg trial, which reported a 35% greater 
reduction in mortality within the first two weeks.  The other two trials in this review were 
Metoprolol In Acute Myocardial Infarction (MIAMI) and the First International Study of 
Infarct Survival (ISIS) trial.  Both of these involved large numbers of patients, 
investigated early intervention and had lower differences in mortality as compared to the 
Goteborg trial in the range of 13-14%.  The reason mainly being that the trials included 
more low-risk patients, fewer older patients and fewer patients with pre-existing cardiac 
complications.  The percent of patients withdrawn from these trials ranged from 19 to 
29%, and the reasons for withdrawal were presence of hypotension and/or bradycardia.   
 The above two reviews were restricted to reports from major trials.  Goldstein 
reviewed 89 separate studies that addressed the effect of beta-blockers in heart disease 
generally (Goldstein, 1996).  In these, 19 focused specifically on outcomes following an 
AMI.  This review was more recent than the meta-analysis conducted by Yusuf et al., and 
reported average effects for late application of beta-blockers following AMI similar to 
those reported by Hjalmarson.  In addition to overall mortality, this review reported 
reduction in cardiovascular mortality, re-infarction rate and sudden death due to beta-
blocker use following an AMI.  Data indicated that the beneficial effects of oral beta-
blocker therapy were maintained for at least six years after an AMI, and discontinuation 
was associated with accelerated mortality.  A trial involving late intervention in patients 
deemed high risk indicated a 48% decrease in overall mortality and a 58% decrease in 
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vascular mortality.  Analysis on subgroups identified by increasing mortality risk 
revealed mortality benefits from a low 2% to a high 23%.  Subgroup analysis was also 
conducted on data from trials, for high-risk patients such as those with congestive heart 
failure (CHF), elderly patients and patients with diabetes.  Beta-blockers had a more 
marked effect in decreasing sudden death in those with CHF.  It clearly illustrated that 
absolute benefits of treatment in older patients were greater than those achieved in 
younger patients.  Additionally, for patients with diabetes the reduction in mortality was 
greater, (22-48%) compared to patients without diabetes, (4-29%).  Thus, higher benefits 
accrue to patients who are at higher risk of mortality.  It is important to consider the fact 
that in all of these studies the proportion of the AMI population determined to be eligible 
for beta-blocker therapy varied significantly in every study.  Hjalmarson reported that 14-
18% of patients were excluded from treatment in the Norwegian, Goteburg and the 
American trials because of contraindications.  However, the specific contraindications 
were not mentioned in this review.  Agusti et al., reported that 23% of the patients in their 
study had contraindications and these were history of chronic obstructive bronchitis, 
intermittent claudication, heart failure and permanent AV block (Agusti, Arnau & 
Laporte, 1994).  Another study, which mentioned specific contraindications, was by 
Whitford and Southern (Whitford & Southern, 1994).  The contraindications specified 
were ‘active reversible airway disease, heart block, and heart failure’.  This deemed 45% 
of the patients ineligible for therapy. 
An examination of the data from BHAT was done by Furberg and Byinton 
(Furberg & Byinton, 1983) wherein they examined the difference in outcomes between 
patients in the tails of the distribution of expected mortality risk.  They found a relative 
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risk reduction of 40% in the group receiving beta-blocker agents in this limited set.  
Olsson et al., took a different approach (Olsson, et al, 1992).  They collected individual 
patient level data from five randomized trials and analyzed the pooled data.  They found a 
relative risk of mortality reduction of 19% overall.  A higher benefit to women (23%) 
was observed compared to men (16%).  The reduction in total mortality was mainly due 
to reduced sudden cardiac deaths.  Additionally, beneficial effect of drug was not 
influenced by risk factors such as age, sex, and smoking habits.  Thus, treatment effects 
were observed both in high and low risk patients.  However, pooling data from different 
studies involves limitations, as each study involved different treatment protocols, 
dosages, treatment initiation and treatment duration time frames.   
 Beta-blockers have four potentially important ancillary properties: intrinsic 
sympathomimetic activity (ISA), beta1- selectivity, membrane stabilizing activity and 
lipophilicity (White, 1999).  A meta-analysis of 73 trials was conducted to determine if 
these properties could help predict the degree of mortality benefit in the peri- and post-
AMI periods (Soriano, Meems, & Grobbee, 1997).  The results were divided among 
drugs with or without each of these properties.  This meta-analysis suggested that the 
absence of intrinsic sympathomimetic effect and membrane stabilizing effect, and the 
presence of beta1- selectivity and lipophilicity were most efficacious at reducing one-
week mortality, long-term mortality, re-infarction and sudden death.  However, when the 
Cooperative Cardiovascular Project (CCP) data was investigated to compare effects of 
three beta-blockers- atenolol, metoprolol and propranolol, the study suggested that the 
specific beta-blocker selected has little influence on mortality (Gottlieb & McCareter, 
2001).  The mortality rates of the lipophilic agent metoprolol and the nonlipophilic agent 
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atenolol were virtually identical.  When comparison was made between the nonselective 
agent propranolol with the selective agents- atenolol and metoprolol, propranolol had 
slightly negative outcomes in patients.  However, patients receiving propranolol were 
sicker, compared to the other two agents, and after adjusting for the confounding 
variables, the difference between the selective and nonselective agents decreased.  
Furthermore, outcomes in patients who received propranolol was much better than 
patients not receiving any beta-blocker.   
 Observational studies involving retrospective database studies investigating beta-
blocker efficacy have also been previously reported.  A retrospective analysis was 
conducted to determine the effectiveness of metoprolol (a beta-blocker) for secondary 
prevention of AMI in Japan (Iskkawa et al, 2000).  All AMI patients who were admitted 
or received regular outpatient treatment for AMI during an 11-year period from 1986 to 
1996 were included.  The primary endpoints were recurrent AMI (fatal and non-fatal), 
sudden death, or death from CHF.  The metoprolol group had a 3% incidence of cardiac 
events compared to the 6.8% of the non beta-blocker group, which represents a 56% 
reduction.  Multivariate analysis revealed that metoprolol was significant in reducing 
cardiac events and in reducing the incidence of sudden death.  Sub-group analysis by 
heart rate (> 65 and <65 beats/min) revealed that the effect of metoprolol on lower 
incidence of cardiac events remained unchanged.   
 Chen et al., investigated the data from the CCP, to determine whether beta-
blockers were effective in reducing mortality after an AMI in patients who undergo 
coronary re-vascularization (Cheng, Radford, Wang, Marchiniak & Krumholz, 2000).  
The CCP collected data on over 200,000 patients in 45 states over an eight-month period 
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from 1994 to 1995.  The study was initiated due to the lack of inclusion of patients who 
undergo coronary re-vascularization such as PTCA or CABG in randomized clinical 
trials.  Mortality at the end of one year between patients who underwent re-
vascularization procedures such as CABG and PTCA and patients who did not undergo 
re-vascularization procedures were compared.  The findings suggested that beta-blocker 
therapy was as effective in reducing-one year mortality for patients who undergo re-
vascularization (CABG Vs. PTCA) as for patients not undergoing re-vascularization.  
Bisoprolol, a beta-blocker, has been shown to reduce cardiac death and myocardial 
infarction when used long-term in high-risk patients after major vascular surgery, further 
establishing the effectiveness of beta-blockers in this cohort of patients (Poldermans et al, 
2001).   
 Due to their negative inotropic and chronotropic effects, beta-blockers are 
contraindicated in patients with pre-existing decompensated heart failure and acute 
pulmonary edema.  However, they can be used in patients with large AMI that may result 
in left ventricular dysfunction (White, 1999).  In a subgroup of Survival And 
Enlargement Ventricular (SAVE) trial, which evaluated patients with left-ventricular 
dysfunction after AMI, beta-blockers reduced the risk of cardiovascular death and the 
risk of developing severe heart failure (Vantrimpont, Rouleau, & Wun, 1997).  Thus, data 
suggests that patients with more severe AMI’s and reduced ejection fraction after an AMI 
have greater benefits than those with less severe AMI’s.  In a subgroup analysis of the 
BHAT, patients with stable heart failure before receiving propranolol (a beta-blocker) 
achieved a mortality reduction similar to that of propranolol-treated patients without heart 
failure (Chadda, Goldstein, Byinton, & Curb, 1986).  Propranolol also reduced the 
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occurrence of sudden death more frequently in patients with heart failure.  Also, 
propranolol therapy did not increase the overall incidence of heart failure exacerbation, 
nor did it increase the incidence of heart failure exacerbation in patients with a prior 
history of heart failure.   
Beta-blockers have shown to induce broncho-constriction in some patients with 
chronic obstructive pulmonary disease (COPD), hence COPD is a relative 
contraindication (White, 1999; ACC/AHA, 1996).  However, it is usually patients with 
reversible obstructive lung disease (bronchial asthma, asthmatic bronchitis) who are at 
risk for bronchospasm.  Additionally, beta1 selective agents such as esmolol have shown 
not to alter pulmonary function in patients with non-reversible obstruction (Gold, Dee, 
Cocca-Spofford & Thompson, 1991).  However, caution is required when used in such 
patients, as increase in dose may increase risk of worsening pulmonary function.  
Treating patients with fixed COPD with a beta1 selective agent poses great benefits.  A 
retrospective trial using beta-blocker in patients with COPD revealed mortality risk 
reduction of 40% (Gottleib, McCarter & Vogel, 1998).   
Beta-blockers are also relatively contraindicated in the patients with diabetes as 
they increase the risk for hypoglycemia (White, 1999).  However, when used in diabetic 
patients during the post-AMI period, they have been associated with a 36% mortality risk 
reduction (Gottleib et al, 1998).  This is important because patients with diabetes are 
historically known to have the worse outcomes compared to patients without diabetes, 
after an AMI.  Thus, there is ample evidence that there are absolute benefits from beta-
blocker therapy among patients with relative contraindications.  Additionally, esmolol, a 
short-acting beta-blocker, has been demonstrated to be relatively safe in AMI patients 
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with relative contraindications (Mooss, Hilleman, Mohiuddin & Hunter, 1994).  Thus, 
this drug can be replaced for conventional beta-blockers such as propranolol or 
metoprolol in such patients.   
There has been debate about use of beta-blockers in patients with low-risk of 
complications associated with AMI (ACC/AHA, 1996).  The risks of drug use could be 
greater than the benefits in these relatively healthy patients.  However, a study including 
low-risk patients and beta-blocker therapy revealed a 40% decrease in mortality (Gottleib 
et al., 1998).  Due to their better long-term prognosis, the absolute benefit in low-risk 
patients was not as great as high-risk patients, but there is a substantial improvement in 
survival.   
  
Recommendation for Beta-Blocker Use for Post AMI 
Due to their effectiveness, beta-blocker therapy has been included in the guidelines 
for management of patients with AMI by the ACC and AHA (ACC/AHA, 1996).  The 
guidelines recommend their use both in hospital and for long-term prevention.  The 
guidelines divide patients into three classes with respect to beta-blocker therapy - Class I, 
Class II and Class III. Class I include those patients with conditions for which there is 
evidence and/or general agreement that the therapy is beneficial, useful, and effective.  
Class II is sub-divided into IIa and IIb.  Class IIa includes patients with conditions for 
which the weight of evidence/opinion is in favor of usefulness/efficacy of therapy and 
Class IIb includes patients with conditions for which usefulness/efficacy of therapy is less 
well established by evidence/opinion. And finally, Class III includes patients with 
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conditions in the presence of which there is evidence and/or general agreement that a 
therapy is not useful/effective, and in some cases may be harmful.   
For long-term therapy with beta-blockers, all patients accept those who are low-risk 
and without a clear contraindication to beta-blockers were included in Class I.  Treatment 
for these patients should begin within a few days of the event and continue indefinitely.  
Low-risk patients without a clear contraindication to beta-blocker were in Class IIa.  
Class IIb did not include anyone.  And Class III included patients with a contraindication 
to beta-blocker therapy.  However, due to the increasing evidence of effectiveness of 
beta-blockers in patients with relative contraindications and low-risk patients, these 
guidelines were updated in 1999.  According to the updated guidelines, Class I still 
includes patients who are not low-risk and have no clear contraindication to beta-blocker 
therapy.  Class IIa includes low-risk patients without a clear contraindication to beta-
blocker therapy and survivors of non-ST elevation AMI.  There was an addition of Class 
IIb patients that included patients with moderate to severe left ventricular (LV) failure or 
other relative contraindications to beta-blockers, provided the patients were monitored 
closely.  The updated guidelines did not include any patients in Class III.   
In addition to being recommended by ACC/AHA, use of these agents long-term for 
secondary prevention after AMI has also been endorsed by other organizations such as 
the HEDIS (Health Plan Employer Data and Information Set).  This organization has 
included long-term beta-blocker therapy as a quality of care indicator to evaluate 
performance of managed care plans (Bradford et al, 1999).   
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Utilization of Beta-blockers at Post AMI 
 Although clinical trails have revealed impressive results, a large population of 
patients who could benefit from this therapy do not receive it in actual practice.  Overall, 
40% of all patients with AMI could be safely treated in the short-term with beta-blockers 
and at least 70% of patients could receive long-term therapy with beta-blockers (White, 
1999).  Surveys indicate that intravenous (IV) beta-blockers are used in <15% of patients 
and oral beta-blockers are used in <40% of patients without specific contraindications.  
Furthermore, 52-89% of patients in clinical practice receive beta-blocker doses that are 
<50% of those studied in clinical trials.   
 The National Registry of Myocardial Infarction (NRMI) reported a 17 to 36% 
beta-blocker use in patients treated with thrombolytics and a 30 to 42% beta-blocker use 
in patients not receiving thrombolytics (Rogers et al, 1994).  NRMI is a phase IV (post 
marketing), observational, collaborative endeavor sponsored by Genetec Inc, in which 
contributing hospitals throughout the United States record demographic, procedural, and 
outcomes data on patients with AMI.  Even in 1996, in the quarterly report, the registry 
indicated that fewer than 50% of patients post AMI were taking beta-blockers (NRMI, 
1996).  However, a follow-up of this study in 1999 revealed a significant increase in beta-
blocker usage at hospital discharge.  This follow-up revealed that beta-blocker use 
increased from 42% in 1994 to over 60% in 1999 (Rogers et al., 2000).   
 McCormik et al., examined utilization of beta-blockers in a different manner.  
They examined receipt of beta-blockers before hospitalization for recurrent AMI during 
1986, 1988, 1990, 1991, 1993 and 1995 in all hospitals in Worcester, MA. (McCormik, 
Gurwitz, Lessard, Yarzebski, Gore & Goldberg, 1999).  They reported a moderate 
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increase of beta-blocker use from 33.2% in 1986 to 44.4% in 1995.  Age and white race 
were negatively associated with beta-blocker use, whereas history of angina, 
hypertension, concurrent use of other cardiovascular medications such as aspirin and 
lipid-lowering drugs were positively associated with receiving beta-blocker agents.   
 Two recent studies that examined the consequences of beta-blocker under-use 
were conducted by Soumerai et al., and Krumholz et al. (Soumerai, McLaughin, 
Spielgelman, Hertzmark, Thibault & Goldman, 1997; Krumholz, Radford, Wang, Chen, 
Heiat, & Marciniak, 1998).  The first study linked Medicare claims data to two databases 
covering pharmaceutical usage in New Jersey for these Medicare patients.  Since the data 
utilized was for administrative claims, they were unable to identify all potential 
contraindications for beta-blocker therapy.  Instead they defined eligibility as the absence 
of a diagnosis or medication reported prior to the AMI that would be suggestive of a 
contraindication.  Thus, they excluded patients with CHF, asthma, COPD, as well as 
those with a prescription consistent with these diagnosis or a prescription for insulin.  
They found that 30% of the patients with AMI had 1 or more contraindications to beta-
blocker treatment, thus 70% were eligible for therapy.  However, only 21% of the eligible 
subjects received a prescription for beta-blockers.  Also, among patients not receiving 
beta-blocker treatment before AMI, only 15% were started on therapy after the AMI.  
The second study collected data through an intensive chart review of Medicare AMI 
patients.  These were selected from the CCP.  For this study, Krumholz et al., excluded 
patients who died, were transferred, and who had contraindications for therapy.  The 
contraindications included were: bradycardia, low blood pressure, high grade AV block, 
asthma, chronic lung disease, heart failure during hospitalizations or chart documented 
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intolerance to beta-blocker.  This study reported an eligible population of about 39%.  Of 
this, only 50% had a prescription for a beta-blocker at discharge.   
 Variation in beta-blocker usage has also been reported geographically.  A 
significant variation in utilization by state and region was present in the CCP (Krumholz 
et al, 1998).  Connecticut (77.1%), Massachusetts (74.2%), Maine (68.3%), New 
Hampshire (68.9%), and Vermont (66.7%) had the highest utilization rates, whereas 
Mississippi (30.2%), Puerto Rico (32.1%), Oklahoma (33.5%), Arkansas (33.5%), and 
Nevada (36.4%) had the lowest utilization rates.  Also, among the different regions, New 
England had the highest utilization rates of 72.6%.  Variations within small areas were 
observed while examining data from six hospitals in Connecticut (Meehan, Hennen, 
Radford, Petrillo, Elstein, & Ballard, 1995).  Overall utilization rate was 41%, however, it 
varied from 39% and 54% for the low-mortality hospitals to 29% and 33% for the high 
mortality hospitals.   
Pilote et al., reported regional variation within the United States, when data from 
the Global Utilization of Streptokinase and Tissue plasminogen activator for Occluded 
coronary arteries trial (GUSTO-1) was explored (Pilote et al, 1995).  Generally, they 
found that New England had the highest utilization of therapy with 71% of patients 
receiving a beta-blocker at discharge.  Compared to this the Mountain and South Central 
regions had the lowest utilization at 47% and 49%, respectively.  The average age of 
patients in this study was between 59 and 62 for the various regions.  An investigation of 
treatment and outcomes of AMI in Quebec from 1988-1995 revealed similar results 
(Pilote, Lavoie, Ho & Eisenberg, 2000).  Increasing beta-blocker utilization was found 
for the duration of the study, with the 50% rate in 1995 being the highest.  Analysis of 
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patient treatment data in 11 geographically defined European regions revealed rates from 
25% to 85% from center to center (Woods et al, 1998).  About 48% of patients had at 
least one contraindication to beta-blocker on admission.  In the patient group not admitted 
on a beta-blocker and without perceived contraindications, only 58% of patients actually 
received therapy at discharge.  Variation in beta-blocker use has also been reported by 
urban-rural location.  An examination of the CCP data in Kansas by rural, semi-rural and 
urban locations revealed utilization rates of 30.7%, 30.2% and 36.4%, respectively, 
among ideal patients (patients who should definitely receive the agents).  The trend was 
repeated even among the less than ideal patients (patients in whom use was controversial 
due to contraindications) with utilization rates of 22.5%, 25.0%, and 31.3% in rural, 
semi-rural and urban locations (Sheikh & Bullock, 2001).   
Underutilization of beta-blockers, following AMI, has also been established in 
specific patient sub-groups.  Fishkind et al., studied elderly patients (mean age =81) and 
found that utilization of beta-blockers following an AMI was quite low at 19% (Fishkind, 
Paris, & Aronow, 1997).  This number is lower than the average usage in the overall AMI 
population.  This suggests that physicians are reluctant to use this therapy in older 
patients, despite age not being a contraindication.  Although age is not a contraindication, 
older patients are more likely to have conditions that will make them ineligible for 
therapy.  Also, the authors included patients without consideration to contraindications.  
A recent study in the rural state of WV revealed similar results (Schade, Behm, Stephens 
& Rezek, 2002).  Around 59.4 % of patients received beta-blockers at discharge over a 
span of six quarters with no detectable trend of improvement over time.  Additionally, 
beta-blocker use declined with patient age.  Gurwitz et al., extracted data from patient 
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charts from 16 hospitals in a single Metropolitan Statistical Area for six years (Gurwitz, 
Goldberg, Chen, Gore, & Alpert, 1992).  They demonstrated a consistent trend toward 
reduced beta-blocker therapy in older patients.  After adjusting for demographic and 
clinical variables (gender, prior history of angina, hypertension, or diabetes mellitus; 
myocardial infarction characteristics; complications including CHF and shock; and use of 
digoxin), odds ratio for receipt of beta blocker therapy relative to patients less than 55 
years of age were 0.61 for those 55 to 64, 0.52 for those 65 to 74, 0.36 for those 75 to 84, 
and 0.26 for those 85 or older.  Utilization of therapy was 39.8% for the overall study 
population.  Male patients and those with a prior history of angina or hypertension were 
more likely to receive therapy than those with diabetes mellitus.   
 Utilization differences have also been reported by gender and race.  Pashos et al., 
conducted a retrospective analysis of administrative data (Pashos, Normand, Garfinkle, 
Newhouse, Epenstein, & McNeil, 1994).  This demonstrated odds ratios of 0.93 for 
women relative to men and 0.81 for blacks relative to non-blacks for receiving beta-
blockers.  Similar findings were reported while examining patient charts in two large 
urban hospitals (Sial, Malone, Freeman, Battiola, Nachodsky, & Goodwin, 1994).  A 
utilization of 38% was reported in patients with no potential contraindications.  It 
reported a variety of conditions to be associated with under utilization of therapy.  These 
include female gender (OR=0.52), health insurance (OR=0.34), presence of COPD 
(OR=0.21), development of CHF (OR=0.46), and AV block (OR=0.28).  CHF has been 
reported to be the reason for underutilization in a number of other studies.  Also, presence 
of contraindications did not determine prescribing behavior.  Up to 24% utilization was 
reported in patients with potential contraindications.  Beta-blockers have certain adverse 
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effects, which may also be responsible for it’s under use.  These include fatigue, 
depression, sexual dysfunction, nightmares and difficulty to detect hypoglycemia and 
diabetics.   
 The CCP data has also demonstrated association of socio-demographic 
characteristics with the use of beta-blockers (Rathore, et al., 2000).  Beta-blockers were 
underused as discharge medications in the treatment of black, female and poor patients 
with AMI.  This variation in treatment was not explained by severity of illness, physician 
specialty, hospital and geographic characteristics.  Variation in beta-blocker use at 
discharge by gender was also reported by Wilkinson et al., in an observational follow-up 
study for 5 years from 1988 to 1992, with fewer women receiving therapy compared to 
men (Wilkinson, Laji, Ranjadayaln, Parson, & Timmis, 1994).   
 Though there are reports of under utilization of these agents for the post AMI 
population, there has been a steady rise in average use of these agents over recent years.  
A recent study examined changes in post-AMI beta-blocker use occurring between 1994 
and 1997 (Heller, Ahern, & Kozak, 2000).  It included patients >65 years of age who 
were enrolled in Pennsylvania’s pharmaceutical assistance contract for the elderly 
(PACE) and who survived AMI between 1994 and 1997.  The results presented an 
increase of beta-blocker use from 39.6% in 1994 to 58.6% in 1997.  Those patients who 
did not use beta-blockers tended to have greater severity of illness, and co-morbidities 
such as CHF, COPD, and asthma.  Other researchers have also pointed out strong time 
trends in the utilization of beta-blocker therapy.  Paschos et al., (1994) documented a rise 
from 29 % to 38% from 1988 to 1992.  Similarly Pilote et al., (2000) reported an increase 
from 33% to 50% from 1991 to 1995.  This may be due to publication of results of 
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rigorous clinical trials.  Recent survey indicates that beta-blockers are prescribed to as 
few as 40% of eligible patients in some health plans, however, there are some plans that 
report 96% prescribing rates (NCQA, 1999; NCQA, 2000).   
Most of the investigations associated with beta-blocker use have excluded patients 
with contraindications.  However, a study which did examine utilization of beta-blockers 
in patients with contraindications revealed that 11% of patients with contraindications 
were receiving beta-blockers at discharge after an AMI (Brand et al., 1995).  Some of 
these patients had absolute contraindications such as AV block, whereas some had 
relative contraindications such as diabetes mellitus, heart failure, and asthma.  Another 
study, reported a 24% utilization in patients with potential contraindications such as CHF, 
hypotension, cardiogenic shock, COPD, asthma, AV block and diabetes (Sial et al.,1994).  
Despite established guidelines there is ample evidence to establish under use of beta-
blockers in patients with no contraindications and a few reports of misuse in patients with 
absolute contraindications.  All these reports establish inappropriate utilization of beta-
blockers in AMI patients for secondary prevention, and thus non-adherence to guidelines.   
 
Implications of Inappropriate Utilization of Beta-Blocker Therapy 
 The inappropriate utilization of beta-blocker therapy raises the primary question 
“What are the consequences of this pattern of care?”  There is very little information that 
addresses this aspect directly.  There can be higher morbidity and mortality due to 
inappropriate care and there is a cost that can be attributed to these effects.  Whenever 
effective treatment is withheld from a patient, or given to a patient not eligible, it can 
result in death or lower quality of life than anticipated.  Each life lost or day of sub 
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optimal health quality increases societal costs.  In addition to having intrinsic value, 
every life saved also contributes to economic productivity.  Second, there is the increase 
in medical resources utilized due to inappropriate care.  This can be in the form of 
increased hospital readmission, frequent physician visits, increase in number of bed days 
and increase in emergency visits.   
Lower mortality rates have been previously reported when there is utilization of 
beta-blockers.  For example, Krumholz et al., reported a 14% lower risk of mortality at 
one year after discharge, among eligible patients who received a prescription for beta-
blockers at discharge, when compared to eligible patients who did not receive a 
prescription (Krumholz et al., 1998).  Similarly, Soumerai et al., reported a 43% lower 
mortality rate among beta-blocker recipients compared to non-recipients (Soumerai et al., 
1997).  Additionally, this study also reported that beta-blocker recipients were re-
hospitalized 22% less often than non-recipients were.   
The costs associated with mortality has been addressed to some extent through 
simulation and modeling techniques for underutilization.  One such study analyzed the 
cost effectiveness of routine use of beta-blockers in three specific ages of 45, 55 and 65 
(Goldman, Sia, Cook, Rutherford & Weinstein, 1988).  Additionally, for each age group 
three prognostic categories were considered - high risk, medium risk and low risk.  The 
estimated cost of six years of therapy to save an additional year of life was $23,400 in 
low-risk patients, $5,900 in medium-risk patients, and $3,600 in high-risk patients for all 
the three age categories.  This was assuming that the entire benefit of earlier treatment is 
lost immediately after six years.  With a more likely assumption that the benefit of six 
years of treatment wears off gradually over the subsequent nine years, the results 
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differed.  Here the estimated cost of therapy per year of life saved was $13,000 in low-
risk patients, $3,600 in medium-risk patients, and $2,400 in high-risk patients.  The study 
disregarded costs savings generated in follow-up medical utilization or potential costs of 
any side effects.   
 Another study investigated health and economic benefits of increased beta-
blocker use following an AMI.  A computer simulated Markov-model of the coronary 
heart disease policy (CHDP) model was used in the US population (Philips et al., 2000).  
The aim of the study was to estimate the epidemiological impact and cost-effectiveness 
of increased beta-blocker use from current to target levels among survivors of AMI aged 
35 to 84 years.  Simulations included one cohort of AMI survivors in 2000 followed up 
for 20 years and 20 annual successive cohorts of all first-AMI survivors in 2000-2020.  In 
the first group, this resulted in 4,300 fewer coronary heart disease (CHD) deaths, 3,500 
fewer AMIs, and 45,000 life-years gained when utilization of therapy was compared to 
current use.  The incremental cost per QALY (quality adjusted life years) gained was 
estimated to be $4,500.  For the second simulation, increase in use resulted in savings of 
$18 million and 72,000 fewer CHD deaths, 62,000 fewer AMIs and 447,000 life years 
gained.  Restricting the therapy to ideal patients however, would reduce the impact of 
beta-blocker therapy by about 60%.  
Thus, there has been some attempt to model effect of underutilization on patient 
outcomes.  However, effect on utilization related variables such as physician visits, 
emergency room visits, length of stay and expenditures have not been investigated.  
Additionally, implications of use of beta-blocker therapy in patients with 
contraindications (misuse) has been ignored.  Similar investigations in other chronic 
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disease management suggests adverse patient outcomes due to misuse of therapy.  For 
example, in asthma the National Heart, Lung and Blood Institute (NHLBI) developed 
guidelines for diagnosing and managing asthma (Podell, 1992).  According to these 
guidelines, a short course of systemic corticosteroids is the most cost-effective way of 
reducing asthma excaberations.  Long term B2 agonists and methylxanthines are 
recommended to be used as adjuvant therapy.  Short-term B2 agonists should be used 
only on an as-needed basis.  When drug therapy patterns and effect of these patterns on 
patient outcomes was investigated, the results demonstrated patterns outside of the 
guidelines (Shireman et al., 2002).  Less than one-half of the population under study 
received sub-optimal dose per day of inhaled corticosteroid.  A large percent (44%) of the 
population received high or very high levels of short–acting B2 agonists.  Additionally, 
patients with high doses of short-acting B2 agonists had the worst asthma outcomes.  
Their odds of receiving an oral steroid burst, an indicator of ambulatory asthma 
excaberations, were more than doubled.  They were also more likely to be hospitalized 
and had significantly more emergency department visits.  Another study which 
investigated effect of inappropriate medication use and outcomes in asthma was 
conducted by Anis et al. (Anis et al., 2001).  This defined inappropriate medication use as 
use of nine or more canisters of short-acting B2 agonists, combined with no more than 
100 ug/day of corticosteroid in a year.  Appropriate medication use was defined as four or 
fewer canisters of short-acting B2 agonists and at least 400 ug/day of corticosteroid.  A 
greater proportion of those patients with inappropriate medication use were admitted to 
hospital on an urgent basis at least once during the year.  Additionally, these patients 
were admitted or admitted on an urgent basis more frequently compared to the 
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appropriate medication use group.  The appropriate medication use groups had fewer 
physician visits overall and also fewer physician visits per physician.  Thus, the 
inappropriately prescribed patients used more health care services, suggesting greater 
morbidity and greater health care costs. 
Another class of drugs that have been investigated for inappropriate prescribing is 
antibiotics.  An investigation of inappropriate antibiotic use in pyelonephritis revealed an 
association between inappropriate prescribing and length of stay (LOS) (Knapp, Knapp, 
Speedie, Yaeger, & Naker, 1979).  Inappropriate prescribing was associated with a two-
day or 50% longer LOS than appropriate prescribing.  This was regardless of disease 
severity.  When a sub-analysis was conducted with the youngest cohort in this study, the 
inappropriately prescribed group still had a longer LOS, indicating that patient age did 
not affect inappropriate prescribing.   
In addition to specific drug classes there have been investigations of multiple drug 
classes and inappropriate prescribing.  Such investigations have examined inappropriate 
prescribing using criteria’s such as indication, effectiveness, dosage, correct directions, 
practical directions, drug-drug interactions, drug-disease interactions, therapeutic 
duplication, duration and cost (Schmader et al., 1997).  One such investigation revealed 
that patients with inappropriate prescribing were more likely to be admitted to the 
hospital or have an unscheduled physician visit during the subsequent 12 months.  
Lindely et al., identified inappropriate prescriptions, defined as unnecessary drugs and 
those with absolute contraindication, and adverse drug reactions (ADRs), defined as 
presenting symptoms that were known adverse effects of admission drugs, in 429 patients 
aged 65 years or over (Lindley, Tulley, Paramsothy, & Tallis, 1992).  Of the total ADRs 
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presented, 72.8% were attributable to inappropriate prescriptions.  Similarly, in a study of 
patients over 65 years, readmitted to the hospital, 17 of the 48 problems in 40 patients 
were drug-related (Bero, Lipton, & Bird, 1991).  These were overdose, under-dose, 
inappropriate choice, allergy and drug-drug interaction.  Stroupe et al., investigated under 
and over supply of required medications using medication possession ratio in a network 
of community based ambulatory care centers (Stoupe et al., 2000).  This revealed that 
patients with over supply had higher average inpatient and outpatient costs compared to 
patients with normal supply.  Both under and over supply of medication were 
independently associated with significantly higher probabilities of hospital admission and 
emergency department visits. 
Thus, there is evidence of inappropriate prescribing of various drugs and their 
consequent adverse health outcomes among patients.  However, such investigations with 
beta-blocker use for post AMI patients for long-term prevention is non-existent, and 
needs to be undertaken.   
 
Physician’s Role in Inappropriate Utilization  
A number of researchers have gone beyond the issue of beta-blocker utilization 
and attempted to understand the physician’s role in beta-blocker therapy.  As most of the 
research associated with beta-blocker utilization has investigated under-utilization, the 
physician’s role has also been investigated in under-utilization more than inappropriate 
utilization.  One of the primary findings is the association between beta-blocker 
prescribing and physician specialty.  Fehrenbach et al. investigated an administrative 
managed care data retrospectively (Fehrenbach, Budnitz, Gazmararian, & Krumholz, 
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2001).  The results revealed that 43.4% of family practice physicians, and 40% of other 
physicians prescribed beta-blockers compared to 67.7% by cardiologists.  Others have 
documented prescribing rates of 77.5% for cardiologists, 63.0 % for internists, and 53.1% 
for family practitioners of beta-blockers as post AMI therapy (Ayanian et al. 1994).  The 
CCP data revealed prescription rates of 52.4% for cardiologists which was much higher 
than 39.7%, 35.4%, 36.1% & 39.4% for internal medicine, family medicine, general 
practice and other specialty, respectively.  In elderly patients, individuals who had 
prescriptions written by cardiologists were more likely to use a beta-blocker than 
individuals who received prescriptions from non-cardiologists (OR=1.52) ( Heller, 
Ahern, & Kozak, 2000).  A recent study in WV revealed similar results (Schade, Behm, 
Stephens & Rezek, 2002).  Around 59.4 % of patients received beta-blockers at discharge 
over a span of six quarters with no detectable trend of improvement over time.  However, 
there was a significant difference in beta-blocker use by physician specialty with 
prescribing rates of 60.8% by cardiologists, 49.7% by primary care practitioners and 
45.8% by other specialties.  All these suggest that physicians in different specialties are 
not equally aware of information and that this information difference may be a reason for 
differential prescribing rates by these physicians.  Though cardiologists are more likely to 
prescribe beta-blockers at discharge, this does not necessarily imply that their prescribing 
behavior is adherent to guidelines.  For example, a study measuring cardiologists’ 
adherence to guidelines revealed a low level of compliance (Brand et al., 1995).  About 
31% of the cases had an error of omission (beta-blocker not given in the absence of a 
contraindication) and 11% of the cases had an error of commission (beta–blocker given 
in the presence of a contraindication).   
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 In addition to physician specialty there are other characteristics which have been 
shown to affect beta-blocker prescribing.  For example Fehrenbach et al, revealed that 
52.6% of physicians trained before 1980 prescribed beta-blocking agents as compared to 
63.2% physicians trained since 1980 (Fehrenbach et al, 2001).  Additionally, region of 
practice was also associated with use of beta-blockers in this study, with the physicians in 
the northeast being more likely to prescribe beta-blocking agents than physicians in other 
regions.  One other factor that affects prescribing is affiliation with university.  Mitra et 
al., reported that patients at a government, university affiliated teaching hospital had high 
prescribing rates for beta-blocker therapy and this was in accordance with the ACC/AHA 
guidelines (Mitra, Findley, Frohnapple & Mehta, 2002).  This study examined the 
frequency with which cardiologists prescribed post AMI medications at discharges and 
evaluated medical management at the end of 24 months after discharge from the acute 
event.  The study reported that over 90% patients were given beta-blockers at discharge, 
this utilization however decreased to 71% at the end of 2 years.  These prescribing rates 
however, were much higher than the national registry rates of 48%.  Similar results were 
found when beta-blocker use was compared in two centers of Perth and Newcastle of 
world health organization (WHO).  The study revealed that more patients were 
discharged from hospital on beta-blockers in Perth (68%) than in Newcastle (45%).  The 
reason attributed to this difference was the fact that higher proportion of patients in Perth 
were treated by cardiologists in large teaching hospitals compared to the more rural 
nature of New-Castle (Nicholls, McElduff, Dobson, Jambrozik, Hobbs, & Leitch, 2001). 
 While the above studies have dealt with association between physician and 
physician practice characteristics and prescribing of beta-blockers, there are also reports 
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of association between physician knowledge and beliefs with prescribing behavior.  For 
example, cardiologists believed more strongly that beta-blockers improve survival as 
long-term therapy after an AMI and they were also more likely to prescribe this therapy 
compared to internists and family practitioners (Ayanian et al., 1994).  In a critical look at 
literature regarding physician under-utilization of beta-blocker therapy, three primary 
reasons were revealed (Kennedy & Rosensen, 1995).  These include exaggerated 
concerns of adverse effects of beta-blockers, undue importance of contraindications, and 
skepticism of drug therapies due to competitive practice of pharmaceutical industry.   
 
Medicaid Program 
 The present study will be undertaken in a Medicaid population.  Thus, it is 
necessary to understand the structure and functioning of this health care system.  
Medicaid is a federal and state jointly funded health insurance program for the indigent, 
disabled, and members of families with dependent children (NPC, 1995).  This program 
was started in 1965.  In managing Medicaid, the federal and the state governments have 
separate responsibilities  (NPC, 1995).  The federal government provides fiscal assistance 
and a framework with regulations, guidelines, and policies for operation to state 
governments.  State governments are responsible for administration of the Medicaid 
program which include - determining eligibility, determining services, claims processing 
and monitoring.  Benefits provided by Medicaid include coverage for physician visits, 
inpatient and outpatient hospitalizations, laboratory tests, nursing home care, family 
planning services and supplies, and home health care.  These benefits are mandated by 
the federal government.  Additionally, there are optional services that are left to the 
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discretion of each state.  Some of these are coverage for pharmaceuticals, eyeglasses, and 
dental services for person 21 and older.  Although optional, all states provide 
pharmaceutical coverage as a part of Medicaid benefits.   
 From the time of its initiation, Medicaid has had a tremendous impact on the US 
health care system.  It has made healthcare accessible to individuals who are not 
financially well off.  However, health care spending through Medicaid programs has 
grown tremendously.  Total federal and state Medicaid expenditures, including 
administrative costs and dis-proportionate share hospital payments, increased from $58 
billion in 1989 to $194.7 billion in 2000 (Coughlin, Ku, & Holahan, 1994; Medicaid 
Consumer Information, 2003).  One of the major reasons for this increase in expenditures 
is the increase in size of the Medicaid-covered populations.  In 1990, there were 25.3 
million recipients which increased to 36.3 million in 1995 and in 2000 there were more 
than 44 million (NPC, 1995; Medicaid Consumer Information, 2003). 
 This national trend for Medicaid growth is also evident in WV.  This growth has 
been witnessed by both increase in enrollment and expenditures.  In WV, the Bureau for 
Medical Services of the WV Department of Health and Human Resources has been 
responsible for the management of the Medicaid program (West Virginia Medicaid 
Program -WVMP).  The total number of recipients in the WVMP has increased from 
178,254 in 1982 to 354,326 in 2000 (NPC, 1998; Medicaid Consumer Information, 
2003).  This growth in number of recipients has resulted in a dramatic increase in 
expenditures from $121 million in 1982 to over $1.391 billion in 2000 (NPC, 1998; 
Medicaid Consumer Information, 2003).  This can be interpreted as an increase in 
average spending per recipient from $678.84 to approximately $3,900 (NPC, 1998; 
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Medicaid Consumer Information, 2003).  Thus, it becomes important to identify areas 
that incur unnecessary costs - appropriate use of medication can be one such area.  
Investigation undertaken to study consequences of inappropriate care will help in 
developing and implementing strategies for minimizing expenditures for this health care 
system.  
 
Thus, this chapter presented a review of literature associated with AMI, beta-
blocker drug therapy, their effectiveness, recommendation for their use, variation in their 
use, implications of this variation in use and physicians role in this variation of use.  It 
also provided a brief introduction to Medicaid, the health system in the study.  The next 
chapter will discuss the methodology employed to fulfill the goals of this study.   
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CHAPTER THREE 
METHODOLOGY 
 
This study had two phases.  In phase I, the study evaluated the impact of 
appropriate and inappropriate prescribing of beta-blocker therapy by physicians, 
following an acute myocardial infarction (AMI), on patient outcomes and utilization of 
health services.  In Phase II, the study determined physician-related factors that were 
related to beta-blocker prescribing in post-AMI patients.  The methodologies required to 
accomplish the two phases were different.  Phase I involved analysis of secondary data 
from paid claims of West Virginia (WV) Medicaid.  Phase II was completed using 
primary data collected from physicians involved in post AMI care in the state of WV.  
 
Phase I 
 The following sections describe the data source, data extraction, modification of 
raw data, and the analytical methods that were utilized for this phase of the study. 
 
Data Source 
 The WV Bureau for Medical Services (WVBMS) contracts with Consultec Inc. 
(Atlanta, Georgia), to serve as its claims processor.  Consultec maintains and operates the 
Medicaid Management Information Systems (MMIS), which process provider claims and 
payments.  MMIS data comprises of 3 files- provider, recipient, and claims files 
(Momani, 1999).   
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The provider file contains specific information regarding various types of 
providers eligible to deliver services to Medicaid recipients.  This includes a provider 
number, the provider’s name, address, specialty, Medicaid eligibility, and tax related 
information.  The recipient file contains information about Medicaid recipients, such as 
name, Medicaid number, eligibility begin date, end date, Social Security Number (SSN), 
aid category, gender, race and address.  The claim files store detailed information specific 
to processed claims.  For each medical claim information, such as invoice type, provider 
number, recipient number, International Classification of Disease 9th edition (ICD-9) 
code of diagnosis for which service was provided, Common Procedural Terminology  4th 
edition (CPT-4) code for procedures and services provided, Diagnosis Related Group 
(DRG) codes, date claims are submitted, date of adjudication through-date of service, co-
ordination of benefit code, total primary carrier code, and total amount paid.  For 
pharmaceutical products, the file contains fields such as name of the drug, begin date, 
number of days supply, metric quantity, National Drug Classification (NDC) code, 
generic code, therapeutic class code, refill number, pharmacy provider number, and the 
amount paid. 
Paid claims data relevant for the study were obtained from Consultec, Inc.  
Consultec stores data going back several years.  However, not all of this data were 
pertinent to this study and so relevant data between January 1, 1996 to June 30th, 2001 
were extracted to conduct the analysis.  
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Data Extraction 
 
 The data obtained from Consultec was loaded on a computer in access files.  
These were extracted through the software BrioIntelligence and converted into statistical 
analysis software (SAS® version 8.2) data sets.  The extraction process involved defining 
selection criteria, defining the time period of the study, inclusion of specific fields 
required, defining exclusion criteria, and classification of groups.  
  
Selection Criteria 
 The main selection criteria for patients was recipient numbers who were 
discharged from a hospital with the primary or secondary diagnosis of AMI, ICD-9 codes 
410.0 to 410.9, during January 1, 1997 to June 30, 2000.  These recipient numbers were 
unduplicated to make sure that each recipient number occurred only once.  Social security 
numbers (SSNs) for these recipients were identified.  This is because SSN is the only 
unique identifier for Medicaid recipients since each recipient can have multiple Medicaid 
ID numbers.   
 
Time Period 
 The total period of study was from January 1, 1997 to June 30, 2000 (42 months).  
From the database, every patient with AMI identified was categorized into two groups.  
The first group consisted of Class I & II patients, who are eligible to receive beta-blocker 
therapy post-AMI and second group consisted of Class III patients, who are not eligible 
to receive beta-blocker therapy post-AMI.  However, in order to do this, in addition to the 
data from the time period of the study, patient information from the previous year was 
also needed.  Therefore, additional patient data for the time period of January 1, 1996 to 
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December 31, 1996 was additionally extracted from the database.  Also, since the study 
involved investigating outcomes for these AMI patients in the following one-year period 
after the AMI, additional data from July 1, 2000 to June 30, 2001 was extracted.  Thus, 
the history file (hospital, ER, and physician), demographic file, managed care file, 
prescription or drug file were obtained for the identified AMI patients from January 1, 
1996 to June 30, 2001.  
 
Specific Fields  
 Appendix A provides the lists of the fields chosen that were essential for the 
study.  From the demographic file, the fields selected were recipient number, recipient 
social security number (SSN), date of birth, sex, race, eligibility begin date and eligibility 
end date.  From the hospital/ER file, the fields selected were recipient number, recipient 
SSN, first date of service, last date of service, billed amount, paid amount, procedure 
code, diagnosis codes and hospital extract indicator.  From the physician file, the fields 
requested were recipient number, recipient SSN, first date of service, last date of service, 
billed amount, paid amount, procedure code, diagnosis codes and physician extract 
indicator.  From the pharmacy file, the fields requested were recipient number, recipient 
SSN, date of prescription filled, billed amount, paid amount, NDC code, generic code, 
and days supply.  From the managed care file, the fields requested were recipient SSN, 
managed care begin date and managed care end date.  The drug file had the NDC code, 
drug name and generic code.  The DRG file had DRG code and DRG name.  The 
procedure file had procedure (CPT-4) codes and code description.  And finally, the 
diagnosis file had the diagnosis (ICD-9) codes and code description.  
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Exclusion Criteria 
 The following exclusion criteria were applied to the selected SSNs with a 
diagnosis of an AMI during the time specified;  
• The first restriction was to include only those patients who were continuously 
eligible in the Medicaid system for a period of one year before the hospitalized 
AMI under study. 
•  From these, managed care recipients were excluded as managed care recipients 
do not have all their utilization information in the Medicaid claims.   
• Patients who were 65 years or older were excluded to avoid the issues of 
incomplete information as they have Medicare as their primary payer for health 
services.  The age limit was set to 64 to avoid including those patients who would 
become eligible for Medicare during the period of follow-up after being initially 
present.   
• Patient who have length of hospital stay less than 3 days were excluded to avoid 
error due to misdiagnosis of AMI. 
• Patients with the primary ICD-9 code of 410.x2 were excluded as this code is 
utilized for subsequent episodes of care for AMI where the initial treatment was 
received less than 8 weeks ago. 
• When patients who had recurrent AMI within the time period of the study were 
present, only the first AMI was considered. 
• Beta-blocker receipt in the study was defined as presence of beta-blocker 
prescription in the claims within 90 days of discharge.  Thus, those patients who did 
not receive a prescription for beta-blockers in the first 90 days after the AMI but 
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received it sometime within the year were excluded to prevent potential bias due to 
misclassification.  
• Patients who died during the AMI or within 30 days of the incident AMI were 
excluded. 
The resultant group of patients was investigated to see the effect of appropriate and 
inappropriate prescribing on mortality 
• Patients who died due to non-cardiac causes in the follow-up period were 
excluded.  
The resultant group of patients was investigated to see the effect of appropriate and 
inappropriate prescribing on cardiac mortality 
• Patients who were not continuously eligible for Medicaid in the follow-up one-
year period after the AMI were excluded.  
The resultant group of patients was investigated to see the effect of appropriate and 
inappropriate prescribing on health care utilization and expenditures.  This process of 
applying inclusion and exclusion criteria is outlined in Figure 4. 
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Figure 4: Data Extraction  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Extracted paid claims 
data for the period 
from January 1, 1997 
to June 30, 2000 
ICD-9 codes for AMI  Identified recipient 
numbers that received 
claims for AMI 
Unduplicated the list of 
recipient numbers and 
identified 
corresponding SSNs 
Extracted all files 
associated with the 
identified SSNs 
Continuously eligible 
for one year before the 
incident AMI,  
N = 1,940 
Managed Care, N = 3 
& 
Medicare and Age >64, 
N = 748 
1,940-(3+748) = 1,189 
Length of stay <3 days 
& ICD-9 of 410.x2 
N = 590 
1,189-590 = 599 
Duplicate AMIs and 
beta-blockers after 90 
days of discharge, N = 
91 
Cohort for mortality 
N = 488 
Death during or within 
30 days of incident 
AMI, N = 20 
508-20 = 488 
Death due to non-
cardiac causes, N = 18 
488-18 = 470 
+ 
Cohort for cardiac 
mortality, N = 470 
Not continuously 
eligible for one year 
after AMI, N = 58 
470-58 = 412 
Cohort for morbidity 
and utilization,  
N = 412
AMI: Acute myocardial infarction, ICD-9: International classification of disease-9th edition, SSN: Social security 
numbers 
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Classification of groups 
Information about procedures, services, medications and medical history were 
extracted during the incident AMI, one year prior to the incident AMI and one year after 
the incident AMI for every patient identified who satisfied all the inclusion and exclusion 
criteria.  Based on their medical history, patients were divided into those with absolute 
contraindications, and those with relative contraindications, using ICD-9, CPT-4 codes 
and DRG-codes (see Appendix B).  For example, a person with the ICD-9 code of 458.x 
was considered to have hypotension, an absolute contraindication.  It is important to point 
out that certain relative contraindications such as a heart rate less than 60 bpm, systolic 
arterial pressure less than 100 Hg, signs of peripheral hypoperfusion, and beta-blocker 
intolerance were not recognized and constitute a limitation of this study.   
Based on presence of the contraindications, patients were classified as Class I, II 
and III for beta-blocker use after AMI.  Prescription claims within 90 days of AMI were 
obtained.  Patients were classified into two groups based on presence of absolute 
contraindications and beta-blocker receipt.  Those who did not have absolute 
contraindications and received therapy and those who had absolute contraindications and 
did not receive therapy constituted the appropriately prescribed group.  Similarly, those 
who did not have absolute contraindications and did not receive therapy and those who 
had absolute contraindications and received therapy constituted the inappropriately 
prescribed group.  Additionally, a sub-classification within the inappropriately prescribed 
group was created to differentiate between patients with under use (those who did not 
have absolute contraindications and were not prescribed) and misuse (those who had 
absolute contraindications and were prescribed) of beta-blocker therapy.   
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Modification of Raw Data 
 The raw data obtained from the hospital, physician and prescription claims data 
was modified to obtain all the relevant variables that were required for the analysis, using 
SAS® version 8.2.  For the pre-phase (before the incident AMI) and during the incident 
AMI, information about various medical conditions, such as left ventricular (LV) failure, 
1st and/or  2nd and /or 3rd degree atrioventicular (AV) block, chronic obstructive 
pulmonary disease (COPD), asthma, insulin dependent diabetes mellitus (IDDM), 
hypotension, bradycardia,  non-insulin diabetes mellitus (NIDDM), hypertension, 
previous AMI, previous coronary artery bypass graft (CABG), previous percutaneous 
transluminal coronary angioplasty (PTCA), congestive heart failure (CHF), stroke and 
renal dysfunction was obtained.  The presence of these were determined by presence of 
either ICD-9 codes or CPT-4 codes in either the hospital or the physician claims during 
the year before the incident AMI or as secondary diagnosis during the incident AMI.  In 
some cases DRG-codes were used (only CABG and PTCA).  These are listed in 
Appendix B.   
The hospital claims had both hospitalization and ER claims in one file and the 
physician file contained claims for clinic, department of health screening, lab tests, 
transportation, family planning, special services and practitioner.  Thus, the 
hospitalization file required to be separated into hospitalizations and ER visits and the 
physician file had to be limited to only outpatient physician visits.  There was a variable 
called hospitalization extract indicator in the hospital claims data, which classified the 
claims as hospitalizations or ER visit.  This variable and the following criteria were 
utilized to separate the hospital claims data into hospitalization or ER visits.  Those 
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claims that had the variable as 1 (indicating hospital claim), had length of stay greater 
than 1 day, and had a specific DRG code were classified as hospitalizations.  Those 
events which had length of stay as zero, had the indicator variable as 2 (indicating ER 
extraction) and CPT-4 codes between 99281 to 99285 (CPT-4 codes for emergency 
department visits) were classified as ER visits.  There were claims that did not fit into 
both these categories.  An inspection of the procedure codes of these claims revealed that 
these were claims associated with laboratory, radiology, & pathology during either 
hospital admissions or ER admissions.  Since the only information needed from these 
claims were billed and paid amounts, they were classified as hospital/ER laboratory 
claims.  Similarly, in the physician claims files there was an extract indicator variable, 
which was utilized to classify the physician visits as outpatient physician visits and 
outpatient laboratory claims.  All claims were converted to one observation per visit.  
However, the billed and paid values for these observations were a sum of all the billed 
and paid values of all the claims associated with that visit.   
The total number of admissions for any cardiac condition in the pre-phase was 
determined by summing the number of hospitalizations in the pre-phase with ICD-9 
codes for cardiac conditions (Appendix B).  Similarly, those hospitalizations that were 
not related to cardiac conditions were summed to get total number of admissions due to 
non-cardiac conditions in the pre-phase.   
The pharmacy claims data was combined with the drug file to get drug names in 
the database.  Based on drug names, the total number of different unique drug claims per 
person in the six months before the incident AMI was utilized to get total number of 
drugs in the pre-phase.  Similarly, any use of drugs such as digoxin, Angiotensin 
 82
converting enzyme (ACE) inhibitors, anti-arrhythmic agents, beta-blockers, and calcium 
channel blockers in the pre-phase was determined.  Use of these agents in the 90-day 
period after the incident AMI was also determined.  Medication possession ratio and total 
days supply of beta-blockers in the post-AMI period was determined.  Medication 
possession ratio is defined as  
Total days supply of medication during study period 
Total number of days between fill date of first and last prescription + days supply on last 
claim 
 
 Total days supply was the sum of the days for which the patient filled a prescription 
during the year after the incident AMI.  In the post-AMI period, the total number of 
hospitalizations, ER visits, physician visits and total length of stay for those who had 
hospitalizations for the cardiac conditions under study were estimated by addition of each 
visit for the specific ICD-9 codes (See Appendix B-outcomes conditions).   
Expenditures were defined as direct costs incurred to Medicaid.  Thus, reimbursed 
amount was obtained by summing the paid amounts for the specific ICD-9 codes from 
the hospitalizations, ER visits, hospital/ER laboratory, physician visits and physician 
laboratory files for each patient.  Similarly, total charges was obtained by adding the 
billed amounts for the specific ICD-9 codes from the hospitalizations, ER visits, 
hospital/ER laboratory, physician visits and physician laboratory files for each patient.   
 
Research Design 
 The research design used for this phase of the study was a quasi-experimental 
longitudinal design.  There was an experimental group and a comparison group, i.e. the 
appropriately prescribed group and the inappropriately prescribed group.  However, since 
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the allocation to group was not randomized it was a quasi-experimental design.  Both the 
groups were followed for a period of 12-months to determine the effect of prescribing on 
outcomes, thus it is also longitudinal.  Additionally, since the study involved following a 
cohort of patients, determining their exposure to inappropriate/appropriate beta-blocker 
use and determining the effect of this exposure on outcomes, it can also be classified as a 
cohort design.   
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Figure 5: Quasi-experimental Longitudinal Research Design 
 
 
 
 NR O1 X -------O1` 
 
 NR O2     -------O2` 
NR: Non randomized, X: Exposure, O1: Experimental group, O2: Control group 
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Data Analysis for Phase I 
 The data analysis used for this phase is presented by research questions proposed.  
The Statistical Package for Social Sciences® (SPSS) version 10) was used for data 
analysis: 
 
Research Question 1: Prescribing Patterns for Beta-blocker Therapy in WV Medicaid 
 Frequencies were calculated to identify what proportion of patients received beta-
blocker therapy, appropriately and inappropriately, as per AHA/ACC guidelines.  There 
were four classes of patients; those who should be prescribed and received a prescription 
– appropriate use, those who should be prescribed and did not receive a prescription – 
under use, those who should not be prescribed and received a prescription – misuse and 
those who should not be prescribed and did not receive a prescription – appropriate use.  
The percentage of patients in the misuse category was low, and hence was pooled with 
the under use category to get an inappropriately prescribed group which was utilized for 
analysis purposes.  Similarly, the two appropriate use groups were pooled into one. 
These two groups (appropriate and inappropriate) were compared on demographic 
and patient history (co-morbidities and drug use) characteristics with t-tests and chi-
squares depending on whether the variable was dichotomous or categorical.  The 
different characteristics compared were: age, gender, presence of diabetes, hypertension, 
peripheral vascular disease, renal dysfunction, previous AMI, previous CHF, previous 
stroke, previous CABG, presence of relative contraindications, presence of absolute 
contraindications, number of cardiac admissions in the year prior to AMI, number of non-
cardiac admissions in the year prior to AMI, number of different drugs in the six months 
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before AMI, CABG during incident AMI, PTCA during incident AMI, length of stay 
during incident AMI, number of secondary diagnosis during incident AMI, use of 
digoxin, ACE inhibitors, anti-arrhythmics, beta-blockers and calcium channel blockers 
before the incident AMI.    
Of these, age, hypertension, presence of absolute contraindications, number of 
non-cardiac admissions, use of digoxin and use of beta-blockers in the pre-period were 
significantly different between the two groups.  These variables were used in a logistic 
regression to predict group status.  Group 1 was for appropriately prescribed patients and 
0 for inappropriately prescribed patients.  The predicted value of this logistic regression 
was used as propensity score for further analysis.  Propensity scores calculated from 
observational characteristics of patients are used to reduce selection bias in observational 
studies.  This is because in observational studies, investigators have no control over 
inherent risks that patients bring into the study.  Thus, large differences on observed co-
variates in the selected groups, may lead to biased estimates of outcomes.  Propensity 
score calculated from these observed co-variates can thus be used to reduce bias and 
increase precision. 
The equation for the logistic regression can be represented as: 
Appropriate assignment (Y)=     X1 (age)  
to treatment with beta-blockers  +X2 (hypertension) 
+X3 (presence of absolute contraindications) 
+X4 (number of previous non-cardiac admissions)  
+X5 (previous use of digoxin) 
+X6 (previous use of beta-blockers) 
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Research Question 2: Effect of Appropriate and Inappropriate Prescribing on Mortality 
 Patients who did not have follow-up information and were confirmed to have died 
from death certificate records in the 12-month period after the AMI were utilized to study 
the relationship between appropriate and inappropriate prescribing of beta-blockers and 
mortality.  This relationship was investigated by Kaplan-Meier survival curves where the 
dependent variable was time to death and the independent variables were appropriate and 
inappropriate use.  A duplicate analysis was conducted with time to cardiac death as the 
dependent variable.  Significant survival analysis is usually followed by Cox-proportional 
hazards regression model, where the effect of the main independent variable on survival 
time is examined after adjusting for other covariates.  However, since the survival time 
for cardiac death was not significant, a follow-up Cox-proportional hazards model was 
not conducted.     
The equations for the survival analysis can be represented as follows; 
Survival Analysis: 
Time to death (Y) = Xi (appropriate use) +Xii (inappropriate use) 
Where, Xi, was 1 for those patients in the appropriate group and Xii was 1 for those 
patients in the inappropriate group. 
 
Research Question 3: Effect of Appropriate and Inappropriate Prescribing on Morbidity 
Patients who had follow-up data and were continuously eligible for the follow-up 
period were utilized to investigate the relationship between beta-blocker prescribing and 
morbidity.  As in the case of mortality, Kaplan-Meier survival curves were utilized to 
examine the relationship between cardiovascular (CV) morbidity and prescribing of beta-
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blockers following an AMI.  However, the dependent variable was time to event during 
the follow-up period where event was first hospitalization due to any of the following: a 
successive AMI, heart failure, stroke, angina, other ischemic disease, essential 
hypertension, cardiogenic shock, disease of endocardium, conduction disorders and/or 
cardiomyopathy, in the follow-up period after the incident AMI.  Since survival analysis 
was found to be significant it was followed by a Cox-proportional regression model to 
adjust for the various co-variates.  Thus the equations were; 
Survival Analysis: 
Time to event (Y) = Xi (appropriate use) +Xii (inappropriate use) 
 
Cox-Proportional Hazards Regression Model: 
Time to event (Y) =    X1 (demographics- age, gender)  
+X2 (appropriate/inappropriate use)  
+X3 (predictors of appropriate beta-blocker assignment or 
propensity score) 
+X4 (presence of absolute contraindications) 
+X5 (current procedures CABG, PTCA, length of stay) 
+X6 (other discharge medications – aspirin, calcium channel  
blockers, ACE inhibitors, loop diuretics) 
+X7 (medication possession ratio) 
+X8 (days supply) 
Where X1, represented demographic characteristics such as age and gender.   
 89
X2, was 1 for those patients who were in the appropriately prescribed group and 0 for 
those who were inappropriately prescribed group.   
X3, was propensity score estimated through the logistic regression with group status as 
the predictor, estimated in research question 1.  An alternative analysis was done where 
this included a list of variables that were significant predictors of appropriate beta-
blocker receipt in the logistic regression for predicting group status in research question 
1. 
X4, was 1 if any of the absolute contraindications such as Bradycardia, Hypotension, 
and/or AV block were present and 0 if none of them were present.  
X5, and X6, were variables associated with procedures undertaken during the incident 
AMI and discharge medications after the incident AMI, respectively.   
X7, was medication possession ratio.  Medication possession ratio is proxy for patient 
compliance calculated as days of supply of the medication divided by the total days 
elapsed between 1st fill and last fill of the medication, which was obtained from the 
prescription data.   
X8, was days supply a total of number of days for which the patient had beta-blockers 
filled. 
 
Research Question 4: Effect of Appropriate and Inappropriate Prescribing on Utilization 
and Expenditure 
Patients who had follow-up data and were continuously eligible for the follow-up 
period were utilized to investigate the relationship between beta-blocker prescribing and 
health care utilization and expenditure.  To examine the relationship between prescribing 
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of beta-blockers and utilization of health care services, multiple regression analyses were 
conducted.  The utilization variables investigated were: 
Y1 = Number of physician visits due to cardiac conditions 
Y2 = Number of hospitalizations due to cardiac conditions 
Y3 = Total hospital length of stay due to cardiac conditions 
Y4 = Number of ER visits due to cardiac conditions 
Cardiac conditions included the following:  a successive AMI, heart failure, stroke, 
angina, other ischemic disease, essential hypertension, cardiogenic shock, disease of 
endocardium, conduction disorders and/or cardiomyopathy, in the follow-up period after 
the incident AMI.  To examine the relationship between prescribing of beta-blockers and 
expenditures, two multiple regression analyses were conducted.  The dependent variables 
were:  
Y5 = Log total charges associated with physician visits, hospitalizations, and ER 
visits due to cardiac conditions 
Y6 = Log total reimbursed amounts associated with physician visits, 
hospitalizations, and ER visits due to cardiac conditions 
Here, cardiac conditions were the same as defined earlier.  Reimbursed amount and 
charges were transformed into log form to decrease effect of skewness associated with 
the cost data.  The independent variables were similar to the regression models for 
morbidity analysis.  Thus, the generic equation can be represented as; 
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Dependent variable (Y) =     X1 (demographics- age, gender)  
+X2 (appropriate/inappropriate use)  
+X3 (predictors of appropriate beta-blocker 
assignment or propensity score) 
+X4 (presence of absolute contraindications) 
+X5 (current procedures CABG, PTCA, length of 
stay) 
+X6 (other discharge medications – aspirin, calcium 
channel blockers, ACE inhibitors, Loop diuretics) 
+X7 (medication possession ratio) 
+X8 (days supply) 
 
Phase II 
The goal of the second phase was to determine association between physician 
characteristics and prescribing behavior for beta-blockers for secondary prevention 
following an AMI.  For this, knowledge of contraindications, willingness to prescribe, 
socio-demographic, and practice characteristics of prescribers in the state were obtained.  
Primary data was collected for this phase using a survey instrument.  The following 
section describes the research design, methodology for identifying the study population, 
development of the survey instrument, the data collection process, and data analytical 
techniques that were used for this phase of the study. 
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Research Design 
 The research design employed for this phase of the study was a cross-sectional 
design.  The assumption made for this phase is that the knowledge, willingness to 
prescribe and socio-demographic and practice characteristics of physicians would affect 
their prescribing behavior.  In this phase of the study, the dependent variable was 
prescribing rate of beta-blocker therapy by physicians, which was obtained from the 
survey.  
 
Study Population and Sample Selection 
 The population of interest for this phase was physicians who were care-providers 
for AMI patients in WV.  A mailing list of all WV board certified physicians in the 
specialties of cardiology, internal medicine, primary practice and general practice was 
obtained from the West Virginia Medical Board (WVMB).  The total number of 
physicians in the state obtained from the WVMB in these specialties was 1151.  Since 
physician surveys are associated with low response rates, all of the listed physicians were 
surveyed.   
 
Instrument Development and Content 
 A self-administered survey was used for this phase.  Mail surveys offer many 
advantages such as the ability to collect data from a larger geographical area at a 
relatively low cost, greater versatility, and absence of interviewer bias.  For respondents, 
it offers the flexibility of replying at their convenience and offers respondent anonymity.  
In developing the survey instrument, attention should be given to the kind of information 
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needed to measure both the independent and dependent variables of interest, length of 
questionnaire, cost, comprehension level of prospective respondents, complexity of the 
questionnaire and the time required to complete it (Dillman, 1978).  All these factors 
collectively can have a significant impact on the kind of data collected and the response 
rate.  
 The survey in this study was designed to assess the WV physicians’ knowledge of 
contraindications according to the guidelines associated with post AMI care and use of 
beta-blockers, and their willingness to prescribe beta-blocker therapy in patients with 
various co-morbidities.  To avoid leading the respondents to desirable responses, 
questions for other post-AMI medications were included in the survey.  Thus, section one 
of the survey was designed to be more general for post-AMI medications.  The first 
question asked the respondents to mark those medications which were important 
secondary preventive agents following an AMI.  The response set included those 
medications which are present in the AHA/ACC guidelines.  A follow-up question 
required the respondents to rate their willingness to prescribe these medications for 
patients after an AMI, on a 1 to 5 Likert scale where 1 was least likely and 5 was most 
likely.  The next two questions in this section asked respondents to indicate how many of 
the last 10 AMI patients they had treated, they had prescribed beta-blockers and ACE 
inhibitors.  Those respondents whose response was less than 10 were instructed to list the 
specific reasons for not prescribing these medications in those patients not prescribed 
beta-blockers or ACE-inhibitors.   
The second section of the survey was primarily designed to measure willingness 
to prescribe beta-blockers in patients with other co-morbidities, on a 1 to 5 Likert scale 
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where 1 was least likely and 5 was most likely.  The respondents were also asked to list 
their willingness to prescribe ACE-inhibitors in these patients with other co-morbidties.  
However, this was done to prevent leading the respondents into giving desirable 
responses to questions with regards to beta-blocker use.  The co-morbidities included a 
list of conditions that were either relative or absolute contraindications for beta-blocker 
use, or conditions that are associated with higher or lower risk of complications, during 
an AMI.  A few other conditions associated with CV disease, but not associated with 
beta-blocker use, were also added to give a better mix of co-morbidities.   
The third section of the questionnaire focused on knowledge of contraindications.  
The respondents were asked to classify a list of conditions into relative and absolute 
contraindications and conditions that were neither relative nor absolute contraindications, 
for use of beta-blockers after an AMI.  The response set consisted of a list of conditions, 
which are either relative or absolute contraindications for beta-blocker use.  A few 
conditions, which were neither relative nor absolute contraindications, were also listed to 
give a good mixture of disease conditions.  These conditions were listed randomly in the 
response set.  
 Socio-demographic and practice information were obtained in the last section of 
the survey.  Data obtained included age, gender, specialty, year of board certification in 
this specialty, the average number of patients with AMI they treat per month (both new 
and repeat), the number of beds in the hospital which is their primary practice site, and 
information about their primary practice site.  The demographic questions were asked on 
a dichotomous or an interval scale.  Open-ended questions were used for obtaining 
information about practice characteristics.   
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Instrument Validation 
The instrument was submitted to experts for face and content validation.  Experts 
in the area of health services research at West Virginia University were approached to 
assess clarity and appropriateness.  Content validity is defined as “ the extent to which 
test exercises reflect and fully cover the curriculum which the test was designed to 
measure” (Mussio, 1987).  Feedback from the experts was incorporated into the survey.  
Institutional review board (IRB) permission was obtained from West Virginia University 
on the validated survey.  The final survey is represented in Appendix F. 
 
Instrument Pilot Testing 
 
The survey instrument was pre-tested to assess clarity, readability, and time for 
completion.  This process helps determine whether any important variable is being 
omitted, any information is redundant, and if any changes are required in the 
questionnaire wording and formatting, determine the ease of use and comprehension of 
the instrument, and helps obtain a mean completion time.  Pilot testing was conducted in 
a convenience sample of cardiology, and internal medicine residents at the West Virginia 
School of Medicine.  A total of six internal medicine residents and two cardiology 
residents responded to the survey.  Seven of these surveys had complete responses to all 
the questions indicating ease of comprehension.  The residents were asked to rate the 
questionnaire for clarity and readability on a 1 to 5 scale where 1 was unacceptable and 5 
was acceptable.  A total of 5 residents responded to this question, and the mean was 5 for 
both the clarity and readability.  The residents were also asked to state the time taken for 
completing the survey.  Five residents responded to this question and the mean time for 
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completion was 11.4 minutes.  No changes were made to the survey and the pilot testing 
suggested that the survey was suitable for the study.   
 
Data Collection  
 The data collection process included survey implementation, and non-response 
assessment. 
 
Survey Implementation 
Physicians’ from the mailing list were mailed an individualized cover letter, the 
survey instrument and a business reply envelope.  The cover letter explained the purpose 
of the study, and assured confidentiality of response (Appendix C).  Respondents were 
asked to return the completed questionnaire in the self-addressed business reply envelope 
provided in the package.  The surveys were coded for follow-up purposes.  All completed 
and returned questionnaires were checked off the mailing list.  A second mailing was 
made two weeks after the first one.  This consisted of the questionnaire survey, the 
second cover letter, and the self-addressed business reply envelope.  The second mailing 
was done only to those physicians who did not respond to the first mailing.  This was 
possible due to the coding procedure utilized during the first mailing.  The second cover 
letter was designed to stress the importance of participating in the study (Appendix D).  
Similar to the first mailing, completed responses were checked off the coding list.  The 
physicians who did not respond to the second mailing were sent a third mailing to boost 
the response rate.  This package contained the third cover letter (Appendix E), which 
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stressed the importance of the physicians’ response, the survey instrument and the self-
addressed envelope.  All three cover letters were pre-approved by the IRB. 
 
Non-Response Survey 
Bias can be introduced into the study due to possible differences between 
respondents and non-respondents.  Therefore a non-response analysis was conducted to 
determine if those physicians, who chose not to respond to any of the surveys, were in 
any way different from those physicians who did respond.  The non-respondents were 
mailed a brief, half-page questionnaire to ascertain their reason for not responding to the 
survey.  Several options were presented including: no time, did not receive the survey, 
forgot, survey misplaced, lost the survey, topic irrelevant, no incentive, don’t like to 
respond to survey, too long, not enough information and not interested.  A few critical 
items from the study survey instrument were also included.  These were utilized to 
compare the demographic and practice characteristics of the non-respondents with the 
respondents of the study survey, thus determine if there were significant differences 
between the two groups on key variables that prevent generalization of the study findings.  
Appendix G represents the non-response survey.  This was also approved by the IRB 
 
Data Handling 
Each questionnaire received was checked for completeness.  The Statistical 
Package for Social Sciences® (SPSS) version 10 was used for data entry and statistical 
analysis.  The data was checked for appropriate entry and to assure that data was free of 
errors.  A total of 20 surveys were not included in the analysis as they had more than 50% 
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of the questions incomplete.  Thus, the data file contained 261 cases that represent usable 
responses.   
 
Data Analysis for Phase II  
The data analysis used for this phase is presented by research questions proposed: 
 
Research Question 5: Knowledge of Contraindications and Prescribing Behavior 
 Descriptive statistics were performed to summarize the correct classification of 
the different conditions listed in the knowledge section (Section C) of the survey 
instrument.  The absolute contraindications were hypotension, bradycardia, second and 
third degree AV block.  The relative contraindications were systolic blood 
pressure<100Hg, heart rate <60bpm, peripheral vascular disease, peripheral 
hypoperfusion, ejection fraction (EF)<40%, first degree AV block, COPD, asthma, 
insulin dependent diabetes mellitus (IDDM), PR interval on ECG>0.24 second, and beta-
blocker intolerance.  The conditions which were neither absolute nor relative 
contraindication, were hypertension, non-insulin dependent diabetes mellitus (NIDDM), 
stroke, and ACE inhibitor intolerance.  Three scores were calculated based on their 
correct classification (number of correct responses) - the absolute contraindication score, 
the relative contraindication score, and the not a contraindication score.    
 Prescribing rate for beta-blocker therapy was calculated by dividing the number 
of patients, of the last 10 AMI patients, the respondents prescribed beta-blockers, divided 
by 10.  This was multiplied by 100 to get the prescribing percent, which was used as a 
proxy for prescribing behavior.  The correlation of this prescribing behavior with the 
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three computed scores was estimated to determine the association of prescribing behavior 
for beta-blockers as a secondary preventive agent after an AMI and knowledge of 
contraindication of beta-blockers. 
 
Research Question 6: Willingness to Prescribe and Prescribing Behavior 
 Descriptive statistics were performed to get the mean of willingness to prescribe, 
for each of the conditions listed in the Section B of the survey.  These were divided into 
those conditions where beta-blockers should definitely be prescribed, as they definitely 
provide benefits, conditions where they may be prescribed, as there is uncertainty about 
their benefits to patients with these conditions, and conditions where they definitely 
should not be prescribed as they do not provide benefits and can be harmful.   
The conditions in the definitely prescribe category were: age greater than 50 
years, large or anterior AMI, previous infarction, angioplasty, by-pass surgery, stroke, 
hypertension, and complex ventricular ectopy.  The conditions in the maybe prescribe 
category were: age less than or equal to 50 years, small infarction, EF<40%, history of 
CHF, systolic blood pressure <100Hg, heart rate <60bpm, LV failure, first degree AV 
block, peripheral vascular disease, COPD, asthma, and IDDM.  The conditions in the 
definitely not prescribe category were: hypotension, bradycardia, second and third degree 
AV block.  Three scores were calculated by summations of the answers to the conditions 
in each of these categories-the definitely prescribe score, the maybe prescribe score and 
the definitely not prescribe score.  The correlation of prescribing behavior calculated in 
research question 5 with these three computed scores were estimated to determine the 
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association of prescribing behavior for beta-blockers as a secondary preventive agent 
after an AMI and willingness to prescribe. 
 
Research Question 7: Demographic and Practice Characteristics and Prescribing 
Behavior 
 The association of prescribing percent/behavior calculated in research question 5 
with demographic and practice characteristics such as age, gender, specialty, year of 
board certification, location, type of primary practice site, number of beds (size of 
hospital) and number of patients (both new and repeat) was investigated.  Association of 
prescribing percent with categorical variables such as gender, specialty, location, year of 
board certification and type of primary practice site were evaluated using t-tests and F-
tests.  Association of prescribing percent with continuous variables such as age, size of 
hospital, and number of patients (both new and repeat) was investigated using Pearson’s 
correlations.   
 
Research Question 8: Knowledge of Contraindications, Willingness to Prescribe and 
Demographic and Practice Characteristics 
 The association of the three knowledge scores estimated in research question 5 
and the three willingness to prescribe scores estimated in research question 6 with 
demographic and practice characteristics such as age, gender, specialty, year of board 
certification, location, type of primary practice site, number of beds (size of hospital) and 
number of patients (both new and repeat) was investigated.  Association of each 
individual score with categorical variables such as gender, specialty, year of board 
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certification, location, and type of primary practice site was evaluated using t-tests and F-
tests.  Association of each individual score with continuous variables such as age, size of 
hospital, and number of patients (both new and repeat) was investigated using Pearson’s 
correlations.  
 
Research Question 9: Physician Characteristics and Prescribing Behavior 
 Association of all physician characteristics with prescribing behavior was 
investigated using multiple regression analysis.  The dependent variable was prescribing 
percent calculated in research question 5.  The independent variables were age, gender, 
specialty, primary practice site, the three knowledge scores estimated in research question 
5, the three willingness to prescribe scores estimated in research question 6, and number 
of AMI patients treated (both new and repeat).  Size of hospital, and location were not 
investigated in this analysis as this question was answered by only those physicians who 
reported their primary practice site as hospitals.  Year of board certification was 
excluded, as more than 33% of the respondents did not answer this question and inclusion 
of this variable would decrease the number of cases in the analysis below the required 
minimum for adequate power.     
 
Research Question 10: Reasons for Not Prescribing Beta-Blockers 
The reasons for not prescribing beta-blockers in post-AMI patients for secondary 
prevention given by respondents were combined and enlisted.   
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 This chapter discussed in detail the methodology employed to fulfill the goals and 
research questions of both phases I and II.  In the next chapter, results of the analysis 
conducted for accomplishing these will be presented. 
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CHAPTER FOUR 
 
RESULTS AND DISCUSSION 
 
 Earlier chapters of this text provided an overview of the effect of beta-blockers on 
outcomes, the effect of physician knowledge on prescribing, need for study, and study 
objectives.  The methods employed to achieve these objectives were also outlined.  This 
chapter presents the findings of the study and discussion for the results obtained.  Results 
of phase I are presented first, followed by phase II in the second half of the chapter.   
 
Phase I 
 Phase I of the study involved analyzing claims data for those patients who 
suffered from an acute myocardial infarction (AMI) from January 1, 1997 to June 30, 
2000.  The purpose was to determine prescribing of beta-blockers as long-term therapy 
following an AMI and effect of this prescribing on patient outcomes such as mortality, 
morbidity, health care utilization, and costs.   
 Paid claims data relevant for the study were obtained from Consultec, Inc.  
Consultec, Inc. stores data going back to several years.  However, not all of this data was 
pertinent to this study and so relevant data between January 1, 1996 to June 30, 2001 was 
obtained to conduct the analysis.  Table 1 outlines the extraction process from the raw 
data.  A total of 1,940 patients had a hospital claim for AMI and were continuously 
eligible for one year before the AMI.  Of these, 3 patients were excluded as they were 
part of managed care.  The next criterion was age limit.  A total of 748 patients were 
excluded, as they were older than 64 years of age.  This also excluded the Medicare 
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eligible patients.  Those patients who had length of stay less than 3 days (indicating a 
possible misdiagnosis) and those with ICD-9 (International Classification of Disease 9th 
edition) codes of 410.x2 were excluded in the next step.  This gave a cohort of 599 
patients.   
In this cohort there were some patients who had a recurrent AMI.  In such 
situations only the first AMI during the selected time frame was included.  Additionally, 
those patients who did not receive beta-blockers in the first 90 days after discharge from 
the incident AMI but received a prescription after the first 90 days were excluded.  The 
reason being the objective of the study, which was to evaluate the effect of beta-blockers 
when given long-term after an AMI according to American College of Cardiology 
(ACC)/American Heart Association (AHA) guidelines.  These patients did receive the 
drug, but this was not according to the guidelines and inclusion of these patients would 
lead to misclassification bias.  A total of 20 patients were excluded because they died 
during the incident AMI or within 30 days of the incident AMI.  Thus, a total of 488 
patients satisfied the inclusion criteria and were further investigated for beta-blocker use 
and its effect on mortality.  A total of 18 patients died due to causes not related to AMI.  
These were excluded from the analysis that investigated effect of 
appropriate/inappropriate beta-blocker use on cardiac deaths.  From this cohort, 58 
patients were excluded for investigating beta-blocker use and morbidity and health care 
utilization, as they were not continuously eligible during the 12-month period after the 
incident AMI.  Thus, 412 patients satisfied all the inclusion criteria for evaluating beta-
blocker use and its effect on morbidity and health care utilization following an AMI.   
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Table 1: Cohort Selection 
 
Inclusion Criteria 
  
 
Patients Excluded 
 
Selected Cohort 
 
First extraction- patients 
with AMI and 
continuously eligible for 
one year before AMI 
 
  
 
1,940 
Managed care recipients 
 
3 1,937 
Age > 64 years and 
Medicare eligible patients 
 
748 1,189 
Length of Stay <3 days 
and/or ICD-9 of 410.x2   
 
590 599 
Duplicates and received 
beta-blockers after the 
initial 90 days of discharge 
 
91 508 
Death during incident AMI 
or within 30 days of 
incident AMI 
 
20 488 => final cohort for all 
cause mortality 
Death due to non-cardiac 
causes 
18 470 => final cohort for 
death due to cardiac 
mortality 
Continuously eligible for 
one year after AMI 
excluding those who died 
within the year  
 
 
58 
 
412 => final cohort for 
morbidity and utilization 
related objectives 
 
AMI: Acute myocardial infarction, ICD-9: International classification of disease 9th edition 
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Demographic and Medical History of Patients in Phase I 
 
The demographic characteristics of the selected cohort is presented in Table 2.  
The mean age of the cohort at incident AMI was 53.76 (S.D. + 8.14) years.  More than 
half (68.2%) were over the age of 50 years with majority between the age of 50 to 60 
years.  About one-third (31.7%) were below the age of 50, with 22.3% in the age group 
of 40 to 50 years.  This positive skewness in the age distribution confirms that AMI is an 
elderly condition and is more prevalent in higher age groups.  The study cohort consisted 
of 246 males (50.4%), 238 females (48.8%) and 0.8% who did not report their gender and 
were excluded.  This is not consistent with the gender distribution of the Medicaid 
population which is predominantly female (In the year 1999, the distribution of WV 
Medicaid was 43:56, M:F).  This could be due to the fact that AMI is more common 
among males in this age group (below 65 years) compared to females.  The majority of 
the cohort (91.6%) was white, 4.1% were black and the remaining 4.3 % belonged to 
other ethnic groups.  This is characteristic of the West Virginia Medicaid population 
which consists of a white majority (In the year 1999, 92% of the Medicaid recipients 
were white). 
 Medical history and other characteristics of the selected cohort are represented in 
Table 3.  About 45% of the patients had hypertension, 37% were diabetic, and about 7% 
had peripheral vascular disease.  Approximately 20% of the patients had suffered from 
congestive heart failure (CHF) in the year before the incident AMI and 28% had suffered 
a previous AMI.  A very small percent of patients had a previous coronary artery bypass 
graft (CABG)  (1.2%) and none had a previous percutaneous transluminal coronary 
angioplasty (PTCA).  Around 6% of the patients had suffered a stroke, and less than 1 
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percent had renal dysfunction.  Over 11% had some absolute contraindications and over 
60% had some relative contraindications for beta-blocker use following an AMI.  The 
mean number of cardiac admissions and non-cardiac admissions in the previous year was 
less than 1.  However, the range was broader for non-cardiac admissions (0-5).  The mean 
number of different prescription drugs the patients were on was 10.49.  Less than one-
third of the patients were on medications associated with AMI such as calcium channel 
blockers (31.6%), Angiotensin converting enzyme (ACE) inhibitors (29.1%), beta-
blockers (22.7%), digoxin (12.3%), and anti-arrhythmics (2.5%), and in the six months 
prior to the incident AMI.  A very small number of the patients underwent a CABG 
(10%) or PTCA (about 16%) during the incident AMI.  The mean length of stay during 
the incident AMI was 7 and the patients had an average of 4 secondary diagnoses at index 
AMI.  Among the discharge medications, about 64% were prescribed beta-blockers, 40% 
were prescribed ACE-inhibitors, 38% were prescribed loop diuretics, 27% were 
prescribed calcium channel blockers, and 12% were prescribed aspirin. 
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Table 2: Demographic Characteristics of the Final Phase I Study Patients 
 
Demographic 
Characteristics  
 
 
N 
 
Percent 
 
Age 
 
  
<  30 years 
 
4 0.8 
30 < to < 40 years  
 
42 8.6 
40 < to < 50 years 
 
109 22.3 
50 < to < 60 years 
 
212 43.5 
60 < to < 64 years 
 
121 24.8 
           Total 
 
488 100.0 
Average Age + S.D. 
 
 
53.76 + 8.14  
Gender 
 
  
Males  
 
246 50.4 
Females  
 
238 48.8 
Unknown  
 
4 0.8 
Total  
 
488 100.0 
Race 
 
  
White  
 
447 91.6 
Black 
 
20 4.1 
Others  
 
21 4.3 
Total 
 
488 100.0 
 
 
N: Number of patients, S.D: Standard deviation 
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Table 3: Medical History and Other Characteristics 
 
Characteristics* 
 
 
N 
 
Percent 
 
Hypertension 
 
 
221 
 
45.3 
Diabetes 
 
179 36.7 
Previous AMI 
 
138 28.3 
Previous CHF 
 
97 19.9 
Peripheral vascular disease 
 
33 6.8 
Previous stroke 
 
30 6.1 
Previous CABG 
 
6 1.2 
Renal dysfunction 
 
4 0.8 
Previous PTCA 
 
0 0.0 
   
Presence of relative contraindications 
 
295 60.5 
Presence of absolute contraindications  
 
55 11.3 
   
Pre-AMI medications received 
 
  
          Calcium channel blockers 
 
154 31.6 
          ACE inhibitors 
 
142 29.1 
          Beta-blockers 
 
111 22.7 
          Digoxin 
 
60 12.3 
          Anti-arhythymics 
 
12 2.5 
   
Procedures during the incident AMI 
 
  
          PTCA 77 15.8 
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Table 3: Medical History and Other Characteristics (contd.) 
 
 
Characteristics* 
 
 
N 
 
Percent 
 
          CABG 
 
50 
 
10.2 
   
Discharge Medications 
 
  
          Beta-blockers 
 
310 63.5 
          ACE-inhibitors 
 
193 39.5 
          Loop diuretics 
 
183 37.5 
          Calcium channel blockers 
 
132 27.0 
          Aspirin 
 
58 11.9 
   
 Mean (S.D.) Min-Max 
 
Number of cardiac admissions in the prior year  
 
0.26 (0.44) 0-1 
Number of non-cardiac admissions in the prior year   
       
0.30 (0.68) 0-5 
Number of different drugs in the prior six months    
          
10.49 (7.18) 0-42 
Length of stay during incident AMI    
        
7.36 (4.49) 4-38 
Number of secondary diagnosis at index AMI 
 
4.17 (2.88) 1-9 
 
 
 
N: Number of patients, AMI: Acute myocardial infarction, CHF: Congestive heart failure, CABG: 
Coronary artery bypass graft surgery, PTCA: Percutaneous transluminal coronary angioplasty, ACE: 
Angiotensin converting enzyme S.D: Standard deviation, Min: Minimum value, Max: Maximum value 
*Medical history and presence of various conditions were determined using International classification of 
disease-9th edition (ICD-9) codes, Common procedural terminology (CPT) codes and Diagnosis related 
group (DRG) codes.  Medication use was determined by using generic and National drug classification 
(NDC) codes 
 
 111
Results for Research Question 1 
The first research question of the study was to determine prescribing patterns of beta-
blocker therapy for secondary prevention following an AMI and to see whether it was 
consistent with recommendations by AHA/ACC.  
A total of 310 (63.5%) patients received beta-blocker prescription within 90 days 
of discharge.  When beta-blocker use was determined at the end of 30 days and 60 days 
from discharge, the number of patients was lower with 282 (57.8%) receiving beta-
blocker prescription at both occasions.  For study purposes, beta-blocker use was defined 
as a prescription of beta-blocker within 90 days of discharge from the incident AMI.  
This allowed sufficient time to pass, after discharge, in case the patients received an 
initial supply of medications with refill orders from the hospital during discharge for 
which there would be no prescription record.  Based on the presence or absence of 
absolute contraindications to beta-blocker and presence of beta-blocker usage, the 
patients were classified to those who received beta-blocker appropriately and those who 
received beta-blocker inappropriately (See Figure 6).  Thus, those who had the absolute 
contraindications and received therapy were classified in the misuse category, and those 
who did not have absolute contraindications and did not received therapy were classified 
in the underuse category.  Both misuse (5.7%) and underuse (30.9%) formed the 
inappropriately prescribed category (36.7%).  Similarly, those patients who did not have 
absolute contraindications and received therapy (57.8%) and those who did have absolute 
contraindications and did not receive therapy (5.5%) were classified as appropriately 
prescribed (63.3%) (See Table 4). 
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 Univariate Analysis was conducted to see if the groups (appropriately prescribed 
and inappropriately prescribed) were different from each other (Table 5).  The two groups 
were compared on the following variables: Age, gender, presence of diabetes, presence of 
hypertension, presence of peripheral vascular disease, presence of renal dysfunction, 
presence of previous AMI, CHF, stroke, previous CABG, presence of relative and 
absolute contraindications, number of cardiac and non-cardiac admissions in the pre- 
period, number of drugs in the 6 months before AMI, procedures during incident AMI 
(CABG, PTCA), length of stay during incident AMI, number of secondary diagnosis at 
incident AMI and pre-AMI medication use (ACE inhibitors, anti-arrhythmic agents, beta-
blockers, calcium channel blockers & digoxin,).  T-tests were done for continuous 
variables and chi-square analysis was performed for categorical variables.  Among these 
different variables, age, presence of hypertension, presence of absolute 
contradindications, number of non-cardiac admissions in the pre period, and use of 
digoxin, and beta-blockers in the pre-period were significantly different between the two 
groups.  The appropriate group was slightly younger, had more hypertensive patients, had 
fewer patients with absolute contraindications, and fewer patients who had fewer non-
cardiac admissions in the pre-period as compared to the inappropriate group.  
Additionally, the appropriate group had more patients who received prescriptions of beta-
blockers but fewer patients who received prescriptions for digoxin in the pre-period 
compared to the inappropriate group.  Though not significant the appropriate group had 
higher percentage of patients with stroke and previous CABG compared to the 
inappropriate group. 
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A logistic regression analysis was conducted to predict assignment of patients to 
the appropriate and inappropriate group.  Those variables that were significant in the 
univariate analysis were used as independent variables.  Thus, the independent variables 
included were age, presence of hypertension, presence of absolute contraindications, 
number of non-cardiac admissions in the pre-period, use of digoxin, and beta-blockers in 
the pre-period.  Table 6 represents results of this analysis.  The model was significant (χ2  
= 58.003, p = 0.000, n = 488) with an R2 of 15.3% and 67.42% correct classification.  
Five of the six independent variables were significant predictors of group status.  These 
were age, hypertension, presence of absolute contraindications, number of non-cardiac 
admissions in the pre-period, and use of beta-blockers in the pre-period.  Those who were 
hypertensive were almost twice as likely to belong to the appropriate group, whereas 
those who received beta-blockers in the pre-period were 2.6 times more likely to belong 
to the appropriate group.  Older patients, those with absolute contraindications and those 
with more non-cardiac admissions in the pre-period were more likely to belong to the 
inappropriate group.  The predicted value of this regression or propensity score, was 
utilized in future analysis as a co-variate to reduce bias due to the differences between the 
two groups. 
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Figure 6: Appropriate/Inappropriate Use of Beta-blockers  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Presence of
Absolute Contraindications
     
 
Yes    No 
 
Beta-blocker   
 Use         
Yes   Misuse  Appropriate use I  
 
 
 
                     No   Appropriate use II Under use 
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Table 4: Prescription Patterns for Beta-blocker Use 
 
Category 
 
 
N 
 
Percent 
 
Appropriate use   
 
 
309 
 
63.3 
         Appropriate use I 282 57.8 
 
         Appropriate use II 27 5.5 
 
 
Inappropriate Use 
          
179 36.7 
         Under use  
 
151 30.9 
         Misuse 
 
28 5.7 
 
 
Total 
 
488 100.0 
 
 
N: Number of patients 
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Table 5: Univariate Comparisons between the Two Groups 
 
Variables 
 
Appropriate 
Group % 
 
 
Inappropriate 
Group % 
 
Test 
Statistic 
 
Significance  
(p) 
 
Age Mean (S.D.) 
 
 
52.72 (8.58) 
 
55.56 (7.00) 
 
t = 3.975 
 
0.000* 
Gender 
 
      Males 
 
      Females 
 
 
 
51.6 
 
48.4 
 
 
49.4 
 
50.6 
χ2   = 0.215
  
 
0.643 
Diabetes 
 
35.3 39.1 χ2   = 0.716 0.397 
Hypertension 
 
50.5 36.3 χ2  = 9.188 0.002* 
Peripheral vascular 
disease 
 
6.8 6.7 χ2  = 0.002 0.969 
Renal dysfunction 
 
1.0 0.6 χ2   = 0.237 0.626 
Previous AMI 
 
29.1 26.8 χ2   = 0.298 0.585 
Previous CHF 
 
19.1 21.2 χ2   = 0.324 0.569 
Previous Stroke 
 
7.1 4.5 χ2   = 1.380 0.240 
Previous CABG 
 
1.6 0.6 χ2   = 1.048 0.306 
Presence of relative 
contraindications 
 
59.2 62.6 χ2   = 0.531 0.466 
Presence of absolute 
contraindications 
 
8.7 15.6 χ2   = 5.403 0.020* 
Number of cardiac 
admissions Mean 
(S.D.) 
 
0.28 (0.45) 0.23 (0.42) t = 1.215 0.225 
Number of non-
cardiac admissions  
Mean (S.D.) 
0.24 (0.61) 0.40 (0.78) t = 2.454 0.015* 
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Table 5: Univariate Comparisons between the Two Groups (contd.) 
 
 
Variables 
 
Appropriate 
Group  % 
 
 
Inappropriate 
Group % 
 
Test 
Statistic 
 
Significance  
(p) 
 
Number of different 
drugs in the prior six 
months Mean (S.D.) 
 
 
10.66 (7.51) 
 
10.20 (6.56) 
 
t = 0.694 
 
0.488 
CABG 
 
10.0 10.6 χ2   = 0.046 0.838 
PTCA 
 
17.2 13.4 χ2   = 1.196 0.274 
Length of stay Mean 
(S.D.) 
 
7.20 (4.63) 7.65 (4.23) t = 1.083 0.280 
Number of secondary 
diagnosis Mean 
(S.D.) 
 
4.30 (2.89) 3.95 (2.85) t = 1.299 0.194 
Pre-AMI medications 
received: 
 
    
      ACE inhibitors 
 
28.2 30.7 χ2   = 0.363 0.547 
      Anti-arhythymics 
 
2.9 1.7 χ2   = 0.723 0.395 
      Beta-blockers 
 
28.8 12.3 χ2   = 17.586 0.000* 
      Calcium channel   
      blockers 
 
31.7 31.3 χ2   = 0.010 0.921 
       Digoxin 10.0 16.2 χ2   = 4.000 0.046* 
     
 * Significant at p < 0.05, S.D: Standard deviation, AMI: Acute myocardial infarction, CHF: Congestive 
heart failure, CABG: Coronary artery bypass graft, PTCA: Percutaneous transluminal coronary 
angioplasty, ACE: Angiotensin converting enzyme 
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Table 6: Predictors for Appropriate/Inappropriate Group 
 
Predictor 
 
 
Estimate 
 
S.E. 
 
Odds Ratio 
 
Significance 
 
Age 
 
 
-0.0529 
 
0.0135 
 
0.9484 
 
0.000* 
Hypertension 
 
0.6420 0.2074 1.9002 0.002* 
Presence of absolute 
contraindications 
 
-0.7914 0.3056 0.4532 0.009* 
Number of non-cardiac 
admissions 
 
-0.4317 0.1478 0.6494 0.003* 
Pre-AMI medications: 
 
    
      Digoxin 
 
-0.3000 0.3010 0.7408 0.318 
      Beta-blockers 0.9916 0.2723 2.6956 0.003* 
     
R2 = 15.3%  (χ2  = 58.003, p = 0.000), n = 488 
 
 
 
 
 
 
 
* Significant at p < 0.05, S.E: Standard error, AMI: Acute myocardial infarction 
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Discussion for Research Question 1   
 An analysis of the data revealed that there was inappropriate utilization of beta-
blockers as secondary preventive agents following an AMI.  Compared to previous 
studies where the utilization among eligible patients ranged from 30-40%, this study 
revealed a utilization of almost 64% (Rogers et al., 2000; Krumholz et al., 1998 & 
Soumerai et al., 1997).  This was also higher compared to the utilization levels reported 
recently in a Medicare population in the state of West Virginia, the same state as the 
study state, where only 59.4% received therapy at discharge (Schade et al., 2002).  Thus, 
there appears to be an increase in utilization of beta-blockers among eligible patients over 
time.  This confirms previous reports of steady rise in average use over years reported by 
Heller et al., (39.6% to 58.6%, 2000) and Pilote et al., (33% to 50%, 2000).  Thus, 
physicians are responding to the increase in awareness about the beneficial effects of 
beta-blockers for AMI patients.  The results also demonstrated a 5.7% use among patients 
with absolute contraindications.  This proportion is smaller than that reported in previous 
studies, where it was 11% (Brand et al., 1995) and 24% (Sial et al., 1994).  A sub-
analysis was conducted to investigate the distribution of age in the misuse, under use and 
appropriate use categories.  This study confirmed the association of age with beta-blocker 
use as reported in previous studies (Fishkind et al., 1997 ;Gurwitz et al., 1992).  Even in 
this younger population, the under use group was older (56.1 years) than the appropriate 
use (52.7 years) and misuse groups (52.7 years) and this was statistically significant (F = 
9.29, p < 0.0001).  Thus, though this study revealed an increase in use of beta-blocker 
therapy in post AMI patients, there is still room for improvement in patients in whom it 
would maximize benefits.  
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 A comparison of the two groups classified for study purposes revealed that they 
were different from each other on a few variables.  However, this could not help identify 
which group was more severely ill between the appropriate and inappropriate.  A 
multivariate comparison revealed that five of these variables were significant predictors 
of group status.  These include- age, hypertension, presence of absolute contraindications, 
number of non-cardiac admission in pre-period, and use of beta-blockers in the pre-
period.  Patients who were older, had presence of absolute contraindications, and had a 
greater number of non-cardiac admissions were in the inappropriate group, whereas 
patients with hypertension and pre-beta-blocker use were in the appropriate group.  
 
Results for Research Question 2 
 Kaplan-Meier survival curves were constructed to investigate effect of 
appropriate and inappropriate prescribing of beta-blocker therapy on mortality for the 
selected patients in the first-year after the incident AMI.  Two separate analyses were 
conducted.  The first included death due to all causes and the second included death due 
to cardiac causes.  Figure 7 illustrates the all-cause death curves and Figure 8 illustrates 
the cardiac-cause death curves.  The two groups (appropriate and inappropriate) differed 
significantly for survival at the end of the one-year period (Log Rank Statistic = 4.44, p = 
0.0351).  The appropriate group had a better survival distribution compared to the 
inappropriate group.  An investigation of only cardiac deaths revealed better survival 
distribution for the appropriate group too (Figure 8), however this was not statistically 
significant (Log Rank Statistic = 1.35, p = 0.245).   
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The different causes of deaths are displayed in Table 7.  The non-cardiac deaths 
were not related to AMI and were mostly due to cancer or diabetes.  A majority of the 
cardiac deaths were due to coronary artery disease (CAD) and acute myocardial 
infarction (AMI).  A frequency of cardiac deaths by group is represented in Table 8.  This 
shows that there were more deaths due to AMI in the inappropriate group.  Power 
analysis revealed that time to all cause death analysis had a power of 88% whereas time 
to cardiac death had a power of 46%.  The numbers of deaths in the two groups were 
investigated by chi-square analysis.  The results were similar to the survival analysis, 
with the difference between the two groups being significant for all cause deaths and not 
significant for cardiac-cause deaths (Table 9).  Additionally, the groups were compared 
for deaths due to an AMI.  Even though the percentage was higher in the inappropriate 
group this was not statistically significant.  When analysis was repeated using beta-
blocker prescribing at 30 and 60 days after the AMI to categorize appropriate and 
inappropriate prescribing, the results for both all-cause and cardiac mortality did not 
change. 
 
 122
Figure 7: Kaplan-Meier Survival Curves (all-cause deaths) for 
Appropriate/Inappropriate Use of Beta-blockers 
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Figure 8: Kaplan-Meier Survival Curves  (cardiac deaths) for 
Appropriate/Inappropriate Use of Beta-blockers 
 
Time to death
4003002001000
C
um
ul
at
iv
e 
Su
rv
iv
al
1.01
1.00
.99
.98
.97
.96
.95
Appropriate use
Appropriate use
-Censored
Inappropriate use
Inappropriate use
-Censored
 124
Table 7: Causes of Death 
 
Non-cardiac Causes (n = 15) 
 
 
Cardiac Causes (n = 16) 
 
Accident (1) 
 
 
Coronary arteriosclerosis (5) 
AIDS (1) 
 
Dysrhythmia (1) 
Cancer of trachea, lung, and bronchi (4) 
 
Heart disease, unspecified (1) 
Chronic obstructive pulmonary disease (1) 
 
Ischemia (1) 
Diabetes (4) 
 
Acute myocardial infarction (8) 
End stage renal disease (1) 
 
 
Injury to peripheral nerves (1) 
 
 
Kidney disorder (1) 
 
 
Pulmonary embolism (1) 
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Table 8: Cardiac Deaths by Group 
 
Appropriate Use (8) 
 
 
Inappropriate Use (8) 
 
Coronary arteriosclerosis (3) 
 
 
Coronary arteriosclerosis (2) 
Dysrhythmia (1) 
 
Heart disease (1) 
Ischemia (1) 
 
Acute myocardial infarction (5) 
Acute myocardial infarction (3) 
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Table 9: Patient Deaths by Group Status 
 
Mortality 
 
 
Percent 
 
χ2 Statistic 
 
Significance 
 
All Cause Death 
 
  
4.699 
 
0.030* 
           Appropriate use 
 
4.5   
           Inappropriate use 
 
 
9.5   
Cardiac Death 
 
 1.370 0.241 
           Appropriate use 
 
2.7   
           Inappropriate use 
 
 
4.7   
Death due to AMI 
 
 2.444 0.118 
           Appropriate use 
 
1.0   
           Inappropriate use 
 
 
2.9   
 
* Significant at p < 0.05, AMI: Acute myocardial infarction 
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Discussion for Research Question 2 
 
 There was a significant relationship between beta-blocker receipt among eligible 
patients for secondary prevention after an AMI and all cause mortality.  Thus, null 
hypothesis A is rejected.  The appropriate group had a significantly better distribution of 
survival in the year after the AMI.  This is consistent with the information associated with 
both clinical trials and observational studies in this area (Soumerai et al., 1997; Bradford 
et al., 1999).  However, beta-blockers have been reported to reduce cardiac mortality by 
reduction in re-infarction rates and sudden death (Goldsetin, 1996).  The chi-square test 
that investigated this relationship between cardiac mortality and beta-blocker use was not 
significant.  Though the numbers were in favor of appropriate use of beta-blocker 
therapy, statistical significance was not observed.  Thus, the null hypothesis B is not 
rejected.  There could be two reasons for this observation.  First, the number of patients 
in this cohort is small, thus the analysis did not have sufficient power to achieve 
statistical significance compared to previous studies that involved large numbers of 
patients.  Soumerai et al., (1997) had a cohort of almost 4,000 patients and Krumholz et 
al., (1998) involved greater than 45,000 patients.  The second more important reason is 
the fact that this study was conducted in a relatively younger population, in which the 
average age was less than 54 years compared to previous retrospective studies.  Thus, 
intuitively, the probability of death in a younger patient due to AMI would be smaller 
compared to an older patient greater than 65 years old, and thus this population probably 
had lower death rates, which did not achieve significance.  However, even in this younger 
population, appropriate use of beta-blocker had a lower proportion of cardiac deaths, 
compared to the inappropriate group.  
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 An important fact to consider is that some of the deaths that were excluded when 
cardiac mortality was investigated were associated with diabetes.  Diabetes can be an 
underlying cause for death but not the actual cause of death, unless it is type I diabetes 
where acute coma is the leading cause of death (NIH, 1995).  The majority of deaths in 
type II diabetics is due to heart disease (NIH, 1995).  Additionally, one of the excluded 
death was due to an accident.  A patient with a previous AMI is more likely to die of an 
AMI during an accident compared to other causes.  Also, another death excluded was due 
to pulmonary embolism.  Pulmonary embolism is one of the complications associated 
with an AMI (Ahdout, Damani, & Ultan, 1989).  However, a pulmonary embolism can be 
due to other causes too (Carson et al., 1992).  Hence, this death had to be excluded.  The 
information obtained from vital statistics for death is for record purposes and not research 
purposes.  More detailed information about death would probably be helpful in getting 
the true cause of death.  Thus, this identifies using death information from Vital Statistics 
as a limitation for determining true cause of death. 
 
Results for Research Question 3 
 Morbidity between the two groups was compared via Kaplan-Meier survival 
curves too.  However, the dependent variable was time to first hospitalization due to a 
cardiovascular event from the date of discharge.  Here cardiovascular event was defined 
as first hospitalization due to various conditions related to AMI (See Table 10).  This 
revealed a statistical significant difference in the distribution for the dependent variable 
by group.  The inappropriate group had a better distribution with fewer events compared 
to the appropriate group (Long rank statistic = 5.42, p = 0.0199, Figure 9).  This analysis 
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had a power of 75.5%.  When the number of patients was compared, this was also 
statistically significant (Table 11).  However, when similar analysis was repeated for 
recurrent AMI, both distribution and number were not significant (Figure 10, Table 11).   
 The significant survival analysis of time to event was followed with Cox-
proportional hazard’s regression model to adjust for patient conditions in the form of co-
variates.  Two models were run, the first one used those variables which were significant 
predictors of group status (appropriate/inappropriate) as co-variates in addition to some 
of the identified variables associated with the incident AMI and post-AMI care.  The 
second model used the propensity score calculated as the predicted probability for group 
status in analysis of research question 1 and the identified variables associated with the 
incident AMI and post-AMI care.   
 The first model revealed that survival distribution was significant by group status 
even after adjusting for the various co-variates.  The hazards ratio (HR) for the group was 
2.00, implying that the hazard for the appropriate group was almost two times the hazard 
for the inappropriate group to suffer from the defined cardiovascular event (Table 12).  
Some of the other co-variates which were significant in this model were number of non-
cardiac admissions in the pre-period (HR = 1.44), use of beta-blockers in the pre-period 
(HR = 1.47), CABG during incident AMI (HR = 0.39), and length of stay during incident 
AMI (HR = 1.04).  Days supply of beta-blockers in the follow-up period was almost 
significant (HR = 0.99, p = 0.06).  Thus, those with greater length of stay during incident 
AMI, pre-period beta-blocker use, and greater number of hospitalization in the pre-period 
were more likely to suffer from a cardiac event, whereas those who underwent CABG 
during incident AMI were less likely to suffer from a cardiac event.  Also, days supply 
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though not statistically significant was associated with lower morbidity.  The second 
model also revealed that survival distribution was significant by group (Table 13).  Here 
the HR for group was 1.98, and two other variables CABG during incident AMI and 
length of stay during incident AMI were significant.  Thus, results did not change much 
using propensity score analysis.  When analysis was repeated using beta-blocker 
prescribing at 30 and 60 days after the AMI to categorize appropriate and inappropriate 
prescribing, the results for morbidity did not change. 
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Table 10: Cardiovascular Events for Morbidity 
 
Conditions for Morbidity 
 
 
 
Angina 
 
 
Cardiogenic shock 
 
 
Cardiomyopathy 
 
 
Conduction disorders 
 
 
Disease of endocardium 
 
 
Essential hypertension 
 
 
Heart failure 
 
 
Ischemia 
 
 
Ischemic heart disease 
 
 
Acute myocardial infarction 
 
 
Stroke 
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Figure 9: Kaplan-Meier Survival Morbidity Curves (time to first cardiovascular 
hospitalization) for Appropriate/Inappropriate Use of Beta-blockers 
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Figure 10: Kaplan-Meier Survival Morbidity Curves (time to recurrent AMI) for 
Appropriate/Inappropriate Use of Beta-blockers 
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Table 11: Cardiac Events by Group Status 
 
Events 
 
 
Percent 
 
χ2 Statistic 
 
Significance 
 
All Cardiac Events 
 
  
4.013 
 
0.045* 
           Appropriate use 
 
47.3   
           Inappropriate use 
 
 
37.2   
Recurrent Myocardial Infarction  
 
 1.260 0.262 
           Appropriate use 
 
18.4   
           Inappropriate use 
 
 
14.1   
* Significant at p < 0.05 
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Table 12: Cox-Proportional Regression Model for Time to First Cardiac Event 
 
Predictor 
 
 
Estimate 
 
S.E. 
 
Hazard’s Ratio 
 
Significance 
 
Age 
 
 
0.0076 
 
0.0105 
 
1.0079 
 
0.449 
Sex 
 
0.0857 0.1621 1.0895 0.597 
Appropriate/Inappropriate use 
of Beta-blockers at post-AMI 
 
0.6931 0.2454 2.000 0.004* 
Hypertension 
 
-0.1201 0.1658 0.8869 0.469 
Presence of absolute 
contraindications 
 
-0.0591 0.2630 0.9426 0.822 
Number of non-cardiac 
admissions 
 
0.3675 0.0979 1.4441 0.000* 
Pre-AMI medications: 
 
    
      Beta-blockers 
 
0.3856 0.1927 1.4705 0.045* 
Procedures during the 
incident AMI 
 
          CABG 
 
 
 
 
-0.9253 
 
 
 
0.3275 
 
 
 
0.3964 
 
 
 
0.004* 
          PTCA 
 
-0.2361 0.2293 0.7897 0.303 
          Length of stay           0.0362 0.0171 1.0369 0.034* 
 
Discharge Medications 
 
    
          Aspirin 
 
0.0716 0.2397 1.0742 0.765 
          ACE-inhibitors 
 
0.1498 0.1614 1.1617 0.353 
          Calcium channel   
          blockers 
 
0.0639 0.1684 1.0660 0.704 
          Loop diuretics 
 
0.1531 0.1695 1.1654 0.366 
Medication Possession Ratio 
 
0.0252 0.3099 1.0256 0.935 
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Table 12: Cox-Proportional Regression Model for Time to First Cardiac Event 
(contd.) 
 
 
Predictor 
 
 
Estimate 
 
S.E. 
 
Hazard’s Ratio 
 
Significance 
 
Day supply 
 
 
-0.0014 
 
0.0007 
 
0.9987 
 
0.061+ 
-2LL = 1989.8 (χ2  = 47.89, p = 0.000*), n = 408 
 
 
* Significant at p < 0.05,  + Significant at p < 0.01, S.E: Standard error, AMI: Acute myocardial infarction, 
CABG: Coronary artery bypass graft, PTCA: Percutaneous transluminal coronary angioplasty, ACE: 
Angiotensin converting enzyme inhibitor 
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Table 13: Cox-Proportional Regression Model for Time to First Cardiac Event 
using Propensity Score 
 
Predictor 
 
 
Estimate 
 
S.E. 
 
Hazard’s Ratio 
 
Significance 
 
Age 
 
 
-0.0063 
 
0.0124 
 
0.9937 
 
0.609 
Sex 
 
-0.0110 0.1587 0.9890 0.944 
Appropriate/Inappropriate use 
of Beta-blockers at post-AMI 
 
0.6844 0.2455 1.9826 0.005* 
Propensity score 
 
-0.8823 0.6585 0.4138 0.180 
Presence of absolute 
contraindications 
 
-0.2401 0.2774 0.7866 0.386 
Procedures during the 
incident AMI 
 
          CABG 
 
 
 
 
-0.9348 
 
 
 
0.3239 
 
 
 
0.3927 
 
 
 
0.003* 
          PTCA 
 
-0.3421 0.2261 0.7102 0.130 
          Length of stay           0.0333 0.0168 1.0339 0.047* 
 
Discharge Medications 
 
    
          Aspirin 
 
0.0420 0.2374 1.0429 0.859 
          ACE-inhibitors 
 
0.1529 0.1605 1.1652 0.340 
          Calcium channel  
           blockers 
 
0.1497 0.1671 1.1615 0.370 
          Loop diuretics 
 
0.2045 0.1681 1.2269 0.223 
Medication Possession Ratio 
 
0.0239 0.3094 1.0241 0.938 
Day supply 
 
-0.0011 0.0006 0.9989 0.126 
-2LL = 2003.3 (χ2  = 34.704, p = 0.001*), n = 408 
 
 
 
* Significant at p < 0.05, S.E: Standard error, AMI: Acute myocardial infarction, CABG: Coronary artery 
bypass graft, PTCA: Percutaneous transluminal coronary angioplasty, ACE: Angiotensin converting 
enzyme inhibitor 
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Discussion for Research Question 3 
 The above analysis rejected the null hypothesis C that there was no significant 
relationship between appropriate use and inappropriate prescribing of beta-blockers and 
morbidity (time to first hospitalization due to a cardiovascular event).  Thus, there was an 
association, but unlike mortality this association revealed that appropriate use was 
associated with a higher probability of a cardiovascular event in the post AMI 12-month 
period as compared to the inappropriate group.  When the event was restricted to 
recurrent AMI, though the distribution was not significant, the survival curves illustrated 
that the association was similar to when all cardiac events were considered.  The Cox-
proportional hazards model confirmed this association even after adjusting for all co-
variates.  Appropriate beta-blocker use was still associated with greater morbidity.  
Additionally, the first model, where the co-variates included predictors of 
appropriate/inappropriate group, days supply was almost significant and was negatively 
associated with morbidity.  This illustrates a conflict (appropriate use is associated with 
greater morbidity, but higher days supply is associated with lower morbidity).  Thus, 
although there is a definite association between appropriate/inappropriate prescribing and 
morbidity, the above results do not clearly help interpret this association. 
 
Results for Research Question 4 
 Utilization of services between the two groups was compared by exploring 
whether there was any difference in the number of hospitalizations, number of ER visits, 
number of physician visits, total length of stay, total charges and total reimbursed 
amounts in the follow-up period due to cardiac conditions.  The descriptive statistics for 
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these are listed in Table 14.  The cardiac conditions were the same as those specified in 
Table 10.  Two multiple regression models were performed for each of the utilization 
variables.  The first model included those co-variates that were significant in predicting 
group status for appropriate/inappropriate beta-blocker receipt in addition to other co-
variates.  The second model included propensity score instead of these predicting 
variables with other co-variates.  The total charges and total reimbursed amounts 
variables were log transformed to decrease skewness of the data.  The following 
utilization models were significant: number of hospital visits (both models), number of 
ER visits (both models), number of physicians visits (only the first model), length of stay 
(both models), log total charges (both models), and log total reimbursed amounts (both 
models) (Tables 15-26).  The R2 values for the significant models ranged between 6 to 
14%.  Thus, there was a lot of variance in the utilization variables that could not be 
explained by the independent variables.  For interpretation of semilogarithmic models, 
the correction of Halverson and Palmquist with a modification by Kennedy was 
employed (Halverson, & Palmquist, 1980; Kennedy, 1981).  All models were checked for 
violation of assumptions associated with linear regression.  The models had no problems 
with multicollinearity, heteroskedasticity and autocorrelation.  The power of analysis for 
the models was 100%.  For these models, the variables that were significant in predicting 
the utilization variables are listed below: 
 
Number of Hospital visits due to Cardiac Conditions (Group when significant is in bold):   
First Model (Table 15): Appropriate/Inappropriate group of beta-blocker at 
post AMI, Number of non-cardiac admissions, Use of beta-blockers in the pre-
period, CABG during incident AMI, and Length of stay during incident AMI. 
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Propensity Score Model (Table 16): Appropriate/Inappropriate group of beta-
blocker at post AMI, CABG during incident AMI, and Length of stay during 
incident AMI. 
 
Number of ER visits due to Cardiac Conditions: 
First Model (Table 17): Appropriate/Inappropriate group of beta-blocker at 
post AMI, Presence of absolute contraindications, Number of non-cardiac 
admissions, Use of beta-blockers in the pre-period, and Medication possession 
ratio (MPR). 
 
Propensity Score Model (Table 18): Appropriate/Inappropriate group of beta-
blocker at post AMI, Presence of absolute contraindications, and MPR. 
 
Number of Physician visits due to Cardiac Conditions:  
First Model (Table 19): Presence of hypertension, Number of non-cardiac 
admissions, and Use of beta-blockers in the pre-period. 
 
Propensity Score Model (Table 20, model not significant): Presence of absolute 
contraindications during or before incident AMI. 
 
Length of Stay due to Cardiac Conditions: 
First Model (Table 21): Appropriate/Inappropriate group of beta-blocker at 
post AMI, Number of non-cardiac admissions, Use of beta-blockers in the pre-
period, CABG during incident AMI, Length of stay during incident AMI, and 
Days supply. 
 
Propensity Score Model (Table 22): Appropriate/Inappropriate group of beta-
blocker at post AMI, CABG during incident AMI, Length of stay during 
incident AMI, and Days supply. 
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Log Total Charges due to Cardiac Conditions: 
 First Model (Table 23): CABG during incident AMI. 
 
 Propensity Score Model (Table 24): CABG during incident AMI. 
 
Log Total Reimbursed Amounts due to Cardiac Conditions: 
First Model (Table 25): CABG during incident AMI and Length of stay during 
incident AMI. 
 
Propensity Score Model (Table 26): CABG during incident AMI and Length of 
stay during incident AMI. 
 
Appropriate/inappropriate use of beta-blockers post AMI was a significant predictor in 
some of the utilization variable models.  It was a significant predictor for number of 
hospitalizations in the follow-up period, number of ER visits in the follow-up period, and 
length of stay in the follow-up period due to cardiac conditions.  It did not affect the 
number of physician visits, charges and reimbursed amounts.  Additionally, for the 
variables where it was significant, the beta coefficients in the models were positive, 
suggesting increased utilization of health care services for the appropriate group.  Among 
the other significant predictors, higher number of non-cardiac admissions in the pre-
period were associated with higher utilization, use of beta-blockers in the pre-period was 
associated with higher utilization, presence of any absolute contraindication was 
associated with higher utilization except for physicians visits where it was associated 
with lower utilization.  Presence of hypertension was associated with fewer physician 
visits, CABG during incident AMI was associated with lower utilization but higher 
expenditures, longer length of stay during incident AMI was associated with lower 
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utilization but higher expenditures, compliance variable (MPR) was associated with 
lower utilization and days supply was also associated with lower utilization.  Propensity 
score was not significant in any of the models and use of propensity score did not affect 
significance of other variables.  When analysis was repeated using beta-blocker 
prescribing at 30 and 60 days after the AMI to categorize appropriate and inappropriate 
prescribing, the results for utilization and expenditures did not change. 
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Table 14: Utilization Variables 
 
Variables 
 
Mean +S.D. 
 
Range 
 
 
Number of Hospital Visits 
 
 
0.86+1.54 
 
0-11 
Number of ER Visits 
 
0.23+0.88 0-12 
Number of Physicians Visits 
 
6.63+9.62 0-64 
Length of Stay 
 
4.65+9.77 0-70 
Total Charges 
 
$17,258.50+33,146.57 0-3,14,066.70 
Total Reimbursed Amounts $15,609.00+30,573.02 0-2,77,218.00 
   
 
  ER: Emergency room, S.D: Standard deviation 
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Table 15: Predictors for Number of Hospital Visits due to Cardiac Conditions 
 
Predictor 
 
 
Estimate 
 
S.E. 
 
t-Statistic 
 
Significance 
 
Age 
 
 
-0.003 
 
0.010 
 
0.368 
 
0.713 
Sex 
 
-0.013 0.152 -0.087 0.931 
Appropriate/Inappropriate use 
of beta-blockers at post-AMI 
 
0.829 0.228 3.627 0.000* 
Hypertension 
 
-0.180 0.155 -1.162 0.246 
Presence of absolute 
contraindications 
 
0.127 0.242 0.525 0.600 
Number of non-cardiac 
admissions 
 
0.500 0.118 4.244 0.000* 
Pre-AMI medications: 
 
    
      Beta-blockers 
 
0.486 0.189 2.575 0.010* 
Procedures during the incident 
AMI 
 
          CABG 
 
 
 
 
-0.647 
 
 
 
0.260 
 
 
 
-2.489 
 
 
 
0.013* 
          PTCA 
 
0.0007 0.205 0.004 0.997 
          Length of stay           -0.043 0.020 2.224 0.027* 
 
Discharge Medications 
 
    
          Aspirin 
 
-0.168 0.231 -0.725 0.469 
          ACE-inhibitors 
 
0.128 0.157 0.816 0.415 
          Calcium channel  
          blockers 
 
0.075 0.167 0.456 0.649 
          Loop diuretics 
 
0.225 0.165 1.366 0.173 
Medication Possession Ratio 
 
-0.129 0.309 -0.419 0.676 
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Table 15: Predictors for Number of Hospital Visits due to Cardiac Conditions 
(contd.) 
 
 
Predictor 
 
 
Estimate 
 
S.E. 
 
t-Statistic 
 
Significance 
 
Days supply 
 
 
-0.001 
 
0.001 
 
-1.503 
 
0.134 
R2 = 13.5 %(F = 3.798, p =  0.000*), n = 407 
 
 * Significant at p < 0.05, S.E: Standard error, AMI: Acute myocardial infarction, CABG: Coronary artery 
bypass graft, PTCA: Percutaneous transluminal coronary angioplasty, ACE: Angiotensin converting 
enzyme inhibitor 
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Table 16: Predictors for Number of Hospital Visits due to Cardiac Conditions using 
Propensity Score 
 
Predictor 
 
 
Estimate 
 
S.E. 
 
t-Statistic 
 
Significance 
 
Age 
 
 
-0.007 
 
0.012 
 
-0.611 
 
0.542 
Sex 
 
-0.096 0.156 -0.622 0.534 
Appropriate/Inappropriate use of 
beta-blockers at post-AMI 
 
0.799 0.232 3.437 0.001* 
Propensity score 
 
-0.650 0.625 -1.039 0.299 
Presence of absolute 
contraindications 
 
-0.026 0.267 -0.101 0.920 
Procedures during the incident 
AMI 
 
          CABG 
 
 
 
 
-0.679 
 
 
 
0.267 
 
 
 
-2.548 
 
 
 
0.011* 
          PTCA 
 
-0.111 0.209 -0.532 0.595 
          Length of stay           -0.045 0.020 2.268 0.024* 
 
Discharge Medications 
 
    
          Aspirin 
 
-0.215 0.237 -0.909 0.364 
          ACE-inhibitors 
 
0.093 0.160 0.588 0.557 
          Calcium channel blockers 
 
0.177 0.169 1.047 0.296 
          Loop diuretics 
 
0.270 0.169 1.593 0.112 
Medication Possession Ratio 
 
-0.143 0.317 -0.450 0.653 
Days supply 
 
-0.0008 0.001 -1.114 0.266 
R2 = 8.3 %(F = 2.529, p = 0.002*), n = 407 
 
 * Significant at p < 0.05, S.E: Standard error, AMI: Acute myocardial infarction, CABG: Coronary artery 
bypass graft, PTCA: Percutaneous transluminal coronary angioplasty, ACE: Angiotensin converting 
enzyme inhibitor 
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Table 17: Predictors for Number of ER Visits due to Cardiac Conditions 
 
Predictor 
 
 
Estimate 
 
S.E. 
 
t-Statistic 
 
Significance 
 
Age 
 
 
-0.006 
 
0.006 
 
-1.188 
 
0.236 
Sex 
 
-0.096 0.090 -1.071 0.285 
Appropriate/Inappropriate use 
of beta-blockers at post-AMI 
 
0.470 0.135 3.484 0.001* 
Hypertension 
 
-0.037 0.091 -0.414 0.679 
Presence of absolute 
contraindications 
 
0.320 0.143 2.242 0.026* 
Number of non-cardiac 
admissions 
 
0.155 0.070 2.233 0.026* 
Pre-AMI medications: 
 
    
      Beta-blockers 
 
0.220 0.111 1.977 0.049* 
Procedures during the incident 
AMI 
 
          CABG 
 
 
 
 
-0.057 
 
 
 
0.153 
 
 
 
-0.376 
 
 
 
0.707 
          PTCA 
 
0.095 0.121 0.794 0.427 
          Length of stay           -0.003 0.012 -0.271 0.786 
 
Discharge Medications 
 
    
          Aspirin 
 
-0.049 0.137 -0.361 0.718 
          ACE-inhibitors 
 
-0.064 0.093 -0.693 0.489 
          Calcium channel   
          blockers 
 
-0.0006 0.098 -0.007 0.994 
          Loop diuretics 
 
0.165 0.097 1.697 0.090 
Medication Possession Ratio 
 
-0.474 0.182 -2.598 .010* 
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Table 17: Predictors for Number of ER Visits due to Cardiac Conditions (contd.) 
 
 
Predictor 
 
 
Estimate 
 
S.E. 
 
t-Statistic 
 
Significance 
 
Days supply 
 
 
-0.00004 
 
0.000 
 
0.095 
 
0.924 
R2 = 8.5 %(F = 2.276, p = 0.003*), n = 407 
 
 * Significant at p < 0.05, ER: Emergency room, S.E: Standard error, AMI: Acute myocardial infarction, 
CABG: Coronary artery bypass graft, PTCA: Percutaneous transluminal coronary angioplasty, ACE: 
Angiotensin converting enzyme inhibitor 
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Table 18: Predictors for Number of ER Visits due to Cardiac Conditions using 
Propensity Score 
 
Predictor 
 
 
Estimate 
 
S.E. 
 
t-Statistic 
 
Significance 
 
Age 
 
 
0.008 
 
0.007 
 
-1.197 
 
0.232 
Sex 
 
-0.125 0.090 -1.380 0.168 
Appropriate/Inappropriate use of 
beta-blockers at post-AMI 
 
0.460 0.135 3.417 0.001* 
Propensity score 
 
-0.006 0.363 -0.017 0.987 
Presence of absolute 
contraindications 
 
0.306 0.155 1.980 0.048* 
Procedures during the incident 
AMI 
 
          CABG 
 
 
 
 
-0.071 
 
 
 
0.155 
 
 
 
-0.464 
 
 
 
0.643 
          PTCA 
 
0.055 0.121 0.462 0.644 
          Length of stay  -0.002 0.012 -0.200 0.842 
 
Discharge Medications 
 
    
          Aspirin 
 
-0.067 0.137 -0.494 0.621 
          ACE-inhibitors 
 
-0.076 0.093 -0.827 0.408 
          Calcium channel blockers 
 
0.035 0.098 0.367 0.714 
          Loop diuretics 
 
0.184 0.098 1.869 0.062 
Medication Possession Ratio 
 
-0.481 0.184 -2.619 0.009* 
Days supply 
 
0.0001 0.000 0.332 0.740 
R2 = 6.4 %(F = 1.935, p = 0.022*), n = 407 
 
 * Significant at p < 0.05, ER: Emergency room, S.E: Standard error, AMI: Acute myocardial infarction, 
CABG: Coronary artery bypass graft, PTCA: Percutaneous transluminal coronary angioplasty, ACE: 
Angiotensin converting enzyme inhibitor 
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Table 19: Predictors for Number of Physician Visits due to Cardiac Conditions 
 
Predictor 
 
 
Estimate 
 
S.E. 
 
t-Statistic 
 
Significance 
 
Age 
 
 
0.008 
 
0.062 
 
-0.136 
 
0.892 
Sex 
 
-0.603 0.980 -0.615 0.539 
Appropriate/Inappropriate use 
of beta-blockers at post-AMI 
 
2.406 1.469 1.639 0.102 
Hypertension 
 
-1.995 0.995 -2.004 0.046* 
Presence of absolute 
contraindications 
 
-2.984 1.554 -1.920 0.056 
Number of non-cardiac 
admissions 
 
2.248 0.757 2.968 0.003* 
Pre-AMI medications: 
 
    
      Beta-blockers 
 
2.885 1.213 2.379 0.018* 
Procedures during the 
incident AMI 
 
          CABG 
 
 
 
 
-3.061 
 
 
 
1.671 
 
 
 
-1.831 
 
 
 
0.068 
          PTCA 
 
-1.560 1.313 -1.186 0.236 
          Length of stay           0.061 0.127 0.489 0.625 
 
Discharge Medications 
 
    
          Aspirin 
 
-1.837 1.487 -1.235 0.217 
          ACE-inhibitors 
 
0.570 1.010 0.564 0.573 
          Calcium channel  
          Blockers 
 
0.250 1.071 0.234 0.815 
          Loop diuretics 
 
0.070 1.060 -0.066 0.947 
Medication Possession Ratio 
 
1.999 1.987 1.006 0.315 
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Table 19: Predictors for Number of Physician Visits due to Cardiac Conditions 
(contd.) 
 
 
Predictor 
 
 
Estimate 
 
S.E. 
 
t-Statistic 
 
Significance 
 
Days supply 
 
 
-0.008 
 
0.005 
 
-1.924 
 
0.055 
R2 = 8.6 %(F = 2.299, p = 0.003*), n = 407 
 
 * Significant at p < 0.05, S.E: Standard error, AMI: Acute myocardial infarction, CABG: Coronary artery 
bypass graft, PTCA: Percutaneous transluminal coronary angioplasty, ACE: Angiotensin converting 
enzyme inhibitor 
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Table 20: Predictors for Number of Physician Visits due to Cardiac Conditions 
using Propensity Score 
 
Predictor 
 
 
Estimate 
 
S.E. 
 
t-Statistic 
 
Significance 
 
Age 
 
 
-0.052 
 
0.074 
 
-0.706 
 
0.480 
Sex 
 
-0.883 0.991 -0.891 0.374 
Appropriate/Inappropriate use of 
beta-blockers at post-AMI 
 
1.977 1.481 1.335 0.183 
Propensity score 
 
-1.941 3.984 -0.487 0.626 
Presence of absolute 
contraindications 
 
-3.571 1.698 -2.103 0.036* 
Procedures during the incident 
AMI 
 
          CABG 
 
 
 
 
-3.139 
 
 
 
1.699 
 
 
 
-1.848 
 
 
 
0.065 
          PTCA 
 
-2.140 1.330 -1.609 0.108 
          Length of stay           0.071 0.129 0.552 0.581 
 
Discharge Medications 
 
    
          Aspirin 
 
-2.044 1.510 -1.353 0.177 
          ACE-inhibitors 
 
0.194 1.017 0.191 0.849 
          Calcium channel blockers 
 
0.641 1.078 0.594 0.553 
          Loop diuretics 
 
0.231 1.079 0.214 0.831 
Medication Possession Ratio 
 
2.027 2.020 1.003 0.316 
Days supply 
 
-0.007 0.005 -1.554 0.121 
R2 = 4.9 %(F = 1.441, p = 0.131), n = 407 
 
 * Significant at p < 0.05, S.E: Standard error, AMI: Acute myocardial infarction, CABG: Coronary artery 
bypass graft, PTCA: Percutaneous transluminal coronary angioplasty, ACE: Angiotensin converting 
enzyme inhibitor 
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Table 21: Predictors for Length of Stay due to Cardiac Conditions 
 
Predictor 
 
 
Estimate 
 
S.E. 
 
t-Statistic 
 
Significance 
 
Age 
 
 
0.055 
 
0.062 
 
0.890 
 
0.374 
Sex 
 
-0.173 0.977 -0.177 0.859 
Appropriate/Inappropriate use 
of beta-blockers at post-AMI 
 
3.417 1.464 2.334 0.020* 
Hypertension 
 
-0.427 0.992 -0.430 0.667 
Presence of absolute 
contraindications 
 
0.785 1.549 0.506 0.613 
Number of non-cardiac 
admissions 
 
1.695 0.755 2.245 0.025* 
Pre-AMI medications: 
 
    
      Beta-blockers 
 
2.343 1.209 1.939 0.053* 
Procedures during the incident 
AMI 
 
          CABG 
 
 
 
 
-5.510 
 
 
 
1.666 
 
 
 
-3.307 
 
 
 
0.001* 
          PTCA 
 
-1.200 1.311 -0.915 0.361 
          Length of stay           0.425 0.126 3.368 0.001* 
 
Discharge Medications 
 
    
          Aspirin 
 
0.316 1.483 0.213 0.831 
          ACE-inhibitors 
 
0.293 1.007 0.291 0.771 
          Calcium channel  
          Blockers 
 
-0.020 1.068 -0.019 0.985 
          Loop diuretics 
 
1.561 1.057 1.476 0.141 
Medication Possession Ratio 
 
1.142 1.981 0.576 0.565 
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Table 21: Predictors for Length of Stay due to Cardiac Conditions (contd.) 
 
 
Predictor 
 
 
Estimate 
 
S.E. 
 
t-Statistic 
 
Significance 
 
Days supply 
 
 
-0.012 
 
0.005 
 
-2.617 
 
0.009* 
R2 = 12.0 %(F = 3.335, p = 0.000*), n = 407 
 
 * Significant at p < 0.05, S.E: Standard error, AMI: Acute myocardial infarction, CABG: Coronary 
artery bypass graft, PTCA: Percutaneous transluminal coronary angioplasty, ACE: Angiotensin 
converting enzyme inhibitor 
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Table 22: Predictors for Length of Stay due to Cardiac Conditions using Propensity 
Score 
 
Predictor 
 
 
Estimate 
 
S.E. 
 
t-Statistic 
 
Significance 
 
Age 
 
 
0.033 
 
0.073 
 
0.455 
 
0.649 
Sex 
 
-0.492 0.979 -0.503 0.615 
Appropriate/Inappropriate use of 
beta-blockers at post-AMI 
 
3.341 1.463 2.284 0.023* 
Propensity score 
 
-0.818 3.936 -0.208 0.835 
Presence of absolute 
contraindications 
 
0.512 1.678 0.305 0.760 
Procedures during the incident 
AMI 
 
          CABG 
 
 
 
 
-5.652 
 
 
 
1.678 
 
 
 
-3.368 
 
 
 
0.001* 
          PTCA 
 
-1.624 1.314 -1.236 0.217 
          Length of stay           0.433 0.127 3.404 0.001* 
 
Discharge Medications 
 
    
          Aspirin 
 
0.105 1.492 0.071 0.944 
          ACE-inhibitors 
 
0.174 1.005 0.173 0.863 
          Calcium channel blockers 
 
0.376 1.065 0.353 0.724 
          Loop diuretics 
 
1.742 1.066 1.634 0.103 
Medication Possession Ratio 
 
1.070 1.996 0.536 0.592 
Days supply 
 
-0.010 0.005 -2.372 0.018* 
 R2 = 10.0 %(F = 3.136, p = 0.000*), n = 407 
 
 * Significant at p < 0.05, S.E: Standard error, AMI: Acute myocardial infarction, CABG: Coronary 
artery bypass graft, PTCA: Percutaneous transluminal coronary angioplasty, ACE: Angiotensin 
converting enzyme inhibitor 
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Table 23: Predictors for Log Charges due to Cardiac Conditions 
 
Predictor 
 
 
Estimate 
 
S.E. 
 
t-Statistic 
 
Significance 
 
Age 
 
 
-0.035 
 
0.039 
 
-0.893 
 
0.372 
Sex 
 
2.311 0.618 1.664 0.097 
Appropriate/Inappropriate use 
of beta-blockers at post-AMI 
 
1.096 0.926 0.562 0.574 
Hypertension 
 
1.138 0.628 0.521 0.603 
Presence of absolute 
contraindications 
 
0.139 0.980 -1.521 0.129 
Number of non-cardiac 
admissions 
 
0.748 0.478 1.566 0.118 
Pre-AMI medications: 
 
    
      Beta-blockers 
 
1.899 0.765 1.222 0.223 
Procedures during the 
incident AMI 
 
          CABG 
 
 
 
 
0.011 
 
 
 
1.054 
 
 
 
-3.715 
 
 
 
0.000* 
          PTCA 
 
0.806 0.829 0.154 0.878 
          Length of stay           0.144 0.080 1.808 0.071 
 
Discharge Medications 
 
    
          Aspirin 
 
1.629 0.938 0.990 0.323 
          ACE-inhibitors 
 
0.854 0.637 0.072 0.942 
          Calcium channel   
          blockers 
 
1.798 0.675 1.206 0.228 
          Loop diuretics 
 
1.539 0.669 0.980 0.328 
Medication Possession Ratio 
 
1.311 1.253 1.046 0.296 
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Table 23: Predictors for Log Charges due to Cardiac Conditions (contd.) 
 
 
Predictor 
 
 
Estimate 
 
S.E. 
 
t-Statistic 
 
Significance 
 
Days supply 
 
 
-0.003 
 
0.003 
 
-1.215 
 
0.225 
R2 = 7.7 %(F = 2.050, p = 0.010*), n = 407 
 
 * Significant at p < 0.05, S.E: Standard error, AMI: Acute myocardial infarction, CABG: Coronary 
artery bypass graft, PTCA: Percutaneous transluminal coronary angioplasty, ACE: Angiotensin 
converting enzyme inhibitor 
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Table 24: Predictors for Log Charges due to Cardiac Conditions Using Propensity 
Score 
 
Predictor 
 
 
Estimate 
 
S.E. 
 
t-Statistic 
 
Significance 
 
Age 
 
 
-0.029 
 
0.046 
 
-0.631 
 
0.528 
Sex 
 
2.186 0.616 1.415 0.158 
Appropriate/Inappropriate use of 
beta-blockers at post-AMI 
 
1.136 0.921 0.600 0.549 
Propensity score 
 
0.955 2.477 0.386 0.700 
Presence of absolute 
contraindications 
 
0.144 1.056 -1.303 0.193 
Procedures during the incident 
AMI 
 
          CABG 
 
 
 
 
0.010 
 
 
 
1.056 
 
 
 
-3.818 
 
 
 
0.000* 
          PTCA 
 
0.669 0.827 -0.072 0.943 
          Length of stay           0.150 0.080 1.868 0.062 
 
Discharge Medications 
 
    
          Aspirin 
 
1.495 0.939 0.898 0.370 
          ACE-inhibitors 
 
0.779 0.632 0.078 0.938 
          Calcium channel blockers 
 
2.233 0.670 1.534 0.126 
          Loop diuretics 
 
1.668 0.671 1.099 0.272 
Medication Possession Ratio 
 
1.219 1.256 0.970 0.332 
Days supply 
 
-0.003 .003 -1.126 0.261 
R2 = 6.7 %(F = 2.003, p = 0.017*), n = 407 
 
 * Significant at p < 0.05, S.E: Standard error, AMI: Acute myocardial infarction, CABG: Coronary 
artery bypass graft, PTCA: Percutaneous transluminal coronary angioplasty, ACE: Angiotensin 
converting enzyme inhibitor 
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Table 25: Predictors for Log Reimbursed Amounts due to Cardiac Conditions 
 
Predictor 
 
 
Estimate 
 
S.E. 
 
t-Statistic 
 
Significance 
 
Age 
 
 
-0.041 
 
0.039 
 
-1.044 
 
0.297 
Sex 
 
2.406 0.621 1.725 0.085 
Appropriate/Inappropriate use 
of beta-blockers at post-AMI 
 
1.380 0.930 0.812 0.418 
Hypertension 
 
1.110 0.630 0.481 0.631 
Presence of absolute 
contraindications 
 
0.164 0.984 -1.343 0.180 
Number of non-cardiac 
admissions 
 
0.846 0.480 1.763 0.079 
Pre-AMI medications: 
 
    
      Beta-blockers 
 
2.032 0.768 1.307 0.192 
Procedures during the 
incident AMI 
 
          CABG 
 
 
 
 
0.011 
 
 
 
1.059 
 
 
 
-3.708 
 
 
 
0.000* 
          PTCA 
 
0.763 0.833 0.093 0.926 
          Length of stay           0.159 0.080 1.981 0.048* 
 
Discharge Medications 
 
    
          Aspirin 
 
1.152 0.942 0.622 0.534 
          ACE-inhibitors 
 
0.816 0.640 0.004 0.997 
          Calcium channel    
          blockers 
 
1.639 0.678 1.067 0.287 
          Loop diuretics 
 
1.403 0.672 0.841 0.401 
Medication Possession Ratio 
 
1.415 1.258 1.124 0.262 
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Table 25: Predictors for Log Reimbursed Amounts due to Cardiac Conditions 
(contd.) 
 
 
Predictor 
 
 
Estimate 
 
S.E. 
 
t-Statistic 
 
Significance 
 
Days supply 
 
 
-0.003 
 
0.003 
 
-1.268 
 
0.206 
R2 = 8.0 %(F = 2.134, p = 0.007*), n = 407 
 
 * Significant at p < 0.05, S.E: Standard error, AMI: Acute myocardial infarction, CABG: Coronary artery 
bypass graft, PTCA: Percutaneous transluminal coronary angioplasty, ACE: Angiotensin converting 
enzyme inhibitor 
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Table 26: Predictors for Log Reimbursed Amounts due to Cardiac Conditions using 
Propensity Score 
 
Predictor 
 
 
Estimate 
 
S.E. 
 
t-Statistic 
 
Significance 
 
Age 
 
 
-0.003 
 
0.046 
 
-0.795 
 
0.427 
Sex 
 
2.027 0.620 1.451 0.148 
Appropriate/Inappropriate use of 
beta-blockers at post-AMI 
 
1.422 0.926 0.843 0.400 
Propensity score 
 
0.863 2.490 0.346 0.729 
Presence of absolute 
contraindications 
 
0.165 1.062 -1.160 0.247 
Procedures during the incident 
AMI 
 
          CABG 
 
 
 
 
0.009 
 
 
 
1.062 
 
 
 
-3.813 
 
 
 
0.000* 
          PTCA 
 
0.621 0.831 -0.158 0.875 
          Length of stay           0.164 0.080 2.044 0.042* 
 
Discharge Medications 
 
    
          Aspirin 
 
1.049 0.944 0.523 0.601 
          ACE-inhibitors 
 
0.816 0.636 0.000 1.000 
          Calcium channel blockers 
 
2.072 0.674 1.419 0.157 
          Loop diuretics 
 
1.534 0.675 0.973 0.331 
Medication Possession Ratio 
 
1.318 1.263 1.044 0.297 
Days supply 
 
-0.003 0.003 -1.166 0.244 
R2 = 6.7 %(F = 2.031, p = 0.015*), n = 407 
 
 
* Significant at p < 0.05, S.E: Standard error, AMI: Acute myocardial infarction, CABG: Coronary 
artery bypass graft, PTCA: Percutaneous transluminal coronary angioplasty, ACE: Angiotensin 
converting enzyme inhibitor 
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Discussion for Research Question 4 
 The null hypothesis D is rejected and appropriate/inappropriate use of beta-
blockers does affect utilization and null hypothesis E is not rejected and 
appropriate/inappropriate use of beta-blockers does not affect expenditures.  
Appropriate/Inappropriate prescribing of beta-blockers following an AMI, did affect 
utilization such as hospital visits, ER visits and length of stay in the follow-up duration.  
This relationship was similar to the morbidity results, which demonstrated that 
appropriate use was associated with greater hazards for cardiac hospitalization.  In other 
words, appropriate use was associated with increased utilization and longer length of stay 
due to cardiac visits.  Physician visits and expenditures were not affected by 
appropriate/inappropriate use. 
A further investigation to explain this association was undertaken.  This revealed 
that the appropriate group had a significantly higher percentage (p = 0.003, n = 412) of 
patients with hypertension (50.4%) - one of the important risk factors for cardiac 
problems, compared to the inappropriate group (35.3%).  A recent study has revealed that 
during the 6-month period after a successful PTCA, patients with hypertension have 
significantly higher adverse event rates that those without hypertension (Tsang, 
Sheppard, Mak, Brown, Huynh et al., 2002).  Hence, it is possible that the patients in the 
appropriate group had worse outcomes (higher utilization-hospitalization, ER visits and 
length of stay and lesser time to first cardiac event in research question 3) due to a higher 
percentage of hypertensive patients.  
Additionally, the two groups were compared for other anti-anginal drug use such 
as nitroglycerin and calcium channel blocker.  Due to the unavailability of other 
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information such as Killip class, ejection fraction (EF), and creatinine phosphokinase 
levels (available in patient charts but not available in patient claims data) this was 
considered to be a proxy for severity of incident AMI.  This revealed that the appropriate 
group had a significantly higher (p = 0.001) percentage (74.4%) of patients on other anti-
anginals compared to the inappropriate group (60.3%).  Both the above characteristics 
(hypertension and anti-anginal use) insinuate that the appropriate group was probably in a 
worse health state during the incident AMI compared to the inappropriate group.  Hence, 
higher utilization in the appropriate group could be because of their more severe illness 
rather than beta-blocker use. 
An important observation is that beta-blockers did have significantly lower all-
cause mortality and a non-significantly lower cardiac mortality.  It is possible that therapy 
actually postponed death in severe patients.  This however, resulted in them being alive 
and utilizing more resources which resulted in higher morbidity and utilization.   
Among the other significant predictors for utilization, higher non-cardiac 
admissions before the incident AMI, presence of absolute contraindications, and use of 
beta-blockers in the pre-period were associated with higher utilization.  These variables 
suggest that patients with more co-morbidities, and thus worse health states, had more 
utilization after the AMI.  In other words, presence of certain co-morbidties can increase 
the risk for the patient to suffer from more cardiac illness.  Presence of hypertension was 
a significant predictor in the number of physician visits model and was negatively 
associated with number of physician visits.  Similarly, CABG during incident AMI and 
higher length of stay during incident AMI was associated with lower utilization.  These 
findings are difficult to interpret.  Logically, a person with hypertension would have more 
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physician visits, compared to a non-hypertensive patient.  Also, a patient with higher 
length of stay and/or CABG during incident AMI would have higher utilization due to 
higher severity of the incident AMI.  Thus, these results identify more gaps due to 
unavailability of other information that would be present on patient charts.  MPR or 
compliance and days supply, were both associated with lower utilization.  Thus, for those 
patients who received beta-blockers, treatment did have a protective effect and thus they 
had lower utilization.   
The above analyses indicated that there was a definite association between 
appropriate/inappropriate use and utilization of health care services.  There was higher 
utilization in the appropriately prescribed group and this could be due to higher severity 
of the patients with AMI in this group compared to the inappropriate group.  This phase 
also identified inability of claims data to recognize severity levels of patients’ conditions 
as a limitation for studying utilization of health care services due to cardiac conditions in 
the follow-up period after an AMI.   
 
Phase II 
 Phase II of the study involved assessing effects of physicians’ knowledge of 
contraindications and willingness to prescribe on their prescribing behavior for post-AMI 
beta-blocker therapy.  It involved surveying physicians associated with post-AMI care.  A 
mailing list was obtained from West Virginia Medical Board.  The mailing list had a total 
of 1,151 physicians from the specialties of cardiology, internal medicine, family practice 
and general practice.  A survey instrument developed for this project was mailed to each 
physician.  Table 27 illustrates the response rate analysis.  Of the 1,151 surveys mailed, 
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132 questionnaires were returned because of incomplete or wrong addresses, and death or 
retirement of the physician.  Thus, 1,019 surveys were assumed to have reached the 
respondents.  A total of 281 responses were obtained giving a response rate of 27.57%.  
Twenty surveys were excluded because they had more than 50% incomplete item 
responses, thereby reducing the response rate to 25.61%.  A higher response rate is 
always desirable, but this response rate is comparable to other studies involving physician 
population surveys.  For example a recent survey by Zeiler et al., had a response rate of 
20% and Chao had a response rate of 17.6%. (Zierler, Meissner, Cain & Strandness, 2002 
; Chao, 2002).   
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Table 27: Response Rate Calculations 
 
Initial survey population 
 
 
1,151 
Wrong addresses/dead/retired 
 
132 
Effective population reached 
 
1,019 
Incomplete responses 
 
20 
Response rate 
 
261/1,019 = 25.61% 
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Non-response Analysis 
 The non-response survey (Appendix G) was mailed to 738 physicians who did not 
respond to one of the three survey mailings.  A total of 121 completed surveys were 
returned, thus giving a response rate of approximately 16.40%.  Table 28 depicts the 
reasons the respondents gave for not responding to the main survey.  The most common 
reasons were: not enough time to complete the survey (30.6%), followed by “don’t like to 
respond to survey” (17.4%), and survey was too long (14.9%).  Among other reasons, 
survey was misplaced (9.9%), and forgot about survey (7.4%) were more common.  A 
few reported topic irrelevant (5.0%), not interested (4.1%), not enough incentive (3.3%), 
did not receive survey (2.5%), and not enough information (2.5%).   
 Table 29 presents demographic and practice characteristics of the respondents to 
the non-response survey.  Of the 89 respondents, who responded to the question, 65 were 
males and 24 were females.  Also, 17.9% were less than 40 years of age, 34.5% were 40-
49, 28.6% were 50-59, and 19.0% were 60 or older.  The mean age was 50.55 (SD = 
11.80) years.  The distribution of the respondents in the different specialty were; 2.2% 
cardiology, 30.3% internal medicine, 39.3% family practice, 5.6% general practice and 
22.5% others.  Of the 63 respondents who answered the question on year of board 
certification, 52.4% were certified before or during 1990, and 47.6% were certified after 
1990.  A total of 43.9% described their primary practice place as solo, 32.9% as group-
based, 11.0% as hospital-based, 11.0% as university-affiliated hospital, and 1.2% as 
other.  The mean number of new AMI patients visiting every month was 2.02 and the 
mean number of repeat AMI patients visiting every month was 2.63.   
 168
 The respondents and non-respondents were compared on the basis of their 
demographic and practice characteristics.  The variables compared were age, gender, 
specialty, year of board certification, practice site, number of new and repeat AMI 
patients treated.  Chi-squares and t-tests were used for comparison of these variables.  
The result of this analysis is reported in Table 30.  The respondents were not different 
from the non-respondents on age, year of board certification, practice site and average 
number of new AMI patients treated per month.  The respondents and non-respondents 
were significantly different on gender, specialty, and average number of repeat AMI 
patients treated per month.  A higher percent of non-respondents were females compared 
to the respondents.  There were more physicians among the non-respondents who 
reported to belong to other specialty compared to respondents.  The respondents reported 
a higher average number of repeat AMI patients treated per month compared to non-
respondents.  Thus, results of the study should be interpreted with caution.  
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Table 28: Reasons for Not Responding to the Study Survey 
 
Reasons 
 
 
N (121) 
 
Percent (%) 
 
Not enough time to complete survey 
 
 
37 
 
30.6 
Don’t like to respond to survey 
 
21 17.4 
Survey was too long 
 
18 14.9 
Survey was misplaced 
 
12 9.9 
Forgot about survey 
 
9 7.4 
Topic was irrelevant 
 
6 5.0 
Not interested in such studies 
 
5 4.1 
Not enough incentive to complete survey 
 
4 3.3 
Did not receive the survey 
 
3 2.5 
Not enough information about study 
 
3 2.5 
Other (retired, don’t treat AMI, leave, sick) 
 
46 38.0 
 
N: Number of physicians, AMI: Acute myocardial infarction 
Multiple responses were checked by the responders of the non-response survey, hence total greater than 
100% 
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Table 29: Demographic and Practice Characteristics of Respondents of the Non-
response Survey 
 
Characteristics 
 
 
N 
 
Percent 
 
Age 
 
            Less than 40 years 
 
 
 
 
15 
 
 
 
17.9 
            40-49 years 
 
29 34.5 
            50-59 years 
 
24 28.6 
            60 years or older 
 
16 19.0 
 Average age +S.D. 50.55+11.80  
   
Gender 
 
            Males 
 
 
 
65 
 
 
73.0 
            Females 
 
24 27.0 
 
Specialty 
 
  
           Cardiology 
 
2 2.2 
           Internal Medicine 
 
27 30.3 
           Family Practice 
 
35 39.3 
           General Practice 
 
5 5.6 
           Other 
 
20 22.5 
Year of Board Certification 
 
  
         <1990 
 
33 52.4 
         >1990 
 
30 47.6 
Primary Practice site 
 
  
          Solo, office-based 
 
36 43.9 
 171
Table 29: Demographic and Practice Characteristics of Respondents of the Non-
response Survey (contd.) 
 
 
Characteristics 
 
 
N 
 
Percent 
 
          Group, office-based 
 
 
27 
 
32.9 
          Hospital-based 
 
9 11.0 
          University-affiliated hospital based 
 
9 11.0 
          Other 1 1.2 
   
Average number of new AMI patients 
Mean (S.D.), Min-Max  
 
2.02+3.53 0-20 
Average number of repeat AMI patients 
Mean (S.D.), Min-Max 
 
2.63+4.99 0-30 
 
N: Number of physicians, S.D: Standard deviation, AMI: Acute myocardial infarction, Min: Minimum 
value, Max: Maximum value 
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Table 30: Analysis of Non-response Bias for Demographic and Practice 
Characteristics 
 
Characteristics 
 
 
 
Respondents 
 
Non-
respondents 
 
Test 
Statistic 
 
Significance 
p 
 
Age Mean (S.D.) 
 
 
49.23+10.96 
 
50.55+11.80 
 
t = -0.938 
 
0.349 
Gender 
 
         Males 
 
 
 
82.6 
 
 
73.0 
χ2 = 3.84 0.050* 
         Females 
 
17.4 27.0   
Specialty 
 
         Cardiology 
 
         Internal Medicine 
 
 
 
9.7 
 
32.6 
 
 
2.2 
 
30.3 
χ2 = 22.23 0.000* 
         Family Practice 
 
47.7 39.3   
         General Practice 
 
3.5 5.6   
         Other 
 
6.6 22.5   
Year of Board 
Certification 
 
         <1990 
 
 
 
53.4 
 
 
52.4 
χ2 = 0.018 0.892 
         >1990 
 
46.6 47.6   
Practice site 
 
          Solo, office-based 
 
 
 
35.1 
 
 
43.9 
χ2 = 5.334 0.255 
          Group, office- 
          based 
 
33.6 32.9   
          Hospital-based 
 
14.7 11.0   
          University- 
          affiliated  
          hospital-based 
10.0 11.0   
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Table 30: Analysis of Non-response Bias for Demographic and Practice 
Characteristics (contd.) 
 
 
Characteristics 
 
 
 
Respondents 
 
Non-
respondents 
 
Test 
Statistic 
 
Significance 
p 
 
          Other 
 
 
6.6 
 
1.2 
  
Average number of new 
AMI patients        
Mean (S.D.) 
 
3.36+5.40 2.02+3.53 t = 1.894 0.059 
Average number of 
repeat AMI patients 
Mean (S.D.) 
9.64+33.92 2.63+4.99 t = 3.005 0.003* 
     
 
* Significant at p < 0.05, S.D: Standard deviation, AMI: Acute myocardial infarction 
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Demographic and Practice Characteristics of Physicians in Phase II 
 Demographic and practice characteristics of the respondents are presented in 
Table 31.  Of the respondents, 214 (82.6%) were males and 45 (17.4%) were females.  
The average age was 49.23 years (SD = 10.96).  Approximately 10% belonged to the 
specialty of cardiology, 33% belonged to internal medicine, 48% belonged to family 
practice, 4% belonged to general practice, and 7% reported other specialties.  The year of 
board certification was divided into two categories, those who received their board 
certification before or during 1990 and those who received their board certification after 
1990.  Among those who responded to the question on year of board certification, a total 
of 95 physicians received board certification before or during 1990 and 83 physicians 
received board certification after the year 1990.   
The distribution of practice site among the respondents was as follows: 35.1% 
were solo office-based, 33.6% were group office-based, 14.7% were hospital-based, 
10.0% were university-affiliated hospital based, and 6.6% reported other practice sites.  
Among those who reported the primary practice site as hospital, 22 described it as rural, 9 
described it as sub-urban and 12 described it as urban.  Also, 6 worked in 
governmental/nonfederal settings, 12 worked in government/federal settings, 24 worked 
in private-not-for-profit settings, and 3 worked in private investor owned settings.  A total 
of 23 respondents reported provision of tertiary care at their hospital and the average 
number of beds in the hospital was 266.56.  The average number of new AMI patients 
treated by the respondents was 3.36 and the average number of repeat AMI patients 
treated was 9.64. 
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Table 31: Demographic and Practice Characteristics of Respondents 
 
Characteristics 
 
 
N 
 
Percent 
 
Age 
 
        Less than 40 years 
 
 
 
 
57 
 
 
 
22.4 
        40 to 49 years 
 
73 28.7 
        50 to 59 years 
 
80 31.5 
        60 or older 
 
Average Age+ S.D. 
 
44 
 
49.23+10.96 
17.3 
 
Gender 
 
        Males 
 
 
 
214 
 
 
82.6 
        Females 
 
45 17.4 
Specialty 
 
        Cardiology 
 
 
 
25 
 
 
9.7 
        Internal Medicine 
 
84 32.6 
        Family Practice 
 
123 47.7 
        General Practice 
 
9 3.5 
        Others 
 
17 6.6 
Year of Board Certification 
 
        <1990 
 
 
 
95 
 
 
53.4 
        >1990 
 
83 46.6 
Primary Practice Site        
  
  
         Solo, office-based 
 
91 35.1 
         Group, office-based 87 33.6 
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Table 31: Demographic and Practice Characteristics of Respondents (contd.) 
 
 
Characteristics 
 
 
N 
 
Percent 
 
         Hospital based 
 
 
38 
 
14.7 
         University-affiliated Hospital based 
 
26 10.0 
         Others 
 
17 6.6 
Hospital Characteristics 
 
         Rural 
 
 
 
22 
 
 
31.4 
         Sub-urban 
 
9 12.9 
         Urban 
 
12 17.1 
         Government/Non-federal 
 
6 8.6 
         Government/Federal 
 
12 17.1 
         Private Not-for-Profit 
 
24 34.3 
         Private Investor Owned 
 
3 4.3 
         Provides Tertiary Care 
 
 
23  32.9 
Number of beds Mean (S.D.), Min-Max 
 
266.56 (208.40) 18-900 
Number of new AMI patients Mean (S.D.), Min-Max 
 
3.36 (5.40) 0-50 
Number of repeat AMI patients Mean (S.D.), Min-Max 
 
9.64 (33.92) 0-450 
 
N: Number of physicians, S.D: Standard deviation, AMI: Acute myocardial infarction, Min: Minimum 
value, Max: Maximum value 
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Results for Research Question 5 
 The guidelines classify three conditions as absolute contraindications: 
hypotension, bradycardia and atrioventricular (AV) block.  The guidelines also classify 
second and third degree AV block as relative contraindications.  Hence, there is 
uncertainty whether AV block is an absolute contraindication or a relative 
contraindication.  For study purposes, first degree AV block was considered to be a 
relative contraindication and second and third degree AV blocks were considered to be 
absolute contraindications.   
Hence, four absolute contraindications used in the questionnaire were 
hypotension, bradycardia, second degree and third degree AV blocks (Table 32).  About 
35% of the respondents classified hypotension as an absolute contraindication and almost 
61% classified bradycardia as an absolute contraindication.  Exactly 50% of the 
respondents classified second degree AV block and greater than 85% classified third 
degree AV block as absolute contraindications.   
 The relative contraindications in the questionnaire were systolic blood pressure 
greater than 100Hg, heart rate less than 60bpm, peripheral vascular disease, peripheral 
hypoperfusion, EF<40%, first degree AV block, COPD, asthma, insulin dependent 
diabetes mellitus (IDDM), PR-interval greater than 0.24 second, and beta-blocker 
intolerance.  A high percent of respondents classified systolic blood pressure <100hg 
(about 78%), heart rate<60bpm(75%), COPD (about 83%) and asthma (about 76%) as 
relative contraindications.  Greater than 50% of the respondents classified peripheral 
vascular disease (58%), peripheral hypoperfusion (55%), first degree AV block (53%), 
IDDM (about 60%) and PR>0.24 second (about 64%) as relative contraindications.  A 
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relatively lower percent of respondents classified EF<40% (34%) and beta-blocker 
intolerance (41%) as a relative contraindication.   
 There were four conditions in the questionnaire, which were neither absolute nor 
relative contraindications for beta-blockers.  These include hypertension, non-insulin 
diabetes mellitus (NIDDM), stroke and ACE-inhibitor intolerance.  A very high 
percentage of respondents classified three of these conditions - hypertension (98%), 
stroke (about 88%), and ACE-inhibitor intolerance (about 91%) as not a contraindication 
for beta-blocker therapy.  However, NIDDM was classified almost equally as a relative 
contraindication (49%) and not a contraindication (50%).   
 Three aggregate scores were computed based on correct classification of each of 
the conditions in the questionnaire in the three groups – absolute contraindication, 
relative contraindication, and not a contraindication (Table 33).  The mean absolute 
contraindication score was 2.29 (SD = 1.20) out of a total of 4 responses.  The mean 
relative contraindication score was 6.73 (SD = 2.10) out of a total of 11 correct responses.  
And the mean not a contraindication score was 3.17 (SD = 0.84) out of a total of 4 
responses. 
 The number of patients prescribed beta-blockers by the respondent among the last 
10 was obtained from the survey question 3, in Section A.  Prescribing percent was 
calculated by dividing the response with 10 and multiplying it by 100.  Thus, the mean 
number of patients prescribed beta-blocker among the last 10 individuals treated by the 
physician was 9.01 (SD = 1.35) and the mean prescribing percent of beta-blockers was 
90.10 (SD = 13.5).  This prescribing percent was a proxy for prescribing behavior.   
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 A correlation matrix was developed for the prescribing percent/behavior with 
absolute contraindication score, relative contraindication score and not a contraindication 
score (Table 34).  The only correlation that was significant was the not a contraindication 
score and it was positively related to prescribing percent.  Thus, those respondents who 
classified the conditions which were not contraindications correctly, were more likely to 
prescribe beta-blockers among the post-AMI patients.  
 
  
 180
Table 32: Knowledge of Contraindications 
 
Patient conditions 
 
Absolute 
contraindication 
 
Relative 
contraindication 
 
Not a 
contraindication 
 N 
 
% N % N % 
 
Absolute 
contraindications 
 
Hypotension (systolic 
pressure <90hg) 
 
 
 
 
 
90 
 
 
 
 
34.75 
 
 
 
 
164 
 
 
 
 
63.32 
 
 
 
 
5 
 
 
 
 
1.93 
Bradycardia (heart 
rate<50bpm) 
 
158 61.00      98           37.84     3           1.16        
Second degree AV block 
 
129         50.00 119           46.12 10           3.88 
Third degree AV block 
 
220 85.27 29 11.24 9 3.49 
 
Relative 
contraindications 
 
      
Systolic blood pressure 
<100hg 
 
13 5.00 203 77.80 45 17.20 
Heart rate <60 bpm 
 
15 5.79 196 75.68 48 18.53 
Peripheral vascular 
disease 
 
7 2.71 150 58.14 101 39.15 
Peripheral hypoperfusion 
 
56 22.22 139 55.16 57 22.62 
EF<40% 
 
13 5.06 88 34.24 156 60.70 
First degree AV block 
 
15 5.84 138 53.70 104 40.47 
COPD 
 
10 3.85 217 83.46 33 12.69 
Asthma 
 
49 18.80 197 75.50 15 5.70 
IDDM 
 
14 5.43 156 60.47 88 34.11 
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Table 32: Knowledge of Contraindications (contd.) 
 
 
Patient conditions 
 
Absolute 
contraindication 
 
Relative 
contraindication 
 
Not a 
contraindication 
 N 
 
% N % N 
 
% 
 
PR >0.24 second 
 
 
38 
 
15.02 
 
165 
 
65.22 
 
50 
 
19.76 
Beta-blocker intolerance 
 
149 57.53 108 41.70 2 0.77 
 
Not a contraindication 
 
      
Hypertension (systolic 
pressure >140hg) 
 
0 0 6 2.31 254 97.69 
NIDDM 
 
3 1.16 126 48.65 130 50.19 
Stroke 
 
1 0.04 31 12.11 224 87.50 
ACE-inhibitor  
Intolerance 
 
8 3.29 15 6.17 220 90.53 
N: Number of physicians, AV: Atrioventricular, EF: Ejection fraction, COPD: Chronic obstructive 
pulmonary disease, IDDM: Insulin dependent diabetes mellitus, NIDDM: Non insulin dependent diabetes 
mellitus, ACE: Angiotensin converting enzyme 
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Table 33: Knowledge Scores 
 
Variables 
 
Mean +S.D. 
 
Range 
 
 
Absolute contraindication score 
 
 
2.29+1.20 
 
0-4 
Relative contraindication score 
 
6.73+2.10 0-11 
Not a contraindication score 
 
3.17+0.84 0-4 
Number of patients prescribed beta-
blockers 
 
9.01+1.35 2-10 
Prescribing percent/behavior  
 
90.10+13.50 20-100 
 S.D: Standard deviation 
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Table 34: Correlation Matrix for Knowledge of Contraindications 
 
Variables 
 
Prescribing 
percent/ 
behavior 
 
 
Absolute 
contraindica-
tion score 
 
Relative 
contraindica-
tion score 
 
Not a 
contraindica-
tion score 
 
Prescribing 
percent/ behavior  
 
 
1.000 
   
Absolute 
contraindication 
score 
 
-0.032 1.000   
Relative 
contraindication 
score 
 
0.050 0.114 1.000  
Not a 
contraindication 
score 
 
0.229* -0.053 -0.098 1.000 
* Significant at p < 0.05 
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Discussion for Research Question 5 
 Greater than 50% of the respondents classified three of the four listed absolute 
contraindications correctly.  The one condition that had a lower percent of physicians 
classifying it as a contraindication was hypotension.  Similarly, except for beta-blocker 
intolerance and EF<40% all the other relative contraindications were also classified 
correctly by greater than 50% of the physicians.  Of the 4 conditions, which were neither 
absolute nor relative contraindications, three- hypertension, stroke and ACE-inhibitor 
intolerance were classified correctly as not a contraindication by greater than 85% of the 
physicians.  However, a relatively high percent of physicians classified NIDDM as a 
relative contraindication.  Thus, there appears to be higher than average awareness about 
the relative and absolute contraindications for beta-blocker therapy in post AMI patients.  
Based on the correct classification of these conditions three scores were computed, the 
absolute contraindication score, the relative contraindication sore and the not a 
contraindication score.  Of these, two scores - the absolute contraindication score and the 
relative contraindication score were not significantly correlated with prescribing percent.  
Thus, the null hypothesis F that there is no association between knowledge of absolute 
and relative contraindications and prescribing behavior is not rejected.  The not a 
contraindication score was significantly correlated with prescribing percent.  Thus, 
correct knowledge of conditions that are not contraindications for use does result in 
positive prescribing behavior. 
 
Results for Research Question 6 
 The questionnaire asked the respondents to give their willingness to prescribe 
beta-blockers in patients with different conditions on a Likert scale from 1 to 5 where 1 
 185
was least likely and 5 was most likely.  These conditions could be divided into three 
categories: those conditions where beta-blockers definitely provide benefits, hence 
therapy should be definitely prescribed to the patient; those conditions where therapy 
may be prescribed as there is uncertainty about benefits to the patient either because of 
lower risk or because of presence of relative contraindications; and those conditions in 
the presence of which beta-blockers should definitely not be prescribed as these are 
absolute contraindications and in the presence of these conditions beta-blockers do not 
provide benefit and may be harmful.   
The conditions in the definitely prescribe category were: age>50 years (Mean = 
4.76), large or anterior AMI (Mean = 4.55), previous AMI (Mean = 4.77), patient who 
had an angioplasty (Mean = 4.64), or by-pass surgery (Mean = 4.67), patients with stroke 
(Mean = 4.23), hypertension (Mean = 4.84) and complex ventricular ectopy (Mean = 
4.19) (Table 35).  The conditions in the maybe prescribe category were: age<50years 
(Mean = 4.74), small infarction (Mean = 4.75), EF<40% (Mean = 4.16), history of CHF 
(Mean = 3.95), systolic blood pressure<100Hg (Mean = 2.97), heart rate<60bpm (Mean = 
2.75), LV failure (Mean = 3.76), first degree AV block (Mean = 3.20), peripheral 
vascular disease (Mean = 3.26), COPD (Mean = 2.89), asthma (Mean = 2.36), and IDDM 
(Mean = 3.58).  The conditions in the definitely not prescribe category were: hypotension 
(Mean = 2.30), bradycardia (Mean = 1.72), second degree AV block (Mean = 1.69) and 
third degree AV block (Mean = 1.31).   
A score was computed for each of the three categories by adding the individual 
answers for each condition within the category (Table 36).  Thus, the definitely prescribe 
score had a mean of 36.75 (SD = 4.28) and ranged from 8 to 40.  The maybe prescribe 
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score had a mean of 42.36 (SD = 8.26) and ranged from 17 to 60.  And the mean for 
definitely not prescribe score was 7.01 (SD = 2.91) and ranged from 2.5 to 18.  The mean 
for prescribing percent/behavior was 90.10 (SD = 13.50).   
A correlation matrix was developed for the prescribing percent with definitely 
prescribe score, maybe prescribe score and the definitely not prescribe score (Table 37).  
All the three scores had significant correlations with prescribing percent.  The correlation 
coefficient was approximately 0.47 for definitely prescribe score, and 0.41 for maybe 
prescribe score, and was 0.13 for the definitely not prescribe score.  Thus, those with 
higher scores in all the three categories were more likely to prescribe beta-blockers 
among the post-AMI patients.   
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Table 35: Willingness to Prescribe Beta-blockers  
 
Patient Characteristics 
 
Mean 
 
S.D. 
 
 
Definitely prescribe 
 
Age >50 years 
 
 
 
 
4.76 
 
 
 
0.56 
Large or anterior MI 
 
4.55 0.87 
Previous infarction 
 
4.77 0.66 
Angioplasty 
 
4.64 0.80 
By-pass surgery 
 
4.67 0.75 
Stroke 
 
4.23 1.07 
Hypertension 
 
4.84 0.53 
Complex ventricular ectopy 
 
4.19 1.17 
Maybe prescribe 
 
Age < 50 years 
 
 
 
4.74 
 
 
0.63 
Small infarction 
 
4.75 0.58 
EF<40% 
 
4.16 1.06 
History of CHF 
 
3.95 1.13 
Systolic blood pressure <100Hg 
 
2.97 1.27 
Heart rate<60bpm 
 
2.75 1.28 
LV failure 
 
3.76 1.21 
First degree AV block 
 
3.20 1.36 
Peripheral vascular disease 
 
3.26 1.38 
COPD 
 
2.89 1.20 
Asthma 2.36 1.17 
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Table 35: Willingness to Prescribe Beta-blockers (contd.) 
 
 
Patient Characteristics 
 
Mean 
 
S.D. 
 
 
IDDM 
 
 
3.58 
 
1.25 
Definitely not prescribe  
 
  
Hypotension 
 
2.30 1.18 
Bradycardia 
 
1.72 0.99 
Second degree AV block 
 
1.69 1.05 
Third degree AV block 
 
1.31 0.92 
 
S.D.: Standard deviation, MI: Myocardial infarction, EF: Ejection fraction, CHF: Congestive heart failure, 
LV: Left ventricular, AV: Atrioventricular, COPD: Chronic obstructive pulmonary disease, IDDM: 
Insulin dependent diabetes mellitus 
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Table 36: Willingness to Prescribe Scores 
 
Variables 
 
Mean +S.D. 
 
Range 
 
 
Definitely prescribe score 
 
 
36.65+4.28 
 
8-40 
May be prescribe score 
 
42.36+8.26 17-60 
Definitely not prescribe score 
 
7.01+2.91 2.5-18 
Number of patients prescribed beta-
blockers 
 
9.01+1.35 2-10 
Prescribing percent/ behavior 
 
90.10+13.50 20-100 
 S.D: Standard deviation 
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Table 37: Correlation Matrix for Willingness to Prescribe 
 
Variables 
 
Prescribing 
percent/ 
behavior 
 
 
Definitely 
prescribe score
 
Maybe 
prescribe score 
 
Definitely not 
prescribe 
score 
 
Prescribing 
percent/ 
behavior 
 
 
1.00 
   
Definitely 
prescribe score 
 
0.474* 1.00   
May be 
prescribe score 
 
0.410* 0.648* 1.00  
Definitely not 
prescribe score 
 
0.134* 0.194* 0.442* 1.00 
 
* Significant at p < 0.05 
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Discussion for Research Question 6 
 The willingness to prescribe beta-blockers as post-AMI medication was high 
(means greater than 4 out of 5) for those conditions where beta-blockers should definitely 
be prescribed for secondary prevention.  For those conditions where beta-blocker maybe 
prescribed as secondary prevention agents, the willingness to prescribe means were 
between 2 and 5.  In addition, the means for willingness to prescribe beta-blockers as 
secondary preventive agents post-AMI in patients with conditions where it should 
definitely not be prescribed were between 1 and 3.  Thus, this indicates that willingness 
to prescribe is evidence–based and physicians definitely are aware of the guidelines.  
When the correlations of the three scores were calculated with prescribing percent, all 
three were significant.  Thus, reject null hypothesis G that there is no relationship 
between physicians’ willingness to prescribe beta-blockers as post AMI secondary 
preventive agents and physicians’ prescribing of these agents is rejected.  The analysis 
revealed a positive relationship between willingness to prescribe and prescribing behavior 
among physicians for beta-blockers post-AMI irrespective of patient co-morbidities.  
 
Results for Research Question 7 
 To assess the effects of demographic and practice characteristics on prescribing 
behavior, t-tests, ANOVA's (Table 38) and correlations (Table 39) were conducted.  
Gender and year of board certification was investigated using t-tests whereas, specialty, 
location and practice site were investigated using F-tests.  Association of age, size of 
hospital, number of new AMI patients, and number of repeat AMI patients treated were 
determined through Pearson’s correlations.   
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Age and size of hospital were significantly correlated with prescribing percent.  
Age was negatively associated with prescribing percent/behavior.  Thus, older physicians 
were less likely to prescribe beta-blockers in post-AMI patients.  Size of hospital was 
positively associated with prescribing percent.  Thus, larger the size of the hospital the 
physicians worked in, the more likely they were to prescribe beta-blockers in post-AMI 
patients.  Prescribing percent/behavior was not significantly different by gender, 
specialty, location, practice site and year of board certification.  Prescribing 
percent/behavior was higher for cardiologists and physicians from internal medicine 
compared to family practitioners and general practitioners, also physicians from urban 
areas had higher prescribing percent compared to rural and sub-urban areas, females had 
a higher prescribing percent compared to males, and finally physicians who were board-
certified after 1990 had higher prescribing percent compared to those who were board 
certified before or during 1990, however, none of these were statistically significant.  
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Table 38: Prescribing Behavior and Demographic Characteristics, Part 1  
 
Variables 
 
Prescribing percent/ 
behavior 
(Mean+S.D.) 
 
 
Statistic 
 
Significance 
 
 
Gender 
 
        Males 
 
 
 
 
89.60+14.21 
 
t = -1.15 
 
 
0.252 
        Females 
 
92.21+9.41   
Specialty 
 
       Cardiology 
 
 
 
90.40+13.38 
F = 1.73 0.143 
       Internal medicine 
 
92.88+9.44   
       Family practice 
 
88.29+15.11   
       General practice 
 
84.29+20.70   
       Other 
 
90.83+13.79   
Location 
 
        Rural 
 
 
 
92.63+14.47 
F = 0.363 0.699 
        Sub-urban 
 
90.00+9.26   
        Urban 
 
95.00+9.72   
Practice site 
 
        Solo, office based 
 
 
 
87.73+16.24 
F = 1.41 0.230 
        Group, office-based 
 
90.18+12.48   
        Hospital-based 
 
93.43+11.87   
        University-affiliated   
        hospital based 
 
92.50+8.47   
       Other 
 
90.77+9.54   
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Table 38: Prescribing Behavior and Demographic Characteristics, Part 1 (contd.) 
 
 
Variables 
 
Prescribing percent/ 
behavior 
(Mean+S.D.) 
 
 
Statistic 
 
Significance 
 
 
Year of board certification 
 
        <1990 
 
 
 
 
88.52+14.15 
 
t = -1.704 
 
0.090 
        >1990 
 
91.79+10.16   
    
 
S.D: Standard deviation 
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Table 39: Prescribing Behavior and Demographic Characteristics, Part 2 
 
Variables 
 
Prescribing 
percent/ 
behavior 
 
Age 
 
Size of 
hospital 
 
Number of 
new AMI 
patients 
 
Number of 
repeat AMI 
patients 
 
 
Prescribing 
percent/ 
behavior 
 
 
1.00 
    
Age 
 
-0.199* 1.00    
Size of 
hospital 
 
0.231* -0.092 1.00   
Number of 
new AMI 
patients 
 
0.061 -0.074 0.184* 1.00  
Number of 
repeat AMI 
patients 
 
0.047 0.130 0.010 0.197* 1.00 
 
* Significant at p < 0.05, AMI: Acute myocardial infarction 
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Discussion for Research Question 7 
 Based on the analysis, the null hypotheses H that there is no relationship between 
demographic and practice characteristics and prescribing behavior is rejected.  Age and 
size of the hospital do have an association with prescribing behavior.  Younger 
physicians and physicians who worked in larger hospitals had higher prescribing 
percentages.  Nicholls et al., (2001) reported higher prescribing rates in a large hospital 
compared to a small hospital.  However, the large hospital in this study was also affiliated 
to a university and cardiologists treated patients in the large hospital.  Thus, it is possible 
that when other characteristics of the hospital are adjusted for, size of hospital may not 
have an impact on prescribing behavior.  Also, age has been reported to be associated 
with prescribing behavior in other disease conditions such as hypertension (Mehta et al., 
1999).  Younger physicians were more likely to prescribe recommended agents compared 
to older physicians.  Since beta-blockers are recommended medications post-AMI, this 
study establishes a similar association between age and prescribing behavior for beta-
blockers too.  This study did not find an association between prescribing behavior and 
other physician characteristics contrary to results of previous studies which have reported 
that specialty, year of board certification, location, and university affiliation do affect 
prescribing behavior of physicians for beta-blockers as secondary preventive agents post 
AMI (Ayanian et al. 1994; Fehrenbach et al, 2001; Sheikh & Bullock, 2001).  
 
Results for Research Question 8 
 Similar to the analyses in research question 7, t-tests, ANOVA’s and Pearson’s 
correlations were conducted on the demographic and practice characteristics with the 
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three knowledge scores and the three willingness to prescribe scores.  The results for the 
three knowledge scores are reported in Tables 40 and 41 and the results for the three 
willingness to prescribe scores are reported in Tables 42 and 43.   
 Thus, we see that the knowledge scores did not differ by gender, location and year 
of board certification.  However, the absolute contraindication score and the not a 
contraindication score were significantly different by specialty, and the not a 
contraindication score was also significantly different by primary practice site.  The 
general practitioners had a higher absolute contraindication score compared to physicians 
from internal medicine.  Thus, the general practitioners classified the absolute 
contraindications more correctly than physicians in internal medicine.  The cardiologists 
had a higher not a contraindication score compared to family practitioners, which implies 
that cardiologists classified those conditions which were not contraindications more 
correctly compared to family practitioners.  The not a contraindication score was also 
significantly different by primary practice site.  Those who practiced in university- 
affiliated hospital settings classified those conditions which were not contraindications 
for beta-blocker therapy more correctly compared those who practices in solo, office-
based settings.  The not a contraindication score was also negatively correlated to age.  
Thus, older physicians were less likely to classify those conditions which were not 
contraindications for beta-blocker therapy correctly.  Similarly, the number of repeat 
AMI patients treated was also negatively correlated to absolute contraindication score.  
Thus, those physicians who treated more repeat AMI patients were less likely to classify 
those conditions which were absolute contraindications for beta-blocker therapy 
correctly. 
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 Willingness to prescribe scores (Tables 42 & 43) were also analyzed in a similar 
manner.  These scores were not different by gender, location, and year of board 
certification.  Specialty was significantly different for the definitely prescribe score and 
the maybe prescribe score.  The general practitioners had a lower definitely prescribe 
score compared to internal medicine physicians.  Thus, physicians in general practice 
were less willing to prescribe beta-blockers as post-AMI medication to those patients in 
whom it should definitely be prescribed when compared to physicians from internal 
medicine.  A similar relation was found for the maybe prescribe score, with the general 
practitioners’ and family practitioners’ scores being significantly lower than physicians’ 
in internal medicine.  Thus, physicians from general practice and family practice were 
less willing to prescribe beta-blockers as post AMI medications in patients with those 
conditions where they maybe prescribed when compared to physicians in internal 
medicine.  
Both ‘definitely prescribe’ score and ‘maybe prescribe’ score were significantly 
different by primary practice site.  Physicians in solo office-based practice had a 
significantly lower definitely prescribe score compared to physicians at university-
affiliated hospitals.  Also, physicians in solo practice had a significantly lower maybe 
prescribe score compared to both physicians from hospital practice and physicians from 
university-affiliated hospitals.  
Age was significantly and negatively correlated to two scores, definitely 
prescribe, and maybe prescribe.  Thus, older physicians were less willing to prescribe 
beta-blockers as post AMI medication in patients with conditions where they should be 
definitely prescribed, and maybe prescribed.  Size of hospital was positively associated 
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with definitely prescribe and maybe prescribe scores.  Thus, physicians from larger 
hospitals were more willing to prescribe beta-blockers in patients where they should 
definitely or maybe be prescribed.  Number of new AMI patients and number of repeat 
AMI patients treated by the physicians were not related to the willingness to prescribe 
scores.   
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Table 40: Knowledge of Contraindications and Demographic Characteristics, Part 1 
 
Variables 
 
Absolute 
contraindication 
score 
 
 
Relative 
contraindication 
score 
 
Not a 
contraindication 
score 
 
Gender 
 
        Males 
 
 
 
 
2.29+1.19 
 
 
 
6.74+2.14 
 
 
 
3.17+0.88 
        Females 
 
2.27+1.21 6.64+1.87 3.22+0.67 
Specialty 
 
       Cardiology 
 
 
 
2.28+0.98 
 
 
6.04+2.09 
 
 
3.60+0.58 a 
       Internal medicine 
 
2.01+1.14a 6.80+2.03 3.24+0.82 
       Family practice 
 
2.33+1.24 6.75+2.09 3.08+0.88 a 
       General practice 
 
3.22+0.97 a 5.89+2.98 2.78+1.20  
       Other 
 
2.76+1.25 7.41+1.66 3.18+0.64 
Location 
 
        Rural 
 
 
 
2.38+1.36 
 
 
6.71+1.79 
 
 
3.10+0.70 
        Sub-urban 
 
2.44+1.13 6.22+2.22 3.44+0.53 
        Urban 
 
2.18+1.40 6.36+1.57 3.45+0.69 
Practice site 
 
        Solo, office based 
 
 
 
2.21+1.25 
 
 
6.42+2.20 
 
 
2.96+1.03 a 
        Group, office-based 
 
2.32+1.16 6.87+1.97 3.28+0.69  
        Hospital-based 
 
2.29+1.39 6.87+2.17 3.34+0.62 
        University-affiliated   
        hospital based 
 
2.35+0.94 6.88+2.08 3.46+0.70 a 
        Other 
 
2.35+1.11 7.00+2.12 2.88+0.78 
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Table 40: Knowledge of Contraindications and Demographic Characteristics, 
Part 1 (contd.) 
 
 
Variables 
 
Absolute 
contraindication 
score 
 
 
Relative 
contraindication 
score 
 
Not a 
contraindication 
score 
 
Year of board 
certification 
 
        <1990 
 
 
 
 
 
2.24+1.46 
 
 
 
 
6.45+2.19 
 
 
 
 
3.17+0.83 
        >1990 
 
2.35+1.11 6.94+1.91 3.33+0.68 
    
 
t-tests: gender and year of board certification 
ANOVA’s: specialty, location, and practice site. Significant ANOVA’s were investigated with post-hoc 
Tukey comparisons 
a: Significant at p < 0.05 
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Table 41: Knowledge of Contraindications and Demographic Characteristics, Part 2 
 
Variables 
 
Absolute 
contrain-
dication 
score 
 
 
Relative 
contrain-
dication 
score 
 
Not a 
contrain-
dication 
score 
 
Age 
 
Size of 
hospital 
 
Number 
of new 
AMI 
patients 
 
Number 
of 
repeat 
AMI 
patients 
 
 
Absolute 
contra-
indication 
score 
 
 
1.000 
      
Relative 
contra-
indication 
score 
 
0.114 1.000      
Not a 
contra-
indication 
score 
 
-0.053 0.098 1.000     
Age 
 
0.001 -0.047 -0.160* 1.000    
Size of 
hospital 
 
-0.053 -0.059 0.069 -0.092 1.000   
Number 
of new 
AMI 
patients 
 
-0.027 -0.060 -0.009 -0.074 0.184* 1.000  
Number 
of repeat 
AMI 
patients 
 
-0.156* -0.026 0.007 0.130 0.010 0.197* 1.000 
 
* Significant at p < 0.05, AMI: Acute myocardial infarction
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Table 42: Willingness to Prescribe and Demographic Characteristics, Part 1 
 
Variables 
 
Definitely 
prescribe score 
 
 
Maybe prescribe 
score 
 
Definitely not 
prescribe score 
 
Gender 
 
        Males 
 
 
 
 
36.68+4.43 
 
 
 
42.32+8.55 
 
 
 
7.00+2.94 
        Females 
 
36.81+3.27 42.52+6.64 7.10+2.86 
Specialty 
 
       Cardiology 
 
 
 
37.16+6.36 
 
 
44.60+8.21 
 
 
6.56+2.79 
       Internal medicine 
 
37.45+3.22 a 44.99+7.13 a,b 7.29+3.00 
       Family practice 
 
36.19+4.34 40.55+8.50 a 6.92+2.88 
       General practice 
 
33.33+4.30 a 36.61+7.37 b 6.67+1.66 
       Other 
 
37.97+3.06 42.76+7.71 7.59+3.50 
Location 
 
        Rural 
 
 
 
37.48+3.44 
 
 
43.31+8.18 
 
 
7.81+4.06 
        Sub-urban 
 
34.22+12.89 40.56+16.28 5.89+3.06 
        Urban 
 
37.82+3.19 48.27+6.25 7.27+3.07 
Practice site 
 
        Solo, office based 
 
 
 
35.59+4.79 a 
 
 
39.77+8.84 a,b 
 
 
6.68+2.63 
        Group, office-based 
 
36.92+4.57 42.80+7.73 6.90+2.85 
        Hospital-based 
 
37.68+2.82 45.09+7.18 a 7.76+3.72 
        University-affiliated   
        hospital based 
 
38.19+2.38 a 45.92+7.25 b 7.23+2.75 
        Other 
 
 
36.18+3.83 42.47+8.23 7.59+2.94 
 204
Table 42: Willingness to Prescribe and Demographic Characteristics, Part 1 
(contd.) 
 
 
Variables 
 
Definitely 
prescribe score 
 
 
Maybe prescribe 
score 
 
Definitely not 
prescribe score 
 
Year of board 
certification 
        <1990 
 
 
 
 
36.34+4.83 
 
 
 
42.64+8.29 
 
 
 
6.79+2.62 
        >1990 37.36+3.02 43.05+7.50 6.97+2.99 
    
 
t-tests: gender and year of board certification 
ANOVA’s: specialty, location, and practice site. Significant ANOVA’s were investigated with post-hoc 
Tukey comparisons 
a,b: Significant at p < 0.05 
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Table 43: Willingness to Prescribe and Demographic Characteristics, Part 2 
 
Variables 
 
Definitely 
prescribe 
score 
 
Maybe 
prescribe 
score 
 
Definitely 
not 
prescribe 
score 
 
 
Age 
 
Size of 
hospital 
 
Number 
of new 
AMI 
patients 
 
Number 
of 
repeat 
AMI 
patients 
 
 
Definitely 
prescribe 
score 
 
 
1.000 
      
May be 
prescribe 
score 
 
0.648* 1.000      
Definitely 
not 
prescribe 
score 
 
0.194* 0.442* 1.000     
Age 
 
-0.273* -0.287* -0.091 1.000    
Size of 
hospital 
 
0.196* 0.193* 0.142 -0.092 1.000   
Number 
of new 
AMI 
patients 
 
-0.002 0.085 0.028 -0.074 0.184* 1.000  
Number 
of repeat 
AMI 
patients 
 
-0.047 0.071 0.002 0.130 0.010 0.197* 1.000 
 
* Significant at p < 0.05, AMI: Acute myocardial infarction 
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Discussion for Research Question 8 
 Based on the results, both the null hypotheses I and J are rejected.  The analysis 
revealed that specialty, type of practice site, age and number of repeat AMI patients 
treated were associated with knowledge scores.  Similarly, specialty, type of practice site, 
age and size of the practice hospital were associated with willingness to prescribe scores.   
 The absolute contraindication score and the not a contraindication score were 
significantly different by specialty.  Physicians from general practice had a higher 
absolute contraindication score compared to physicians from internal medicine and 
physicians from family practice had a lower not a contraindication score compared to 
cardiologists.  Also, physicians from general practice had lower definitely prescribe score 
compared to physicians from internal medicine and physicians from both general and 
family practice had lower maybe prescribe score compared to physicians in internal 
medicine.  Degree of specialization has been reported to be associated with knowledge of 
contraindications in other disease conditions like hypertension (Huse et al., 2001).  An 
association between degree of specialization and knowledge was also reported by 
Sanchez et al. (2001) when they investigated cardiovascular diseases and Chlamydia 
pneumoniae.  It makes intuitive sense that correct knowledge would result in higher 
willingness to prescribe scores, which in turn would eventually result in better 
prescribing behavior.  Thus, though knowledge did not demonstrate a direct effect on 
prescribing behavior in research question 5, an indirect relationship may be present.  
Type of practice site has not been reported to be associated with knowledge or 
willingness to prescribe before.  On the other hand, type of primary practice site has been 
reported to be associated with prescribing behavior and this association usually involves 
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presence of university or teaching affiliation, which results in higher prescribing rates of 
certain recommended medications such as aspirin (Venturini et al., 1999).  This study 
revealed an association of university affiliation with both knowledge and willingness to 
prescribe scores.  Thus, it is possible that university affiliation results in updated 
knowledge which increases willingness to prescribe and this may affect prescribing 
behavior.   
Older physicians were less likely to identify those conditions that are not 
contraindications for beta-blockers correctly and were also less willing to prescribe beta-
blockers in patients who should definitely receive them and those who may receive them.  
Previous reports have revealed that younger physicians are more likely to select 
medications consistent with guideline recommendations in other disease areas such as 
hypertension (Mehta et al., 1999).  This study revealed an association between age and 
prescribing behavior, age and knowledge, and age and willingness to prescribe.  Thus, 
this suggests that younger physicians are more aware of clinical practice guidelines, in 
other words are up to date with knowledge, which results in a higher willingness to 
prescribe which in turn results in their prescribing behavior being more consistent with 
such guidelines.   
Among other variables, size of hospital was positively associated with two of the 
three (‘definitely prescribe’ and ‘maybe prescribe’) willingness to prescribe scores.  It is 
possible that larger hospitals have better in-house seminars, and/or continuing medical 
education which help keep their physicians up to date about changes in guidelines and 
this results in a positive effect on their willingness to prescribe recommended therapies.   
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Finally, number of repeat AMI patients was negatively associated with absolute 
contraindication score.  It is possible that higher workload gives physicians less time to 
keep up with changes and this affects their knowledge.   
  
Results for Research Question 9 
 Effect of all physician characteristics such as demographic, practice, knowledge 
and willingness to prescribe on physician prescribing percent/behavior was investigated 
by regression analysis.  The dependent variable was prescribing percent/behavior.  The 
independent variables included; age, gender, specialty, practice site, absolute 
contraindication score, relative contraindication score, not a contraindication score, 
definitely prescribe score, maybe prescribe score, definitely not prescribe score, number 
of new AMI patients and number of repeat AMI patients treated by the physician per 
month.  Specialty was converted to a dichotomous variable where 1 was cardiology and 
all the other specialties were grouped together as 0, which implied non-cardiology or 
internal medicine, family practice, general practice or others.  Similarly, practice site was 
converted into a dichotomous variable, where 1 implied university affiliation and 0 
implied either solo or group office-based, non-university affiliated hospital or others.  
Location and size of hospital was not included in the analysis as only those physicians 
who worked in a hospital were asked to answer these questions.  Year of board 
certification was not included in analysis as the data was missing for more than 33% of 
the respondents.   
 The resultant model was significant and had an R2 of 26.8%, implying that the 
model explained almost 27% of the variance in prescribing percent/behavior (Table 44).  
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The models were checked for violation of assumptions associated with linear regression.  
The model had no problems with multicollinearity, heteroskedasticity and 
autocorrelation.  The analysis had a power of 95.6%.  However, the only independent 
variable that was a significant predictor of prescribing percent/behavior was the definitely 
prescribe score.  Thus, physicians with higher willingness to prescribe beta-blockers in 
those patients where it should be definitely prescribed were more likely to have a higher 
prescribing percent for beta-blockers as secondary prevention agents post-AMI.   
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Table 44: Predictors of Prescribing Percent/Behavior 
 
Predictor 
 
 
Estimate 
 
S.E. 
 
t-Statistic 
 
Significance 
 
Age 
 
 
-0.006 
 
0.082 
 
-0.084 
 
0.934 
Gender 
 
-1.202 2.106 -0.571 0.569 
Specialty- Cardiology 
 
-0.518 2.905 -0.179 0.859 
Practice site – University affiliation 
 
-0.262 3.035 -0.086 0.931 
Absolute contraindication score 
 
0.529 0.753 0.703 0.483 
Relative contraindication score 
 
-0.107 0.383 -0.281 0.779 
Not a contraindication score 
 
-0.375 1.082 -0.346 0.730 
Definitely prescribe score 
 
1.138 0.251 4.538 0.000* 
Maybe prescribe score 
 
0.233 0.148 1.577 0.116 
Definitely not prescribe score 
 
0.276 0.337 0.818 0.415 
Number of new AMI patients 
 
0.057 0.194 0.295 0.768 
Number of repeat AMI patients 
 
0.02 0.023 0.862 0.390 
R2 = 26.8%(F = 5.908, p < 0.000*), n = 206 
 
 
* Significant at p < 0.05, S.E: Standard error, AMI: Acute myocardial infarction 
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Discussion for Research Question 9 
 The null hypothesis K that there is no relationship between physicians prescribing 
of beta-blocker therapy post-AMI and the interaction of physician characteristics 
(demographic, practice, knowledge and willingness to prescribe) is rejected.  Regression 
analysis which included physician knowledge scores, willingness to prescribe scores and 
demographic and practice characteristics helped in understanding how each of these traits 
affected prescribing behavior when the others were adjusted for.  The results revealed 
that one of the willingness to prescribe scores explained a high percent of the variance in 
prescribing behavior for beta-blockers when it is used as a post-AMI medication when all 
the other characteristics were used as covariates.   
Figure 11 provides a summary of the findings based on the results of research 
questions 5, 6, 7, 8 & 9.  The figure demonstrates all the significant associations that were 
obtained.  Thus, specialty of internal medicine and more number of repeat AMI patients 
treated was associated with higher absolute contraindication score.  The specialty of 
cardiology, younger age of physician and university affiliation was associated with higher 
not a contraindication score.  Younger age, and university affiliation were also associated 
with higher definitely prescribe score, in addition to larger size of practicing hospital, and 
internal medicine specialty.  Larger size of practicing hospital, internal medicine 
specialty and practicing in a hospital was associated with higher maybe prescribe score.  
Among all the tested variables, not a contraindication score, definitely prescribe score, 
maybe prescribe score, definitely not prescribe score, younger age and larger size of 
hospital were all associated in univariate analysis with higher prescribing rates or 
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prescribing behavior.  However, when all these variables were entered in a multivariate 
model, definitely prescribe score was the only significant variable.   
The knowledge scores, willingness scores and prescribing behavior, were all 
proxy variables.  Thus, the findings of this phase indicate a profile of a general 
specialty/family practice physician, older in age, non-university or non-hospital affiliated 
and attached to a smaller hospital as the target for interventions to improve beta-blocker 
prescribing behavior.     
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Figure 11: Summary of Univariate and Multivariate Findings 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Internal Medicine 
Number of repeat 
AMI patients 
Absolute Contraindication Score 
Relative Contraindication Score 
Not a Contraindication Score 
Age  
University Affiliation 
Definitely Prescribe Score 
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Cardiology 
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Internal Medicine 
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Prescribing Behavior  
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Size 
AMI: Acute myocardial infarction,             : Univariate association,             : Multivariate association     
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Results for Research Question 10  
 
 This included a descriptive summarization of the various reasons reported by 
physicians for not prescribing beta-blockers in their post-AMI patients.  It was an open-
ended question and most physicians reported multiple reasons.  These reasons were 
broadly categorized based on their similarities.  For example bronchospasm, COPD, 
severe COPD, lung disease, and severe lung disease were included in one category and 
called as bronchospasm/COPD/lung disease.  Similarly, contraindications, relative 
contraindication, partial contraindication, intolerance, cannot tolerate, complications were 
grouped together in contraindications/complications/intolerance.   
The most important reasons reported by physicians for not prescribing beta-
blockers as post-AMI medication were bronchospasm/COPD/lung disease, 
Bradycardia/bradyarrhythmia, and contraindications/complications/intolerance (Table 
45).  Among other reasons reported some included relative contraindications such as 
asthma/bronchial asthma, heart block, low blood pressure, low heart rate, pulse rate, 
peripheral vascular disease, CHF or low EF, and diabetes.  A few reported hypotension, 
an absolute contraindication.  A few reported side effects or adverse effects as the general 
cause and one physician reported fatigue and another reported non-compliance as a 
cause.  Very few physicians reported co-morbidity, cost, depression, and severe systolic 
dysfixia as a reason.  The non-specific reasons were grouped in the other category and 
included-already on medication, don’t treat MI, forgot, did not think about it, medication 
has new indications, not in active patients, symptomatic, and patient transferred for care.  
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Table 45: Reasons for Not Prescribing Beta-blockers in Post-AMI Patients 
 
Reason 1 (n = 116) 
 
Reason 2 (n = 57) 
 
Reason 3 (n = 13) 
 
 
Reason 4 (n = 3) 
 
Bronchospasm/COP
D/lung disease (28) 
 
Bronchospasm/COP
D/lung disease (11) 
 
 
Diabetes (2) 
 
CHF/ low EF (1) 
Bradycardia/ 
Bradyarrhythmia (20) 
Contraindications/ 
complications/intole
rance (10) 
 
Low BP (3) Depression (1) 
Contraindications/co
mplications/intoleran
ce (17) 
 
Bradycardia/ 
Bradyarrhythmia (8) 
Bronchospasm/CO
PD/lung disease (1) 
Side/adverse 
effects (1) 
Asthma/bronchial 
asthma (13) 
Hypotension (6) Bradycardia/ 
Bradyarrhythmia 
(1) 
 
 
Side/adverse effects 
(7) 
 
Asthma/bronchial 
asthma (4) 
CHF/ low EF (1)  
Hypotension (5) Heart block (4) 
 
Cost (1)  
Low heart rate (5) Low pulse (3) 
 
Heart block (1)  
Low BP (4) Side/adverse effects 
(3) 
 
Low heart rate (1)  
Heart block (3) Low BP (2) Peripheral Vascular 
disease (1) 
 
 
Co-morbidity (2) Low heart rate (2) Side/adverse effects 
(1) 
 
 
CHF/ low EF (1) Diabetes (1) 
 
  
Fatigue (1) Peripheral Vascular 
disease (1) 
 
  
Non compliance (1) 
 
Low EF (1) 
 
  
Peripheral Vascular 
disease (1) 
 
Others (1)   
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Table 45: Reasons for Not Prescribing Beta-blockers in Post-AMI Patients 
(contd.) 
 
Reason 1 (n = 116) 
 
Reason 2 (n = 57) 
 
Reason 3 (n = 13) 
 
 
Reason 4 (n = 3) 
 
Severe systolic 
dysfixia (1) 
 
   
Others (7) 
 
   
Others: Already on medication, don’t treat AMI, forgot, did not think, new indications, not in active 
patients, symptomatic, transferred for care 
AMI: Acute myocardial infarction, n: Number of physicians, COPD: Chronic obstructive pulmonary 
disease, BP: Blood pressure, CHF: Congestive heart failure, EF: Ejection fraction 
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Discussion for Research Question 10 
 The above summarization reveals that the most common reasons reported for not 
prescribing beta-blockers as post-AMI medications were COPD, bradycardia and 
contraindications.  Bradycardia is an absolute contraindication of beta-blockers and is a 
correct reason for not prescribing as per the guidelines.  However, COPD is a relative 
contraindication and patients should be prescribed beta-blocker therapy, thus this 
suggests inappropriate prescribing behavior.  Also, the third most common reason given 
by physicians was contraindications, most physicians did not specify what the 
contraindication was.  Thus, these could be relative contraindications or absolute 
contraindications, but due to lack of sufficient information it cannot be determined 
whether the reasons were appropriate or not.  The other frequently mentioned reasons 
were asthma, hypotension, low heart rate, and adverse or side effects of therapy.  Asthma 
and low heart rate are relative contraindications and not adequate reasons for not 
prescribing.  Hypotension is an absolute contraindication and thus a correct reason for not 
prescribing as per the guidelines.  Adverse reactions have been reported to be a barrier for 
prescribing beta-blockers in a previous study too (Kennedy & Rosensen, 1995).  This 
study reported that physicians believed that adverse reactions of beta-blockers could 
result in a negative quality of life.  This study also reported exaggerated concerns for 
relative contraindications.  Thus, based on the previous report by Kennedy and Rosensen 
and present findings, it appears as though physicians’ reasons for not prescribing beta-
blockers in post-AMI patients for secondary prevention haven’t changed much.  This is 
despite additional studies which have reported that beta-blockers can be used in all 
patients except those with absolute contraindications (Phillips et al., 2000).  This gives 
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rise to the need of increasing awareness of these newer study reports to physicians who 
attend to post-AMI patients and thus increase prescribing rates of beta-blockers in post-
AMI patients.  A few physicians in this study also reported reasons such as forgot, and 
did not think.  Effective reminder cards or services could be beneficial in increasing 
prescribing rates of such physicians.  Thus, this summarization illustrates that reasons 
given by physicians for not prescribing beta-blockers may not necessarily be adequate 
and there is room for improving prescribing rates of this important therapy in post-AMI 
patients. 
 
 This chapter presented results and discussion for each research question that was 
proposed by the study.  The next chapter will give summarization and make conclusion 
from these results.   
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CHAPTER FIVE 
SUMMARY AND CONCLUSIONS 
 This chapter presents a review of the study findings, draws conclusions, presents 
research implications, lists limitations for each phase of the study, and provides 
recommendations for future research.   
 
Phase I 
 Acute myocardial infarction (AMI) is a condition responsible for high mortality 
and has a lot of economic implications.  Hence, therapeutic interventions that reduce 
mortality and improve morbidity, as well as primary and secondary prevention strategies 
for an AMI are important.  Beta-blocker therapy has been proven to be effective when 
used as a secondary preventive agent following an AMI.  Due to its effectiveness, it has 
been recommended by American College of Cardiology (ACC)/ American Heart 
Association (AHA) guidelines for long-term use following an AMI.  However, this 
important therapy has been reported to be inappropriately prescribed (underused and 
misused) in patients following an AMI.  There have been a few investigations to 
understand the consequences of under use of this therapy.  However, very little has been 
done to understand the effect of inappropriate use.  Also, previous research has been in an 
elderly population, despite the fact that this condition is present in younger age groups.  
 Thus, the goal of this phase of the study was to evaluate the prescribing of beta-
blockers as long-term therapy following an AMI in a Medicaid population.  Another aim 
was to investigate the effect of appropriate and inappropriate prescribing of beta-blockers 
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following an AMI on patient outcomes such as mortality, morbidity, health care 
utilization and expenditures. 
 
Conclusions for Phase I 
 The conclusions for this phase of the study are presented based on the research 
questions proposed in the study: 
 
Research Question 1: Prescribing Patterns for Beta-blocker Therapy in WV Medicaid 
 This was an exploratory question to assess prescribing of beta-blockers in the 
Medicaid population with regards to the published guidelines.  The prescription rates 
were higher in eligible patients and lower in ineligible patients, compared to prescription 
rates reported in previous research.  Another important observation was that there was a 
tendency to not prescribe in older patients.  All these findings suggest that prescribing in 
this patient population is better that the previously reported prescribing in other 
populations, but there is abundant room for improvement in prescribing. 
 
Research Question 2: Effect of Appropriate and Inappropriate Prescribing on Mortality 
 The null hypothesis this research question aimed to investigate was that there is 
no difference in mortality and cardiac mortality between the appropriately and 
inappropriately prescribed groups after controlling for confounding factors.  Appropriate 
therapy with beta-blockers did affect all-cause mortality.  The appropriate group had 
lower mortality compared to the inappropriate group.  However, appropriate therapy was 
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not significant when cardiac mortality was investigated.  Thus, appropriate therapy did 
not affect cardiac mortality in this cohort of patients.  
 
Research Question 3: Effect of Appropriate and Inappropriate Prescribing on Morbidity 
 The null hypothesis this research question aimed to investigate was that, there is 
no difference in morbidity due to: successive AMI, heart failure, stroke, angina, other 
ischemic disease, essential hypertension, cardiogenic shock, disease of endocardium, 
conduction disorders or cardiomyopathy between the appropriately and inappropriately 
prescribed groups after controlling for confounding factors.  Appropriate beta-blocker 
therapy did affect morbidity due to these conditions.  The inappropriate group had better 
survival compared to the appropriate group in the 12-month follow-up period in this 
patient population.  The patients in the appropriate group were twice as likely to suffer 
from a cardiac event in the follow-up period compared to the inappropriate group after 
adjusting for all the co-variates available in the claims.  However, there were indications 
that the appropriate group had a more severe condition and thus in a worse health state 
during the hospitalized AMI compared to the inappropriate group.  Thus, whether the 
increase in morbidity in the follow-up period was because of appropriate therapy or 
because of patient severity could not be determined.   
 
Research Question 4: Effect of Appropriate and Inappropriate Prescribing on Utilization 
and Expenditure 
 The null hypothesis this research question aimed to investigate was that, there is 
no difference in utilization of resources and expenditure due to successive AMI, heart 
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failure, stroke, angina, other ischemic disease, essential hypertension, cardiogenic shock, 
disease of endocardium, conduction disorders or cardiomyopathy between the 
appropriately and inappropriately prescribed group after controlling for confounding 
factors.  Appropriate beta-blocker therapy did affect utilization, but it did not affect 
expenditures.  The inappropriate group had lower utilization-hospital visits, ER visits, 
and total length of stay in the 12-month follow-up period in this patient population.  
However, there were indications that the appropriate group had a more severe condition 
and thus in a worse health state during the incident AMI compared to the inappropriate 
group.  Thus, whether the increase in utilization was because of appropriate therapy or 
because of patient severity could not be determined.   
 
Phase II 
 This phase of the study involved exploring the association of physician 
characteristics such as physician knowledge of contraindications, physicians’ willingness 
to prescribe and demographic and practice characteristics with their prescribing of beta-
blocker therapy as a post-AMI secondary preventive agent.  Previous studies have 
reported ample variation of medication use by different physician characteristics.  This 
phase of the study aimed to understand effect of these factors individually and in 
combination with prescribing behavior in the state of WV for beta-blockers in post-AMI 
patients. 
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Conclusions for Phase II 
 The conclusions of this phase of the study are presented based on the research 
questions proposed in the study: 
 
Research Question 5: Knowledge of Contraindications and Prescribing Behavior 
 The null hypothesis this research question aimed to investigate was that, there is 
no relationship between knowledge of contraindications and prescribing behavior for 
beta-blocker therapy in post AMI patients.  Physicians’ knowledge of both absolute and 
relative contraindications did not reveal any association with prescribing behavior.  On 
the other hand, knowledge of conditions which were not contraindications was positively 
associated with prescribing behavior.   
 
Research Question 6: Willingness to Prescribe and Prescribing Behavior 
 The null hypothesis this research question aimed to investigate was that, there is 
no relationship between willingness to prescribe beta-blockers and prescribing behavior 
for beta-blocker therapy in post AMI patients.  Physicians’ willingness to prescribe beta-
blockers was positively associated with their prescribing of this therapy in post-AMI 
patients as secondary preventive agents irrespective of patient co-morbidity. 
 
Research Question 7: Demographic and Practice Characteristics and Prescribing 
Behavior 
 The null hypothesis this research question aimed to investigate was that, there is 
no relationship between demographic and practice characteristics and prescribing 
behavior for beta-blocker therapy in post AMI patients.  Of the various characteristics 
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investigated age and size of hospital were associated with physician prescribing of beta-
blocker in post-AMI patients as secondary preventive agents.  Age was negatively 
associated with prescribing behavior and size of the hospital was positively associated 
with prescribing behavior.   
 
Research Question 8: Knowledge of Contraindications, Willingness to Prescribe and 
Demographic and Practice Characteristics 
 The null hypothesis this research question aimed to investigate was that, there is 
no relationship between demographic and practice characteristics and knowledge of 
contraindications and willingness to prescribe beta-blocker therapy in post AMI patients.  
Of the various characteristics investigated specialty, practice site, age, and number of 
repeat AMI patients treated by physicians were associated with physicians’ knowledge of 
contraindications.  Similarly, specialty, practice site, age, and size of hospital were 
associated with willingness to prescribe beta-blockers as secondary preventive agent in 
post-AMI patients.  Age was negatively associated with both knowledge and willingness 
to prescribe scores.  Primary practitioners from family practice and general practice 
generally had lower knowledge and willingness to prescribe scores.  University affiliation 
of the practice site was associated with higher knowledge and willingness to prescribe 
scores.  More number of repeat AMI patients treated was associated with lower 
knowledge score and larger size of the practice hospital was associated with higher 
willingness to prescribe score.   
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Research Question 9: Physician Characteristics and Prescribing Behavior 
 The null hypothesis this research question aimed to investigate was that, there is 
no relationship of prescribing behavior and physician characteristics such as 
demographics, practice characteristics, knowledge of contraindications, and willingness 
to prescribe beta-blocker therapy in post AMI patients.  The study revealed that when all 
physician characteristics are controlled for, physician willingness to prescribe is the most 
significant predictor of physicians’ prescribing behavior.  However, when the various 
associations were individually assembled; age, specialty, university affiliation and size of 
the hospital emerged to be the modifiable factors which can be targeted with educational 
efforts to increase prescribing of beta-blockers in post-AMI patients.   
 
Research Question 10: Reasons for Not Prescribing Beta-Blockers 
 This was an exploratory question to enlist reasons reported by physicians for not 
prescribing beta-blockers in post-AMI patients.  The most common reasons were COPD, 
bradycardia, and contraindications.  Comparison of the reasons with those reported in 
previous reports revealed that though prescribing has increased over the years, the 
reasons for not prescribing haven’t changed much, thus there is a need to increase 
awareness which would further improve prescribing of beta-blockers as secondary 
preventive agents in post-AMI patients.   
 
Implications of Study 
 This study was undertaken to study prescribing of beta-blockers as post-AMI 
secondary prevention agents and its effects on patient outcomes in a Medicaid 
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population.  The study also aimed to assess the physicians’ role in prescribing beta-
blockers following an AMI.  The findings of the study should be useful to the Medicaid 
program to help them improve prescribing of beta-blockers for post-AMI long-term use.  
The study also has implications for patients, prescribers and decision-makers.  These 
implications are described in the following sections. 
 
Implication to the Medicaid Program 
 The results of this study demonstrated that there is indeed inappropriate 
prescribing of beta-blockers in this patient cohort of Medicaid.  There is both under use 
and misuse.  Inappropriate use of an important therapeutic agent can have adverse 
consequences on patient outcomes.  This study revealed that appropriate use of beta-
blocker therapy is associated with a significant lower mortality rate.  Thus, this further 
stresses the importance of increasing appropriate prescribing of beta-blockers in these 
patients.  However, the results did not show a significant association of appropriate 
prescribing with cardiac mortality and also revealed that patients with appropriate 
prescribing were associated with higher morbidity and utilization of resources.  But it was 
not clear whether this increase in morbidity and utilization was associated with 
appropriate use of beta-blockers or patient severity.  And the data suggests that patient 
severity maybe responsible for higher utilization.  Thus, there is a need to improve 
appropriate prescribing of beta-blockers in these patients.  The Medicaid program can 
develop and implement active interventions such as group or one-on-one education, and 
individual outreach visits that will increase the prescription of beta-blockers in eligible 
patients, and decrease the prescription of beta-blockers in ineligible patients.  This could 
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improve patient quality of life and reduce healthcare utilization and costs, as this would 
result in better quality of care, fewer deaths, better control of symptoms and 
exacerbations due to cardiovascular (CV) disease.    
 
Implication to Patients 
 The findings of this study are also relevant to patients.  AMI is a condition that 
affects quality of life, productivity, incurs high expenses to patients (Example; insurance 
plans where patients pay a 80:20 deductible) and can result in death.  This study is one of 
the primary attempts to investigate outcomes of AMI in a younger population.  Although 
no significant difference was demonstrated, mortality was lower in the appropriate group 
for cardiac conditions.  Hence, increasing awareness of importance of beta-blockers 
among patients would result in patients asking their physicians about prescribing this 
therapy (they may want to know about contraindications).  This will eventually lead to 
increases in appropriate prescribing and thus better outcomes (postponement of death) for 
AMI patients. 
 
Implications to Prescribers 
 The study demonstrated lower mortality in the appropriately prescribed group.   
This will help those physicians who are skeptical about prescribing beta-blockers in 
patients with low risk, or presence of relative contraindications increase prescribing, and 
those physicians who prescribe in patients with absolute contraindications decrease 
prescribing.  Both these scenarios will lead to increase in appropriate prescribing 
behavior.   
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Implications to Decision-Makers 
 Decision-makers can benefit from this study in two ways.  First, the study shows 
that beta-blockers are being inappropriately prescribed.  Thus, they can develop and 
implement strategies which will increase appropriate prescribing of beta-blockers.  
Secondly, the study shows that a physician willingness to prescribe affects their 
prescribing behavior, and is dependent on their demographics, practice characteristics, 
and their knowledge about guidelines.  Thus, they can target physicians who are older, 
from general practice, who work in solo settings or who work in small hospitals with 
interventions which will increase their willingness to prescribe beta-blockers.  Ultimately, 
this should affect their prescribing of beta-blockers in post AMI patients.   
 
Limitations of Study 
The study had two phases, phase I used secondary data and phase II used primary 
data collection.  Both phases have limitations, these are discussed in the following 
sections: 
 
Limitations of Phase I 
 The study group for the phase was continuously eligible recipients of Medicaid, 
and excluded managed care and/or Medicare recipients.  Beta-blockers are known to 
provide more benefits for high-risk patients.  Age greater 65 is one of the high-risk 
criteria (ACC/AHA, 1996).  Thus, a significant portion of those individuals, who would 
probably have more benefits of appropriate prescribing, were eliminated in the study due 
to unavailability of all utilization data.  Also, since managed care recipients and those 
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recipients who were not continuously eligible were excluded, the results cannot be 
generalized for these excluded patients.   
 The study used data collected for claims purposes and not research purposes, thus, 
errors due to billing and coding cannot be ruled out.  Severity indicators which would 
have helped to adjust for patient risk were not available.  Also, some of the relative 
contraindications could not be identified such as peripheral hypoperfusion, and 
intolerance or allergy to beta-blockers.   
 The death records obtained from Vital Statistics did not contain detailed 
information about the patients.  This information would have helped determine the true 
cause of death and aid in deciding whether the deaths were cardiac or non-cardiac.  Due 
to limitations of this missing information, a lot of deaths were excluded from the cardiac 
death investigation and the result for cardiac mortality was not significant.   
 Patients are generally advised to modify certain life-style related characteristics 
that affect their risk for future cardiac morbidity.  These include smoking cessation, 
cardiac rehabilitation, exercise, and dietary modifications.  This information is not 
available in Medicaid claims and could not be adjusted for in the analysis used. 
    
Limitations of Phase II 
 This phase involved 1,019 physicians associated with post-AMI care.  However, 
only a response rate of 25.61 percent was obtained.  The non-response bias analysis 
revealed that the respondents and the non-respondents were significantly different from 
each other on some of the variables compared.  There are chances that they can also be 
different in their prescribing behavior, knowledge and willingness to prescribe and thus 
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the effect of non-response bias cannot be completely eliminated.  This limits 
generalization of the results to the entire state.  Additionally, the survey was conducted in 
the state of WV.  The physicians in this state may have different characteristics compared 
to physicians in other states.  Thus, the results may not be as easily extrapolated to other 
regions. 
 Another limitation of this phase is the way the instrument was designed.  The 
respondents had to give their willingness to prescribe beta-blocker therapy for patients 
with different conditions.  However, in clinical settings, patients may not have just one of 
these conditions.  They can have multiple conditions, with different severity levels.  
These conditions will influence the prescribing of the physicians.  This phase also suffers 
from another drawback-the absence of patient preferences.  With side effects of beta-
blockers such as decreased libido, impotence, and fatigue there is a possibility that 
patients’ preference will affect physician prescribing.  Also, beta-blocker prescribing 
percent or prescribing behavior was estimated based on prescription of beta-blockers to 
the last 10 post-AMI patients treated by the physicians.  Treatment of the last 10 patients 
may not be representative of the physicians’ general prescribing behavior for beta-
blockers in post-AMI patients.  Also, it could not be determined through the survey 
whether the prescribing of the physicians for the last 10 patients was appropriate or 
inappropriate.  However, due to time and resource constraints this method of getting a 
proxy for prescribing behavior appeared to be the best.  Another discrepancy was the fact 
that the guidelines classify atrioventricular (AV) block as both relative and absolute 
contraindication, hence there is uncertainty whether to classify it as an absolute 
contraindication or relative contraindication.  For study purposes, first degree AV block 
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was considered to be a relative contraindication and second and third degree AV blocks 
were considered to be absolute contraindications.  
 Based on the survey’s estimation, greater than 90% of the physicians were 
prescribing beta-blockers to their post-AMI patients.  Phase I of the study which 
investigated beta-blocker prescribing for WV Medicaid demonstrated a 64% prescribing 
rate.  Recent data reported by Schade et al., (2002) for the WV Medicare population, 
reported 59.4% prescribing rates for beta-blockers in Medicare AMI patients.  Both these 
rates are well below the rates obtained from the survey.  Thus, it is likely that the 
respondents of the survey gave desirable responses and this introduces bias due to self-
reported data collection method.  
 Finally, other limitations of using a self-administered mail questionnaire for data 
collection would apply for this study.  Although mail questionnaires possess the 
advantages of being relatively inexpensive to administer, access to larger population, 
anonymity, and elimination of interviewer bias, there are substantial limitations.  These 
include measurement errors due to respondents not understanding the instructions and 
items, item non-response, insensitivity to substitution, and recall bias. 
 
Directions for Future Research 
 The two phases in this study have given rise to several interesting questions.  
These questions will provide the impetus for future research purposes.  The simplest 
study that arises from phase I involves a prospective study evaluating utilization of beta-
blockers and its effects on patient outcomes.  The inability of this phase to adjust for 
patient severity and risk levels and the inability to adjust for life-style modifications can 
be adjusted by undertaking a prospective study where patients with AMI will be 
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identified from one or multiple health systems and followed for a pre-specified duration 
of time to determine outcomes such as mortality, morbidity, utilization and expenditures.  
Patient chart information can be used to adjust for severity and patients can be 
interviewed to know any life-style modification/s undertaken. 
 Another limitation of the study was the inability to determine beta-blocker use 
and its effects on outcomes in the elderly.  Linking Medicaid and Medicare records will 
allow inclusion of this cohort and thus extending the results of phase I of this study and 
hence should be pursued in future. 
 By conducting the study in Medicaid, phase I of the study involved younger 
patients who belong to lower socio-economic status.  It would be interesting to duplicate 
this study in a third party setting, where the patients would be in a comparable age group 
to Medicaid and belong to a higher socio-economic class.   
 Phase II of the study provided current knowledge and willingness to prescribe 
among physicians.  Interventions should be designed to educate the physicians about the 
gaps in their knowledge and a post study should be undertaken to find out the 
effectiveness of such interventions.  This would help design interventions that enhance 
adherence to practice guidelines.   
 And finally, since there hasn’t been much reported from the patient’s perspective, 
a study that measures and compares effect of beta-blocker therapy on patients’ quality of 
life in patients with AMI should be undertaken.   
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APPENDIX A: CLAIM FILES 
Demographic File 
1. RECIPIENT NUMBER 
2. RECIPIENT SOCIAL SECURITY NUMBER 
3. DATE OF BIRTH 
4. SEX 
5. RACE 
6. ELIGIBILITY BEGIN DATE 
7. ELIGIBILITY END DATE 
 
Hospital / ER File 
1. RECIPIENT NUMBER 
2. RECIPIENT SOCIAL SECURITY NUMBER 
3. FIRST DATE OF SERVICE 
4. LAST DATE OF SERVICE 
5. BILLED AMOUNT 
6. PAID AMOUNT 
7. DRG CODE 
8. PROCEDURE CODE 
9. DIAGNOSIS CODES 
10. HOSPITAL EXTRACT INDICATOR 
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Physician File 
1. RECIPIENT NUMBER 
2. RECIPIENT SOCIAL SECURITY NUMBER 
3. FIRST DATE OF SERVICE 
4. LAST DATE OF SERVICE 
5. BILLED AMOUNT 
6. PAID AMOUNT 
7. DRG CODE 
8. PROCEDURE CODE 
9. DIAGNOSIS CODES 
10. PHYSICIAN EXTRACT INDICATOR 
 
Pharmacy File 
1. RECIPIENT NUMBER 
2. RECIPIENT SOCIAL SECURITY NUMBER 
3. DATE OF PRESCRIPTION FILLED 
4. BILLED AMOUNT 
5. PAID AMOUNT 
6. NDC CODE 
7. GENERIC CODE 
8. DAYS SUPPLY 
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Managed Care File 
1. RECIPIENT SOCIAL SECURITY NUMBER 
2. MANAGED CARE BEGIN DATE 
3. MANAGED CARE END DATE 
 
Drug File 
1. NATIONAL DRUG CODE 
2. DRUG NAME 
3. GENERIC CODE 
 
DRG File 
1. DRG CODE 
2. DRG NAME 
 
Procedure File 
1. PROCEDURE  
2. CODE DESCRIPTION 
 
Diagnosis File 
1. DIAGNOSIS CODE 
2. CODE DESCRIPTION 
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APPENDIX B: CODES FOR IDENTIFICATION 
Relative Contraindications to Beta-blocker Therapy Post Acute Myocardial Infarction 
(AMI) 
Heart rate less than 60 bpm    Cannot be identified 
Systolic arterial pressure less than 100 Hg  Cannot be identified 
Moderate or severe left ventricular failure  ICD-9 code 428.1 
Signs of peripheral hypoperfusion Cannot be identified, Proxy ICD-9 
code 443 
Second or third degree atrioventricular(AV) block ICD-9 code 426.11, 426.13 
PR interval greater than 0.24 second   proxy AV block 
Severe Chronic Obstructive Pulmonary Disease ICD-9 codes 490, 491.x, 492.x, 
494.x, 495.x, and 496 
Asthma ICD-9 code 493.x 
Severe peripheral vascular disease CPT-4 code 35456, 35521, 35533, 
35546, 35551-58, 35566, 35621, 
35646, 35651-61, 35666, 35700 
 ICD-9 code 443 
Insulin dependent diabetes mellitus ICD-9 code 250.x1 and 250.x3 
Beta-blocker intolerance Cannot be identified 
 
Absolute Contraindications to Beta-blocker Therapy Post AMI 
 
AV block ICD-9 code 426.0 
Bradycardia ICD-9 code 427.89 
Hypotension ICD-9 code 458.x 
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Identifying Codes for Other Conditions Utilized in the Study 
 
AMI ICD-9 code 410.x 
Diabetes ICD-9 code 250.x 
Hypertension ICD-9 code 401 
Congestive heart failure ICD-9 code 428.x 
Coronary artery bypass graft  CPT-4 coded 33517-30, 33533-36, 
33542, 33545 DRG-code 107, 109 
Percutaneous transluminal coronary  CPT-4 codes 35470-73 
angioplasty  DRG-code 112, 116 
Stroke ICD-9 code 430-436 
Renal dysfunction ICD-9 code 588.0 
 
Cardiac Conditions  
 
Essential hypertension ICD-9 code 401.x 
AMI  ICD-9 code 410.x 
Acute Ischemia ICD-9 code 411.x 
Angina pectoris ICD-9 code 413.x 
Other Ischemia ICD-9 code 414.x 
Pulmonary heart disease ICD-9 code 416.x 
Disease of Endocardium ICD-9 code 424.x 
Cardiomyopathy ICD-9 code 425.x 
Conduction Disorders ICD-9 code 426.x 
Cardiac Dysrhythmias ICD-9 code 427.x 
Shock ICD-9 code 785.5-785.51 
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Medications 
 
Aspirin  
Angiotensin converting 
enzyme inhibitor Benazepril, Captopril, Cilazapril, Enalapril, Enalaprilat, 
Fosinopril, Lisinopril, Moexipril, Perindopril, Quinapril, 
Ramipril, Trandolapril 
Calcium Channel blockers Bepridil, Diltiazem, Felodipine, Flunarizine, Isradipine, 
Nicardipine, Nifedipine, Nimodipine, Verapamil 
Loop diuretics   Bumetanide, Ethacrynic Acid, Furosemide 
Digoxin 
Beta blockers Acebutolol, Atenolol, Betaxolol, Bisoprolol, Carteolol, 
Labetalol, Metoprolol, Nadolol, Oxprenolol, Penbutolol, 
Pindolol, Propranolol, Sotalol, Timolol 
Lipid Lowering Drugs Atorvastatin, Cerivastatin, Fluvastatin, Pravastatin, 
Simvastatin, Lovastatin 
Nitroglycerine 
Antiarrhythmics Amiodarone, Flecainide, Mexeletine, Procanamide, 
Propafenone 
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APPENDIX C: FIRST COVER LETTER 
January 6, 2003 
 
Dear Doctor, 
 
Acute Myocardial Infarction (AMI) is the number one killer among both men and 
women in the United States.  It is an area of high expenditures in the health care system. 
Thus, therapeutic interventions that reduce morbidity, mortality, as well as prevention 
strategies for AMI are extremely important and can have a significant impact on the 
quality and cost of patient care in the US health system.  
 
Therapy with beta-blockers and ACE-inhibitors has been investigated in 
numerous clinical trials for reducing mortality following an AMI.  The objective of this 
study is to identify current opinions and beliefs among WV physicians about the use of 
secondary preventive agents for long-term therapy in patients who have had an AMI. 
This study is part of a doctoral research project and is being undertaken by West Virginia 
University, School of Pharmacy.  Information obtained from this study will be useful in 
developing educational strategies for use of secondary preventive medications in post-
AMI patients.    
 
We hope that you will choose to participate by completing the attached 
questionnaire that asks about your opinions and beliefs regarding use of secondary 
preventive agents in post-AMI patients.  To assure confidentiality, your responses will be 
coded and your name will not appear in any data analysis or study reports.  Your 
participation in this study is voluntary.  Although we hope that you will answer all of the 
questions, you do not have to answer any question that makes you uncomfortable.  
 
Your response will provide valuable information and is critical to the results of 
the study. Thank you for taking a few minutes to complete the survey.  Please return it in 
the enclosed postage-paid envelope.  If you have any questions, please do not hesitate to 
contact Ancilla Fernandes at (304) 293-6991 or Dr. Suresh Madhavan at (304) 293-1652. 
 
Thank You. 
 
Sincerely, 
 
 
 
Ancilla Fernandes, M.S.    Suresh Madhavan, M.B.A, Ph.D. 
Ph.D. Candidate      Professor and Chairperson  
 252
 
APPENDIX D: SECOND COVER LETTER 
January 20, 2003 
 
Dear Doctor,  
 
About two weeks ago, we sent you a survey asking your opinions and beliefs 
related to use of secondary preventive agents in post-AMI patients.  We have not yet 
received your completed survey.   
 
We understand that you are busy or may not have received the survey.  However, 
your responses are extremely important to us, and the information obtained for the study 
will be very useful to develop educational strategies for enhancing use of secondary 
preventive agents in post-AMI patients. Therefore, we are sending you another copy of 
the survey and would appreciate it if you could take a few minutes to complete and return 
it in the enclosed postage-paid envelope.  If you have responded, please disregard this 
letter and accept our gratitude for your time and effort. 
 
This study is part of a doctoral research project and is being undertaken by West 
Virginia University, School of Pharmacy. Your participation in this study is voluntary. 
To assure confidentiality, your responses will be coded and your name will not appear in 
any data analysis or study reports.  Although we hope that you could answer all of the 
questions, you do not have to answer any question that makes you uncomfortable.  
 
Thank you for your participation.  If you have any questions or concerns, please 
do not hesitate to contact Ancilla Fernandes at (304) 293-6991 or Dr. Suresh Madhavan 
at (304) 293-1652. 
 
 
Thanks you. 
 
Sincerely, 
 
 
 
 
Ancilla Fernandes, M.S.    Suresh Madhavan, M.B.A, Ph.D. 
Ph.D. Candidate      Professor and Chairperson  
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APPENDIX E: THIRD COVER LETTER 
February 3, 2003 
 
Dear Doctor,  
 
About two weeks ago, we made our second attempt to reach you regarding our 
study, asking your opinions and beliefs related to use of secondary preventive agents in 
post-AMI patients. We have not yet received your completed survey.   
 
We have undertaken this study because it is our belief that your opinions should 
be taken into account for developing educational strategies for enhancing use of 
secondary preventive agents in post-AMI patients. 
 
We are writing to you again to emphasize the significance of your response and 
how important your opinions are in understanding patient care for AMI patients.  We 
have enclosed a questionnaire just in case your earlier copies have been misplaced.  We 
would appreciate it if you could take a few minutes to complete and return it in the 
enclosed postage-paid envelope.  If you have responded, please disregard this letter and 
accept our gratitude for your time and effort. 
 
This study is part of a doctoral research project and is being undertaken by West 
Virginia University, School of Pharmacy. Your participation in this study is voluntary. 
To assure confidentiality, your responses will be coded and your name will not appear in 
any data analysis or study reports.  Although we hope that you could answer all of the 
questions, you do not have to answer any question that makes you uncomfortable.  
 
Thank you for your participation.  If you have any questions or concerns, please 
do not hesitate to contact Ancilla Fernandes at (304) 293-6991 or Dr. Suresh Madhavan 
at (304) 293-1652. 
 
 
Thanks you. 
 
Sincerely, 
 
 
 
 
Ancilla Fernandes, M.S.    Suresh Madhavan, M.B.A, Ph.D. 
Ph.D. Candidate      Professor and Chairperson  
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APPENDIX  F: STUDY SURVEY 
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Opinions and Beliefs about Long-term Secondary Preventive Agents following an Acute Myocardial Infarction 
(AMI) 
INSTRUCTIONS: Your professional opinions and beliefs are extremely important for understanding the use of secondary preventive 
agents following an AMI.  Please answer the questions carefully.  Your response will be kept absolutely confidential. 
 
SECTION A 
1. Of the following medications, which according to you are the important secondary preventive agents following an 
AMI:(Check all that apply) 
 
 Aspirin     Angiotensin Converting Enzyme (ACE) inhibitors    Digitalis  
 Anti-arrhythymics   Calcium Channel blockers      Nitroglycerin 
 Beta-blockers   Lipid-lowering drugs       Anticoagulants 
 Magnesium    Others, please specify ___________________________________________________________  
 
2. How likely are you, on a scale from 1 to 5 where 1 is least likely and 5 is most likely, to prescribe these medications for 
secondary prevention following an AMI: 
Please answer this question by using: 
1  2  3  4  5 
     Least likely       Uncertain        Most likely  
                                                                   Enter response (any number from 1 to 5) 
1. Aspirin       __________ 
2. Angiotensin Converting Enzyme (ACE) inhibitors  __________ 
3. Digitalis       __________ 
4. Anti-arrhythymics     __________ 
5. Calcium Channel blockers     __________ 
6. Nitroglycerin      __________ 
7. Beta-blockers       __________ 
8. Magnesium       __________ 
9. Lipid-lowering drugs     __________ 
10. Anticoagulants      __________ 
11. Others       __________ 
3. A) Of the last 10 new AMI/post-AMI patients that you treated, you prescribed a beta-blocker as long- term therapy for  
secondary prevention in….( Please circle the appropriate number) 
 
1 2 3 4 5 6 7 8 9 10     of these patients 
 
B) If your answer for the previous question is less than 10 please specify the reasons for not prescribing beta-blockers in  
these patients: 
____________________________________________________________________________________________________ 
____________________________________________________________________________________________________
4. A) Of the last 10 new AMI/post-AMI patients that you treated, you prescribed a ACE inhibitor as long-term therapy for  
secondary prevention in….( Please circle the appropriate number) 
 
1 2 3 4 5 6 7 8 9 10     of these patients 
 
B) If your answer for the previous question is less than 10 please specify the reasons for not prescribing ACE inhibitors  
in these patients: 
____________________________________________________________________________________________________ 
____________________________________________________________________________________________________ 
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SECTION B 
 
Clinical trials have consistently demonstrated lower mortality in AMI patients when they are treated with beta-
blockers and ACE inhibitors.  However, there are certain conditions in the presence of which beta-blockers and/or ACE 
inhibitors are not beneficial and can be harmful.  
 
Given the normal side effects of beta-blockers (fatigue, sexual dysfunction, nightmares and difficulty to detect 
hypoglycemia in diabetics) and ACE inhibitors (dry cough, diarrhea, fatigue, dizziness) how likely are you, on a scale 
from 1 to 5 where 1 is least likely and 5 is most likely, to prescribe these for long-term use for secondary prevention in 
AMI patients with the following attributes: 
 
Please answer this question by using: 
1  2  3  4  5 
    Least likely       Uncertain        Most likely  
 
Enter response (any number from 1 to 5)            Beta-blockers        ACE inhibitors 
1. Age > 50 years     __________  __________ 
2. Age < 50 years     __________  __________ 
3. Large or anterior AMI    __________  __________ 
4. Small infarction     __________  __________ 
5. Previous infarction     __________  __________ 
6. EF<40%      __________  __________ 
7. History of Chronic Heart Failure   __________  __________ 
8. Had an angioplasty     __________  __________ 
9. Had by-pass surgery    __________  __________ 
10. Stroke      __________  __________ 
11. Hypotension (systolic pressure <90Hg)  __________  __________ 
12. Hypertension (systolic pressure >140Hg)  __________  __________ 
13. Systolic blood pressure <100 Hg   __________  __________ 
14. Bradycardia (heart rate <50 bpm)   __________  __________ 
15. Heart rate < 60 bpm     __________  __________ 
16. Left Venticular (LV) failure    __________  __________ 
17. Complex Ventricular ectopy   __________  __________ 
18. First degree Atrio-Ventricular (AV) block  __________  __________ 
19. Second degree AV block    __________  __________ 
20. Third degree AV block    __________  __________ 
21. Peripheral vascular disease    __________  __________ 
22. Chronic Obstructive Pulmonary Disease (COPD) __________  __________ 
23. Asthma      __________  __________ 
24. Insulin dependent diabetes mellitus   __________  __________ 
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SECTION C 
 
Patient conditions in the presence of which medications such as beta-blockers and ACE inhibitors are not 
beneficial are divided into absolute contraindications (i.e. medication should not be used), and relative contraindications 
(i.e. medication can be used if patient is monitored).  There are other conditions that are not contraindications (i.e. 
medication can be used without concern).   
 
Which of the following conditions in your opinion are – absolute contraindications (AC), relative 
contraindications (RC), or are not contraindications (NC) for long-term use of these drugs (beta-blockers and ACE 
inhibitors) in AMI patients. Please answer this question by marking (X) in the box that represents your answer. 
 
Patient conditions:            Beta-blockers         ACE inhibitors 
   AC  RC    NC     AC    RC    NC 
1. Hypotension (systolic pressure <90 Hg)   1 1 1  1 1 1 
2. Systolic blood pressure < 100Hg    1 1 1  1 1 1 
3. Hypertension (systolic pressure >140Hg)   1 1 1  1 1 1 
4. Heart rate < 60 bpm      1 1 1   1 1 1 
5. Bradycardia (heart rate <50 bpm)    1 1 1  1 1 1 
6. Peripheral vascular disease     1 1 1  1 1 1 
7. Peripheral hypoperfusion     1 1 1  1 1 1 
8. EF<40%       1 1 1  1 1 1 
9. First degree Atrio-Ventricular (AV) block   1 1 1  1 1 1 
10. Second degree AV block     1 1 1  1 1 1 
11. Third degree AV block     1 1 1  1 1 1 
12. Chronic Obstructive Pulmonary Disease (COPD)  1 1 1  1 1 1 
13. Asthma       1 1 1  1 1 1 
14. Non-insulin dependent diabetes mellitus   1 1 1  1 1 1 
15. Insulin dependent diabetes mellitus    1 1 1  1 1 1 
16. PR interval on Electrocardiogram (ECG)>0.24 second 1 1 1  1 1 1 
17. Stroke       1 1 1  1 1 1 
18. Beta-blocker intolerance      1 1 1  1 1 1 
19. ACE-inhibitor intolerance     1 1 1  1 1 1 
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SECTION D 
A few questions about you and your primary site of practice. 
1. Age:  _________    Years ________    Months 
2. Gender:  Male    Female 
3. Specialty or Primary Area of Practice:  ______________________________________ 
4. Year of board certification in this specialty/primary area of practice:  _______________ 
5. Your primary practice site is:   
 Hospital based          (go to question 6) 
 University-affiliated Hospital   (go to question 6) 
 Solo, office-based     (go to question 8)  
 Group, office-based   (go to question 8)  
 Others, please specify _____________________________________________(go to question 8) 
6.   The hospital where you practice is: Check all that apply 
 Rural      Government/Non-Federal   Provides Tertiary Care 
 Urban    Government/Federal  
 Sub-urban    Private Not-For-Profit 
     Private Investor Owned  
 Others, please specify ___________________________________________________________ 
7. Number of beds at this hospital:           _______________ 
8. Average number of new AMI patients you see per month:  _______________ 
9. Average number of repeat AMI patients you see per month:  _______________ 
 
COMMENTS 
If there is anything else that you would like to tell us about your beliefs or opinions with using beta-blockers and ACE-
inhibitors as secondary preventive agents after an AMI, please use this space to provide your comments. 
 
 
 
 
 
 
 
 
 
THANK YOU 
Please return the complete survey in the enclosed business reply envelope. 
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APPENDIX G: NON-RESPONSE SURVEY 
February 17, 2003 
 
Dear Doctor, 
 During the past two months you may have received two-three mailings of a questionnaire regarding your 
opinions and beliefs for use of secondary preventive agents in post-Acute Myocardial Infarction (AMI) patients.  We 
realize that you have been very busy and have chosen not to answer the survey or did not have the time.  Since your view 
is extremely important to us, we would like to know your reason for not responding and obtain some key information for 
the study.  This study is part of a doctoral research project and is being undertaken by West Virginia University, School of 
Pharmacy. Your participation in this study is voluntary.  To assure confidentiality, your responses will be coded and your 
name will not appear in any data analysis or study reports.  Although we hope that you could answer all of the questions, 
you do not have to answer any question that makes you uncomfortable.  Please answer the few questions below and mail 
it to us in the business reply envelope provided.  If you have any questions or concerns, please do not hesitate to contact 
us at (304) 293-6991 or  (304) 293-1652. 
 
Sincerely, 
 
Ancilla Fernandes, M.S.    Suresh Madhavan, M.B.A, Ph.D. 
Ph.D. Candidate      Professor and Chairperson  
 
Q1. I did not respond to the survey because: 
 Did not have enough time to complete it   Did not receive it  
 Forgot about the survey      Survey was too long  
 Survey was misplaced      Don’t like to respond to surveys 
 No incentive to complete it    Not enough information about benefits  
 Not interested in such studies    Topic was irrelevant  
 Others (Please specify) ______________________________________________ 
 
Q2. Demographics: 
1. Age:  _________    Years ________    Months 
2. Gender:  Male    Female 
3. Specialty or Area of Practice:  ______________________________________ 
4. Year of board certification in this specialty/area of practice:  _______________ 
5. Your primary practice site is:   
 Solo, office-based     
 Group, office-based  
 Hospital based 
 University affiliated-Hospital based 
6.   Average number of new AMI patients you see per month:  _______________ 
7.   Average number of repeat AMI patients you see per month:  _______________ 
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